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Abstract 
Chemokines regulate the migration of leukocytes through binding to chemokine 
receptors. The inflammatory CC chemokine receptors CCR1, CCR2, CCR3 and 
CCR5 (iCCRs) are expressed by several different leukocytes and are important in 
orchestrating inflammatory responses. These receptors can bind to multiple CC 
chemokines and many of these chemokines share receptors, resulting in a highly 
complex system in which the exact role of each receptor is not understood. To 
aid understanding of these receptors, two unique mouse strains have been 
developed. These are mice that are deficient for all four iCCRs (iCCR-KO) and 
mice that express fluorescent reporter proteins for each of the iCCRs (REP 
mice). 
Hypertension is when blood pressure (BP) is elevated above 140/90 mmHg. There 
is evidence for a role of inflammation in the development of hypertension and 
the consequent end organ damage which increases the risk of cardiovascular 
disease. Several chemokines and chemokine receptors have been implicated in 
hypertension but due to the complexity of the chemokine system, the role they 
play in the pathogenesis of the disease is unclear. Therefore the role of iCCRs in 
hypertension was investigated using iCCR-KO and REP mice. 
WT, REP and iCCR-KO mice were subject to 7 or 14 days of Angiotensin (Ang) II 
induced hypertension. iCCR expression was characterised in REP and WT mice 
and the effect of iCCR deficiency on BP, vascular function, inflammation and 
cardiac and vascular remodelling was assessed using the iCCR-KO mice. Aortic 
CCR2 and CCR5 expression increased in Ang II treated WT mice compared to 
control WT mice. Further, iCCR-KO mice were protected from Ang II induced 
vascular dysfunction but iCCR deficiency did not influence BP or remodelling. 
iCCR-KO mice were also shown to have altered circulating leukocyte populations 
in Ang II induced hypertension. 
Control iCCR-KO mice tended to have a lower BP than WT mice so the effect of 
iCCR deficiency on regulators of BP in the kidneys and kidney leukocyte 
infiltration was investigated. iCCR-KO mice had fewer inflammatory monocytes 
and reduced mineralocorticoid receptor mRNA expression. This could influence 
BP but further studies are needed. 
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Overall, novel mouse models have been used to identify how iCCRs are involved 
in hypertension. The results described here suggest that iCCRs, in particular 
CCR2 and CCR5, are involved in regulating vascular dysfunction in hypertension. 
Through improving understanding of these receptors in the disease, there is 
increased potential to target them as treatments that would ultimately reduce 
the risk of cardiovascular disease. 
 
  
Aortic CCR2 and CCR5 
expression 
Ang II 
No change in leukocyte 
iCCR expression 
Vascular dysfunction 
protection 
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Introduction 
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1 Introduction 
1.1 The immune system and inflammation 
The immune system is a complex defence system that acts to protect against 
damage and pathogens. This is split into the innate and adaptive immune 
responses in which the innate system provides a quick, but non-specific, 
response whilst the adaptive response involves a more specific, coordinated 
defence. Inflammation occurs when leukocytes infiltrate a tissue to protect 
against an infection or damage. This is a necessary response to maintain a 
healthy state but if not resolved, inflammation can become chronic and cause 
damage to healthy tissues. 
1.1.1 Innate immunity  
The innate immune response is the first stage of defence against pathogens and 
also activates cells of the adaptive immune response. There are several 
components to innate immunity. These include physical barriers, such as the 
skin, which separate the internal environment from pathogens in the external 
environment, humoral factors found in the plasma and mucosal secretions and 
cellular mechanisms (Riera Romo et al., 2016). 
There are various humoral factors that possess antimicrobial activity or 
modulate the immune response. Antimicrobial peptides (AMPs), such as 
defensins, have antimicrobial, antifungal or antiparasitic activity. Defensins have 
been shown to be elevated in Hepatitis C infections (Mattar et al., 2016), 
suggesting antiviral activity as well. The complement system is a cascade of 
proteins found in the circulation and tissues that results in lysis of microbes and 
enhances the inflammatory response (Harboe et al., 2011; Ricklin et al., 2010). 
Cytokines are small proteins that mediate communication between cells to 
modulate the immune response. Cytokines can be proinflammatory or anti-
inflammatory and include interferons (IFNs), interleukins (ILs), tumour necrosis 
factors (TNFs) and transforming growth factors (TGFs) (Riera Romo et al., 2016). 
IFNs are grouped into type I (IFN- and IFN-β), type II (IFN-γ) and type III (IFN-λ) 
and have antiviral activity (Takaoka and Yanai, 2006). As well as this, IFN-λ has 
1 21 
 
recently been reported to have antifungal activity (Espinosa et al., 2017). There 
are many different ILs which have a wide range of functions. IL-1 and IL-1β are 
proinflammatory and activate leukocytes such as neutrophils, B cells and T cells 
(Keyel, 2014). IL-1β induces the differentiation of Th17 cells and can inhibit IL-10 
production by these cells (Acosta-Rodriguez et al., 2007; Zielinski et al., 2012). 
IL-1β also mediates neutrophil recruitment and is found at many sites of 
inflammation, for example, in the liver during Hepatitis C infection (Miller et al., 
2007; Negash et al., 2013). IL-10 is generally thought to be anti-inflammatory 
but has been reported to have proinflammatory functions, depending on the 
cellular context. In macrophages, IL-10 exerts an anti-inflammatory effect as it 
inhibits lipopolysaccharide (LPS)-induced NFκB activation and TNF- production 
(Dokka et al., 2001). However, following LPS stimulation in humans, IL-10 
enhances the production of IFN-γ (Lauw et al., 2000). Another proinflammatory 
IL is IL-17, which can induce expression of the genes for IL-1, TNF and 
defensins (Amatya et al., 2017). 
The cells of the innate immune system recognise pathogen associated molecular 
patterns (PAMPs) and danger associated molecular patterns (DAMPs) via pattern 
recognition receptors (PRRs), such as Toll-like receptors (TLRs). PAMPs are 
molecules that are common to pathogens, while DAMPs are endogenous 
molecules released by necrotic cells. These allow the immune cells to make a 
quick response to infected or damaged tissues (Bianchi, 2007; Elliott et al., 
2014). The innate immune system utilises many cell types, each with different 
functions, including neutrophils, monocytes and dendritic cells (DCs). 
1.1.1.1 Neutrophils 
Neutrophils are typically involved in acute inflammation and are the first 
leukocytes recruited to an inflammatory site. They release oxidants, proteases 
and antimicrobial proteins to remove pathogens and can also stimulate 
inflammatory monocyte recruitment (Kolaczkowska and Kubes, 2013; Soehnlein 
et al., 2008). It has been reported that there are different subsets of neutrophils 
with varying surface antigen expression and macrophage activation potential 
(Tsuda et al., 2004). Another role of neutrophils is to regulate the adaptive 
immune response. It has been suggested that a subset of neutrophils can 
suppress T cell proliferation after LPS stimulation in humans (Pillay et al., 2012) 
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and that splenic neutrophils can stimulate B cells (Puga et al., 2012). 
Neutrophils also produce cytokines such as IFN-γ (Yin and Ferguson, 2009). 
1.1.1.2 Monocytes 
Monocytes are phagocytic cells that circulate in the blood, are recruited to sites 
of inflammation and function in wound healing and tissue repair. In mice, 
monocytes are characterised based on expression of the marker Ly6C as either 
classical/inflammatory (Ly6Chi) or alternative/patrolling (Ly6Clow) monocytes. 
Ly6Chi monocytes are pro-inflammatory whilst Ly6Clow monocytes have roles in 
tissue repair (Geissmann et al., 2003; Kratofil et al., 2017). Once recruited to an 
inflamed tissue, monocytes can differentiate into macrophages or DCs, 
depending on the cytokine environment (Crane et al., 2014; Nakano et al., 
2009). Monocyte phenotype can also switch between classical and alternative 
states, depending on the local cytokine environment (Dal-Secco et al., 2015). 
During homeostasis, monocytes are involved in replacement of tissue-resident 
macrophages (Mitchell et al., 2014; Tamoutounour et al., 2013). 
1.1.1.3 Macrophages 
Macrophages are a heterogenous population of cells with various functions, 
including phagocytosis of pathogens and cell debris. They can be broadly classed 
as either inflammatory (M1) or anti-inflammatory (M2) macrophages. Polarisation 
towards an M1 or M2 phenotype depends on the cytokines the cell is exposed to. 
IFN-γ tends to induce an M1 phenotype whereas IL-4 will stimulate an M2 
phenotype (Murray, 2017). M1 macrophages produce proinflammatory cytokines, 
proteases and reactive oxygen species (ROS), providing defence against 
pathogens. M2 macrophages are involved in resolving the immune response, 
angiogenesis and tissue repair. M1 and M2 macrophages secrete distinct cytokine 
patterns, orchestrating distinct immune responses (Sica et al., 2015). 
Many tissues are host to tissue-resident macrophages. Examples of these are 
alveolar macrophages in the lung, Kupffer cells in the liver and microglia in the 
brain. These cells are established during embryonic development and can self-
renew independently of monocytes. (Schlitzer and Schultze, 2017; Yona et al., 
2013). They differentiate from erythro-myeloid progenitors (EMPs) which 
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originate in the yolk sac and then colonise the fetal liver, a hematopoietic 
organ, during embryonic development. Microglia exclusively originate from the 
yolk sac whilst other resident macrophages have fetal liver origins (Ginhoux et 
al., 2010; Hoeffel and Ginhoux, 2015; McGrath et al., 2015). Tissue-resident 
macrophages have been reported to have functions other than immune roles. 
Cardiac resident macrophages modulate electrical activity of cardiomyocytes 
and Kupffer cells remove red blood cell (RBC)-derived haemoglobin from the 
circulation (Hulsmans et al., 2017; Willekens et al., 2005). 
1.1.1.4 Dendritic cells 
DCs are a family of antigen presenting cells (APCs) that stimulate the adaptive 
immune response by presenting antigens to T cells and producing cytokines. DCs 
can maintain T cell homeostasis by regulating T cell reactivity in the absence of 
foreign antigen (Hochweller et al., 2010) whilst DCs in the thymus also regulate 
immune tolerance by mediating negative selection of T cells (Hubert et al., 
2011). Following LPS stimulation, DCs in the spleen have been shown to produce 
the cytokines IFN-γ, TNF- and TGF-β (Zhang et al., 2005). DCs are 
characterised by expression of the markers CD11c and major histocompatibility 
complex (MHC)-II and can be further grouped into subsets based on expression of 
CD4, CD8, CD11b and CD80 (Waisman et al., 2017; Zhang et al., 2005). 
1.1.1.5 Natural killer cells 
Natural killer (NK) cells are cytotoxic cells that induce lysis of virally infected 
and transformed cells. This is mediated by the secretion of perforin and 
granzymes which induce target cell apoptosis or by caspase-dependent apoptosis 
(Mandal and Viswanathan, 2015). NK cells have been reported to produce 
multiple cytokines when activated such as IFN-γ, TNF-, IL-1β, IL-6 and IL-10, 
stimulating cells of the adaptive response (Fauriat et al., 2010). In mice, NK 
cells express CD27 which can distinguish two NK cell subsets, CD27hi and CD27low. 
CD27hi NK cells are reported to have greater effector activity compared to 
CD27low NK cells (Hayakawa and Smyth, 2006). Although part of the innate 
immune system, NK cells can be primed by DCs to acquire effector functions 
(Lucas et al., 2007). 
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1.1.1.6 Mast cells 
Mast cells are granular leukocytes found at the interface between the external 
and internal environments such as the skin and lungs and respond to pathogens 
via PRRs. Activation of mast cells results in degranulation and the release of 
AMPs, proteases and cytokines (da Silva et al., 2014; Di Nardo et al., 2003; 
Supajatura et al., 2002). Mast cells express TLR2 which, when stimulated by the 
PAMP peptidoglycan, results in release of IL-4 and IL-5 (Supajatura et al., 2002). 
Mast cells can also be activated by viral RNA binding to TLR3, leading to release 
of IFN-β (Orinska et al., 2005). Mast cells express Fc receptors which bind to 
immunoglobulins so can be considered to be part of the adaptive immune 
response. Mast cells have been widely studied in the context of allergy as IgE 
activation of FcεR1 induces an allergic response, mediated by the release of 
histamine, prostaglandins and leukotrienes (da Silva et al., 2014). 
1.1.1.7 Eosinophils 
Eosinophils are typically thought of as cells that protect against parasitic 
infections but also express PRRs which allow responses to viruses, bacteria and 
fungi. They can secrete cytotoxic proteins such as major basic protein (MBP) and 
eosinophil peroxidase (Rothenberg and Hogan, 2006). They express TLR7 and 
TLR9 which bind to viral ligands, leading to CXCL8 secretion and superoxide 
generation (Mansson and Cardell, 2009; Nagase et al., 2003). Eosinophils can 
function as APCs, presenting antigens to activate T cells (Del Pozo et al., 1992). 
They store preformed cytokines, including IL-4, IL-10 and IFN-γ, which enables 
rapid release following activation (Spencer et al., 2008). Eosinophils have been 
strongly implicated in asthma and allergy. This is partly due to cross-talk 
between eosinophils and mast cells. Mast cells secrete IL-5, promoting eosinophil 
activation, and eosinophils can activate mast cells via production of MBP 
(Rothenberg and Hogan, 2006). 
1.1.2 Adaptive immunity 
The adaptive immune response is characterised as being specific and provides 
immunological memory. Upon first exposure to a pathogen, a slow primary 
response is formed. Any subsequent exposure elicits a quicker and more specific 
secondary response. The adaptive system involves lymphoid organs and the 
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response is mediated by lymphocytes (T cells and B cells). Bone marrow and the 
thymus are primary lymphoid organs, where B cells and T cells mature, 
respectively. Secondary lymphoid organs coordinate the interaction between 
APCs and lymphocytes and include the spleen and lymph nodes. T cells and B 
cells migrate to secondary lymphoid organs where they can be activated and 
then migrate to other areas and exert effector functions (Boehm and Swann, 
2013; Bonilla and Oettgen, 2010). Traditionally it was thought that only 
lymphocytes could produce a memory response but there is evidence of innate 
cells, such as monocytes, developing a trained response following an initial 
infection (Quintin et al., 2012). 
1.1.2.1 T cells 
T cells express the T cell receptor (TCR) and can express one of the co-
stimulatory molecules CD4 or CD8. Activation of T cells requires the interaction 
of the TCR with a specific antigen complexed with an MHC molecule and the 
interaction of CD8 or CD4 with the MHC-I or MHC-II molecule, respectively. CD8+ 
T cells are cytotoxic (Tc) cells which can remove infected or transformed cells. 
CD4+ T cells are helper (Th) cells which regulate the immune response through 
the production of cytokines (Castellino and Germain, 2006; Germain, 2002). 
CD4+ T cells are further grouped into subsets based on their function and 
cytokine production. Th1 cells produce IL-2 and IFN-γ and can stimulate 
monocytes, NK cells and Tc cells in response to viral, bacterial and parasitic 
infections (Bonilla and Oettgen, 2010; Caza and Landas, 2015). Th2 cells 
facilitate antibody production by B cells and are implicated in hypersensitivity 
responses. These cells produce IL-4 and IL-5 (Caza and Landas, 2015). Th17 cells 
are proinflammatory, produce IL-17 and are involved in autoimmunity (Langrish 
et al., 2005) whilst Th9 cells are induced by TGF-β, and produce IL-9 in response 
to helminth infections (Veldhoen et al., 2008). Regulatory T (Treg) cells are also 
CD4+ and have a role in suppressing the immune response to maintain immune 
homeostasis (Josefowicz and Rudensky, 2009). 
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1.1.2.2 B cells 
B cells are essential mediators of humoral immunity. Once activated, B cells can 
differentiate to antibody producing plasma cells or enter the germinal centre 
(GC) of a secondary lymphoid organ where they develop into memory cells. In 
the GC, B cells undergo somatic hypermutation and antibody class switching 
which allows rapid production of high affinity antibodies during a secondary 
immune response (Bonilla and Oettgen, 2010; Vazquez et al., 2015). Antibodies 
consist of a light chain and a heavy chain, which undergo gene rearrangements 
during B cell development, resulting in the ability to recognise an extensive 
repertoire of antigens. Several different immunoglobulin (Ig) isotypes can be 
produced. These are IgM, IgG, IgA, IgD and IgE and this enables various functions 
to be carried out whilst maintaining antigen specificity (Pieper et al., 2013). 
Naïve B cells express IgM and IgD antibodies and predominantly switch to IgG-
expressing B cells once activated (Horns et al., 2016). IgM and IgD are found on 
the surface of B cells but can also be secreted. IgM is released as a multimer, is 
associated with the primary immune response and can activate the complement 
system. IgG class antibodies are the most abundant and are further grouped into 
the subclasses IgG1, IgG2, IgG3 and IgG4. IgA antibodies are found at high levels 
in secretions and at mucosal surfaces whilst IgE antibodies are involved in 
hypersensitivity and parasitic infections (Schroeder and Cavacini, 2013). B cells 
are important for mediating an adaptive immune response but there is some 
evidence for a regulatory role of B cells as they can produce IL-10, leading to 
suppression of the immune response (Mizoguchi et al., 2002). 
1.2 Chemokines 
Chemokines are cytokines that regulate the migration of leukocytes. They are 
therefore fundamental for immune and inflammatory processes, but also play a 
role in many pathologies. Traditionally, chemokines are described as being 
secreted by infected or damaged tissues. Cells with the appropriate chemokine 
receptors can then migrate to the tissue and carry out their effector function 
(Fernandez and Lolis, 2002; Figure 1-1). 
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Figure 1-1. Leukocyte migration in response to chemokines 
Chemokines are secreted by injured or infected tissue. Leukocytes with appropriate chemokine 
receptors roll along the endothelium and extravasate into the tissue. 
1.2.1 Classification and structure of chemokines 
Chemokines are characterised by having positionally conserved cysteine 
residues. They are divided into four subfamilies based on the position of the first 
two cysteines. These are CC, CXC, XC and CX3C. Chemokine nomenclature is 
based on the subfamily a chemokine is part of, for example CC, followed by L 
(for ligand) and a number (Table 1-1). The majority of chemokines are in the CC 
or CXC subfamilies whilst humans have only two XC chemokine ligands (XCL1 and 
XCL2) and one CX3C ligand (CX3CL1) (Turner et al., 2014). CXC chemokines can 
be further characterised by the presence or absence of an ELR motif. 
Chemokines are typically 8–12 kDa and generally all chemokines have a similar 
structure. An example of this is CCL2 which has four strands of β-sheet and two 
-helices (Handel and Domaille, 1996). The N-terminus of a chemokine forms the 
key signalling domains (Allen et al., 2007). 
Endothelial 
cell 
Leukocyte Chemokine 
receptor 
Chemokine Proteoglycan 
with GAGs 
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1.2.2 Homeostatic and inflammatory chemokines 
Chemokines can be classed as being homeostatic or inflammatory. Homeostatic 
chemokines are constitutively expressed and regulate baseline immune function, 
immune system development and immune surveillance. These chemokines 
include CCL19 and CCL21, which bind to CCR7, and direct T cells and DCs to 
secondary lymphoid organs (Förster et al., 2008). CCL25 binds to CCR9 on T cell 
progenitors and plasmacytoid DCs, directing these cells to the thymus and small 
intestine, respectively (Forster et al., 2009; Wendland et al., 2007). CCL27 is 
expressed by keratinocytes and mediates T cell recruitment through CCR10 to 
the skin (Homey et al., 2002). CXCL12/CXCR4 signalling is required for 
haematopoiesis and bone marrow recruitment and retention of haemopoietic 
stem cells (HSCs), as well as development of B cells, monocytes, macrophages 
and NK cells (Sokol and Luster, 2016). CXCL13 regulates B cell migration and 
localisation within lymph nodes (Förster et al., 1996). 
The majority of chemokines are inflammatory. Their expression by immune and 
non-immune cells is induced by infection or tissue damage and they have a role 
in innate and adaptive immune responses (Allen et al., 2007). Inflammatory 
chemokines include CCL2, CCL3, CCL4, CCL5, CXCL1, CXCL2, CXCL3 and CXCL5. 
Some chemokines can function in both inflammatory and homeostatic ways. 
Examples of these are CCL17, CCL20, CCL22, CXCL9, CXCL10 and CXCL11 
(Palomino and Marti, 2015). 
1.3 Chemokine receptors 
Chemokine receptors are G protein-coupled receptors (GPCRs). Nomenclature of 
these receptors consists of the subfamily of ligands the receptor binds followed 
by an R and a number (Table 1-1). They are expressed on many different cell 
types including monocytes, macrophages, T cells and DCs. Chemokines are 
usually promiscuous, binding to more than one receptor, and each receptor 
tends to have more than one chemokine ligand. This makes the chemokine 
system highly complex (Zlotnik et al., 2006). The majority of chemokine 
receptors are involved in cell migration but a subset of atypical chemokine 
receptors (ACKRs) do not signal through G proteins and have a role in chemokine 
scavenging (Bonecchi and Graham, 2016). These are ACKR1, ACKR2, ACKR3 and 
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ACKR4. ACKR1 has been shown to regulate neutrophil recruitment whilst ACKR2 
has a role in regulating lymphangiogenesis (Lee et al., 2014; Zarbock et al., 
2007). ACKR3 binds to CXCL11 and CXCL12 and is important in cardiac 
development as ACKR3 deficiency in mice is lethal due to heart defects (Sierro 
et al., 2007). ACKR4 binds to the homeostatic chemokines CCL19 and CCL21 and 
is important for establishing gradients of these chemokines in lymph nodes 
(Ulvmar et al., 2014). 
Chemokine 
receptor 
Ligands 
CCR Subfamily  
CCR1 CCL3, CCL3L1, CCL5, CCL7, CCL8, CCL13, CCL14, CCL15, 
CCL16, CCL23 
CCR2 CCL2, CCL7, CCL8, CCL13, CCL16, β-defensin 2, 3 
CCR3 CCL3L1, CCL5, CCL7, CCL11, CCL13, CCL14, CCL15, 
CCL24, CCL26, CCL28 
CCR4 CCL17, CCL22 
CCR5 CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL8, CCL11, CCL16 
CCR6 CCL20, β-defensin 2 
CCR7 CCL19, CCL21 
CCR8 CCL1 
CCR9 CCL25 
CCR10 CCL27, CCL28 
CXCR Subfamily  
CXCR1 CXCL6, CXCL7, CXCL8, acPGP 
CXCR2 CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, 
acPGP, MIF 
CXCR3 CXCL4, CXCL9, CXCL10, CXCL11, CXCL14 
CXCR4 CXCL12, MIF, ubiquitin 
CXCR5 CXCL13 
CXCR6 CXCL16 
XCR Subfamily  
XCR1 XCL1, XCL2 
CX3CR Subfamily  
CX3CR1 CX3CL1 
ACKR Subfamily  
ACKR1 CCL2, CCL5, CCL11, CCL13, CCL14, CCL17, CXCL1, CXCL2, 
CXCL3, CXCL7, CXCL8 
ACKR2 CCL2, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL7, CCL8, 
CCL11, CCL12, CCL13, CCL14, CCL17, CCL22, CCL23, 
CCL24 
ACKR3 CXCL11, CXCL12 
ACKR4 CCL19, CCL21, CCL25, CXCL13 
ACKR5 CCL19, chemerin 
Table 1-1. Chemokine receptors and ligands in humans 
The chemokine receptors identified in humans and the ligands that bind to the receptors (Zlotnik 
and Yoshie, 2012). 
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1.3.1 Chemokine receptor structure and signalling 
GPCRs consist of seven transmembrane helices linked by extracellular and 
intracellular loops. The extracellular N-terminus of chemokine receptors is 
involved in ligand binding and the intracellular C-terminus regulates signalling. A 
key modulator of chemokine signalling is the DRYLAIV motif in the second 
intracellular loop which is lacking in ACKRs (Nibbs and Graham, 2013; Nomiyama 
and Yoshie, 2015). GPCRs are coupled to heterotrimeric G proteins (βγ) and in 
the inactive state, the  subunit is coupled to GDP. Upon ligand binding, GDP is 
displaced by GTP, leading to dissociation between the - and βγ-subunits which 
then activate downstream signalling pathways. During resolution of the 
response, the C-terminal tail is phosphorylated, leading to β-arrestin 
recruitment. This prevents interaction of the receptor and the G protein and 
results in receptor internalisation (Hanlon and Andrew, 2015). Chemokine 
receptors appear to form homodimers and heterodimers which may influence 
the downstream signalling pathways and affect chemokine function (Mellado et 
al., 2001). 
1.3.2 Inflammatory chemokine receptors 
Humans and mice have a cluster of genes for the inflammatory chemokine 
receptors CCR1, CCR2, CCR3 and CCR5 (collectively referred to from now on as 
iCCRs). This cluster is found on chromosome 9 and chromosome 3 in mice and 
humans, respectively (Figure 1-2). These receptors are important in 
orchestrating the inflammatory response to various stimuli (Dyer et al., 2019; Shi 
and Pamer, 2011). They are expressed on multiple cell types and expression 
pattern changes with different disease states and pathologies. These receptors 
share multiple ligands which has made understanding the role of these receptors 
challenging (Figure 1-3). 
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Figure 1-2. Physical map of iCCR gene cluster 
Gene position and orientation of CCR1, CCR2, CCR3 and CCR5 on chromosome 3 in humans and 
chromosome 9 in mice. 
1.3.2.1 CCR1 
The ligands for CCR1 include CCL3, CCL5, CCL7, CCL8, CCL14, CCL15, CCL16 and 
CCL23 and CCR1 has been reported to be expressed by several different cell 
types. These include T cells, B cells, DCs and neurons (Armas-González et al., 
2018; Coates et al., 2004; Llorián-Salvador et al., 2016; Mikolajczyk et al., 
2016). CCR1 is also expressed by immature monocyte-derived DCs and expression 
is downregulated as these cells mature (Gouwy et al., 2014). In the pathology of 
haemolytic uraemic syndrome (HUS), monocytes can express CCR1 and the level 
of CCR1 correlates with severity of renal dysfunction in HUS patients (Ramos et 
al., 2015). Basophils can express CCR1 and this increases in patients with 
systemic lupus erythematosus (SLE) (Pan et al., 2017). The ligands for CCR1, 
CCL3 and CCL5, increase in the kidney after ischaemia-reperfusion injury 
(Furuichi et al., 2008). 
1.3.2.2 CCR2 
CCR2 binds to ligands including CCL2, CCL7 and CCL8 and is expressed by 
monocytes and macrophages. CCR2 is required for the migration of monocytes 
from the bone marrow to the blood and then from the blood to inflamed tissues 
(Dyer et al., 2019; Tsou et al., 2007). CCR2 is also expressed on HSCs and 
haematopoietic progenitor cells (HPCs) and mediates the migration of these cells 
to sites of inflammation (Si et al., 2010). NK cells can express CCR2 which 
correlates with the tumour killing activity of these cells (Hansell et al., 2018). 
CCR1 CCR3 CCR2 CCR5 
Human 
(Chr.3) 
Ccr1 Ccr3 Ccr2 Ccr5 
Mouse 
(Chr.9) 
170 kb 
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CCR2 has been demonstrated to have a role in several cancers. For example, 
CCR2 is expressed in the tumours of patients with renal cell carcinoma and this 
expression correlates with survival time (Wang et al., 2016). As well as this, 
CCR2+ macrophages are found in the tumours of lung cancer patients and CCR2 
antagonism reduces tumour burden and metastasis in a mouse model of lung 
cancer (Schmall et al., 2015). 
1.3.2.3 CCR3 
CCR3 is expressed on eosinophils, mast cells, basophils and some T cells 
(Brightling et al., 2005b; Danilova et al., 2015; Hausmann et al., 2011). The 
ligands for CCR3 include CCL11, CCL24, CCL26, CCL5, CCL7, CCL8 and CCL13. 
This receptor has been implicated in asthma and atopic dermatitis (AD). Airway 
smooth muscle cells (ASMCs) and airway epithelial cells can express CCR3 and 
ASMC CCR3 expression is greater in asthmatic patients than healthy controls 
(Joubert et al., 2005; Stellato et al., 2001). CCR3 expression has also been 
reported in keratinocytes and dermal fibroblasts and epidermal CCR3 expression 
is higher in AD lesions than non-lesional areas or healthy controls (Gaspar et al., 
2013; Wakugawa et al., 2001). An increase in CCR3 expression has also been 
reported in synovial cells of rheumatoid arthritis (RA) patients (Liu et al., 2017). 
1.3.2.4 CCR5 
CCR5 is expressed on monocytes, macrophages, NK cells and T cells and binds to 
ligands including CCL3, CCL4 and CCL5. Expression of CCR5 increases as 
monocytes mature into monocyte-derived macrophages (Fox et al., 2015; Lima 
et al., 2015). CCR5 is most widely studied in the context of HIV infection as it is 
a coreceptor for viral entry into target cells (Deng et al., 1996) but it has also 
been implicated in pulmonary arterial hypertension (PAH) and cancer. CCR5 
expression increases in the lungs of PAH patients and is found on smooth muscle 
cells and endothelial cells (ECs) (Amsellem et al., 2014). In skin squamous cell 
carcinoma, Tregs express CCR5 which directs these cells to the tumour. CCR5 
deficiency reduces the number of Tregs in the tumour which results in increased 
anti-tumour activity of CD8+ T cells (de Oliveira et al., 2017). CCR5 has also 
been reported to be expressed by osteoclasts and to regulate osteoclast function 
(Lee et al., 2017). 
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Figure 1-3. iCCR and chemokine interactions 
CCR1, CCR2, CCR3 and CCR5 bind to multiple CC chemokines whilst the majority of these 
chemokines also bind to more than one iCCR, resulting in a highly complex system. 
1.4 Evolution of chemokines and chemokine receptors 
Chemokine receptors originated at the time vertebrates first evolved. These 
receptors can be classed into two phylogenetic groups. One group binds mainly 
homeostatic chemokines and appeared first, in jawless fish, while the other 
group mainly binds inflammatory chemokines and appeared later in jawed 
vertebrates (Nomiyama et al., 2011). It is likely that these genes evolved as 
complex vertebrate systems that increased exposure to pathogens developed, 
such as blood based oxygen transport, and a more complex immune response 
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was required. It may also suggest a role for chemokines and cell migration in the 
development of these systems. The number of receptors and chemokines varies 
widely between species. For example the zebrafish has 24 receptor genes and 63 
chemokine genes whilst chickens have only 14 receptor genes and 23 chemokine 
genes (DeVries et al., 2006). This could reflect a difference in exposure to 
certain pathogens. Only mammals have the cluster containing the genes for the 
iCCRs. 
Chemokine genes are mainly found in clusters, for example most human CC 
chemokine genes are part of two major clusters on chromosome 17 (Naruse et 
al., 1996). This is likely a result of tandem gene duplication where genes are 
copied and then independently evolve. Genes that do not appear in a cluster are 
more conserved between species and tend to have only one receptor. These are 
often genes for homeostatic chemokines (Zlotnik et al., 2006). 
1.5 Non-immune roles of chemokines and receptors 
Several chemokines and their receptors have been shown to have a role outside 
of orchestrating an immune or inflammatory response. For example, the ligand 
receptor pair CXCL12/CXCR4 is involved in development of the brain. These are 
both expressed in the embryonic nervous system and mice without functional 
CXCR4 have impaired hippocampal development (Lu et al., 2002; Tissir et al., 
2004). More recently, a role for chemokine receptors in postnatal development 
has been demonstrated. The atypical chemokine receptor ACKR2 regulates 
epithelial branching in mammary gland development (Wilson et al., 2017). The 
receptor CCR8 can be expressed by vascular smooth muscle cells (VSMCs) and 
mediates chemotaxis of these cells (Haque et al., 2004). Many CXC chemokines 
are involved in regulating angiogenesis and therefore may be important in 
embryonic development and wound healing but also some pathologies like 
tumorigenesis. CXC chemokines with the ELR motif such as CXCL1, CXCL2, CXCL3 
and CXCL5 are pro-angiogenic whilst those without, such as CXCL4, CXCL9, 
CXCL10 and CXCL11, are angiostatic (Dimberg, 2010). A balance of both types of 
chemokine may be important for appropriate wound healing and angiogenesis in 
cancer. 
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1.6 Chemokine receptors in disease 
Chemokine receptors have been implicated in many disease states. They 
mediate the migration of leukocytes to inflammatory sites in various 
inflammatory diseases such as psoriasis and asthma (Koelink et al., 2012). They 
also play a role in cancer, which can be defensive or promote the disease, and 
are involved in the pathogenesis of HIV (Nagarsheth et al., 2017; Wang et al., 
2017). 
1.6.1 Inflammatory diseases 
Inflammatory diseases are characterised by infiltration of immune cells into 
various tissues which is mediated by chemokine receptors. In asthma, eosinophils 
and mast cells are activated in the lungs. Mast cell migration to the lungs is 
regulated by CCR1, CCR3, CXCR1 and CXCR3 whilst eosinophils are regulated by 
CCR3. CXCR3, CCR3 and CCL11, the ligand for CCR3, are increased in bronchial 
biopsies from asthma patients (Brightling et al., 2005a; Koelink et al., 2012; Ying 
et al., 1997). Chronic obstructive pulmonary disease (COPD) is another disease 
involving lung inflammation. In COPD, CCR2 and CXCR2 mediate monocyte and 
neutrophil recruitment to the lungs, respectively. CXCR2 is increased in 
bronchial biopsies of COPD patients (Donnelly and Barnes, 2006; Qiu et al., 
2003). 
RA is characterised by chronic inflammation of the joints in the hands and feet. 
CXCR3 has been implicated in RA as blocking CXCR3 can reduce T cell infiltration 
into the inflamed joints and disease severity of arthritic mice. CCR1 and CCR5 
are also expressed in the synovial tissue of RA patients, suggesting accumulation 
of CCR1+ and CCR5+ immune cells (Haringman et al., 2006; Mohan and Issekutz, 
2014). The inflammatory skin disease psoriasis involves T cell infiltration, 
mediated by CCR4, CCR10 and CXCR3, as well as neutrophil recruitment via 
CXCR2. CXCR2 and CXCR3 are elevated in psoriatic lesions (Chen et al., 2010; 
Koelink et al., 2012; Kulke et al., 1998). CXCR2 is also implicated in 
inflammatory bowel disease (IBD). Antibodies against CXCR2 can inhibit 
intestinal inflammation in mouse IBD models (Farooq et al., 2009). 
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1.6.2 Cancer 
Chemokines can be expressed by tumour and stromal cells. Chemokine and 
chemokine receptor signalling can drive anti-tumour immunity but has also been 
widely reported to promote tumour survival and metastasis. The effect of 
chemokine receptor signalling depends on the cancer type and the chemokines 
involved (Nagarsheth et al., 2017). CD8+ T cell infiltration into a tumour is 
associated with decreased metastasis and increased survival in colon and ovarian 
cancer. This infiltration can be mediated by CXCR3 and CXCL9 and CXCL10 
(Nagarsheth et al., 2017; Pagès et al., 2005; Sato et al., 2005). CCR2 is involved 
in the recruitment of tumour associated macrophages (TAMs) and CCL2 
correlates with the number of TAMs and poor prognosis in some cancers. TAMs 
promote tumour progression and metastasis and may inhibit T cell activation 
(Nagarsheth et al., 2017; Wan et al., 2014). 
Tumour cells can also express chemokine receptors which can be associated with 
severity of the cancer. CCR2 is upregulated in breast cancer and interaction with 
CCL2 promotes cancer cell migration and survival (Fang et al., 2012). CCR9 is 
expressed by ovarian cancer cells. CCL25-CCR9 signalling can prevent apoptosis 
of these cells in response to chemotherapy (Johnson et al., 2010). Expression of 
CXCR1 in pancreatic duct adenocarcinoma and CXCR4 in prostate cancer 
correlates with metastasis. CXCR4 antibodies in prostate cancer may inhibit 
tumour growth and vascularisation (Chen et al., 2014; Darash-Yahana et al., 
2004). 
1.6.3 HIV 
The chemokine receptors CCR5 and CXCR4 are co-receptors for the infection of 
CD4+ T cells by HIV. A 32 base pair deletion of the CCR5 gene (CCR5Δ32) confers 
resistance to HIV infection (Dean et al., 1996; Deng et al., 1996; Wang et al., 
2017). CXCL10 is elevated in HIV infection and is associated with disease 
progression. It has been suggested that CXCR3+ T cells are recruited to the HIV-
infected lymph node via CXCL10 where they are retained, disrupting the 
peripheral T cell response and aiding infection between T cells (Foley et al., 
2014; Jiao et al., 2012). CCR6+ T cells are also susceptible to HIV infection and 
CCR6 may be a weaker co-receptor for HIV in vitro (Islam et al., 2013). 
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1.6.4 Targeting chemokine receptors 
There is a lot of evidence for a role for chemokine receptors in many disease 
states, making them potential therapeutic targets. GPCRs are the most common 
pharmacological targets but there has been very limited success in developing 
drugs that target chemokine receptors. One reason for this is the complexity of 
the chemokine system as well as a limited understanding of the function of 
chemokines in distinct receptor and cell contexts (Solari et al., 2015). As well as 
this, GPCRs with multiple ligands can show signalling bias which needs to be 
further understood in order to develop better drugs (Liu et al., 2012). There 
have only been three drugs that target chemokine receptors that have made it 
to market. Maraviroc, a CCR5 antagonist, is used to treat HIV and the CXCR4 
antagonist Plerixafor is used to treat cancer patients as it mobilises stem cells 
from the bone marrow to the blood (Dorr et al., 2005; Teusink et al., 2016). 
More recently Mogamulizumab, a monoclonal antibody to CCR4, has been used to 
treat certain types of cutaneous T cell lymphoma (Duvic et al., 2015). 
1.7 Mice used to study iCCRs 
To improve understanding of iCCRs, unique mouse strains have been developed. 
These mice can be used to identify the individual, combinatorial and redundant 
roles of iCCRs in various contexts which will hopefully aid the development of 
drugs that target iCCRs. 
1.7.1 iCCR-KO mice 
iCCR-KO mice are deficient for the gene cluster on chromosome 9 containing the 
genes for CCR1, CCR2, CCR3 and CCR5. These mice show no overt developmental 
abnormalities and can be used alongside individual receptor KO mice to 
determine the roles of the iCCRs (Dyer et al., 2019). These are particularly 
useful as only single receptor deficient mice have been generated so far, due to 
the close proximity of the iCCR genes. 
1.7.2 iCCR reporter mice 
iCCR reporter (REP) mice have been generated using a bacterial artificial 
chromosome (BAC) in which genes for fluorescent reporter proteins are under 
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control of the promoters for each of the iCCR genes. Therefore, cells that 
express a particular iCCR can be detected by the reporter protein, enabling 
individual and combinatorial iCCR expression to be determined in a temporal and 
spatial manner. 
1.8 The cardiovascular system and cardiovascular 
diseases 
The cardiovascular system consists of the heart, arteries, veins and capillaries 
and functions to deliver blood to tissues. Blood vessels are comprised of three 
layers. These are a thin inner intima layer of ECs, a medial layer consisting of 
VSMCs and an outer adventitia layer made up mostly of fibroblasts (McCurley and 
Jaffe, 2012). Cardiovascular diseases (CVDs) are a class of diseases that involve 
the cardiovascular system and are a leading cause of morbidity and mortality 
(Benjamin et al., 2019). These include atherosclerosis, hypertension, PAH, 
myocardial infarction (MI), cardiomyopathy and stroke. Atherosclerosis is the 
narrowing of an artery due to the build up of lipid in the arterial wall and 
formation of a fibrous plaque. If the plaque ruptures, a blood clot forms which 
can cause a blockage to an artery. If this occurs in the coronary artery it can 
result in MI, or a stroke if the blockage occurs in the brain (Bergheanu et al., 
2017). 
1.9 Hypertension and blood pressure regulation 
Hypertension is when blood pressure (BP) is elevated above 140/90 mmHg. This 
is a risk factor for atherosclerosis, and therefore MI and stroke, as well as 
aneurysms, cardiomyopathy and kidney disease (Kannel, 1996; Lip et al., 2000; 
Mennuni et al., 2014; Wong et al., 2007). Most cases of hypertension have an 
unknown cause. These are classed as essential hypertension and are thought to 
have multiple genetic and environmental factors contributing to the disease 
(Tanira and Al Balushi, 2005). There are several systems in place that regulate 
BP which can be altered in hypertension but also represent targets to lower BP. 
Despite current treatments, BP remains uncontrolled in about a third of 
hypertensive patients (Hales et al., 2017), showing a need for new treatments 
that lower BP or prevent end organ damage. 
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1.9.1 The renin-angiotensin system  
The renin-angiotensin system (RAS) is a key regulator of BP but also has a role in 
the pathogenesis of CVD (Figure 1-4). The RAS is initiated by the kidneys which 
release renin into the blood when a reduction in BP is detected. Renin is an 
enzyme which cleaves circulating angiotensinogen to the decapeptide 
angiotensin (Ang) I. This is then further cleaved to the octapeptide Ang II by 
angiotensin converting enzyme (ACE). Ang II causes an increase in BP by various 
mechanisms and binds to the GPCRs, angiotensin type 1 (AT1) or type 2 (AT2) 
receptors. In the adrenal glands, Ang II acts on the AT1 receptor which results in 
the release of aldosterone. Aldosterone is a steroid hormone that binds to the 
mineralocorticoid receptor (MR). MR activation in the kidney nephrons leads to 
increased activation of the epithelial sodium channel (ENaC). This results in an 
increase in sodium retention, followed by retention of water, and an increase in 
BP (Soundararajan et al., 2010; Sparks et al., 2014). Ang II also acts on the 
vasculature via the AT1 receptor, regulating vasoconstriction as well as 
migration and proliferation of VSMCs (Benigni et al., 2010; Lee et al., 2018; 
Wang et al., 2017). It is thought that the AT2 receptor acts to antagonise the 
functions of the AT1 receptor, mediating vasodilation (Benigni et al., 2010). Ang 
II also induces vascular inflammation and is involved in vascular fibrosis, both of 
which are associated with hypertension induced end organ damage (Carver et 
al., 2015; Piqueras et al., 2000). 
There is a counter-regulatory axis to the RAS, mediated by angiotensin 
converting enzyme 2 (ACE2). This enzyme cleaves the C-terminal amino acids 
from Ang I and Ang II to form Ang-(1-9) and Ang-(1-7), respectively. Ang-(1-7) 
acts on the Mas receptor to inhibit the proliferative and migrative effects 
mediated by Ang II and can also bind to the AT2 receptor (McKinney et al., 
2014). Ang-(1-7) can inhibit the vascular fibrosis induced by Ang II (Carver et al., 
2015). 
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Figure 1-4. The renin angiotensin system 
Circulating angiotensinogen is converted to Ang I by renin which is cleaved to Ang II by ACE. Ang 
II mediates BP increasing effects via the AT1 receptor and BP lowering effects via the AT2 
receptor. ACE2 converts Ang I to Ang-(1-9) and Ang II to Ang-(1-7) in the counter regulatory RAS 
axis in which Ang-(1-7) mediates BP lowering and cardioprotective effects via the Mas and AT2 
receptors. 
1.9.2 Atrial natriuretic peptide 
Atrial natriuretic peptide (ANP) is a 28 amino acid peptide that induces BP 
lowering effects and is secreted by the heart in response to increased atrial 
tension. ANP binds to the natriuretic peptide receptors (NPR) NPR-A, NPR-B and 
NPR-C which are expressed in the kidney, heart, brain and vasculature (Wong et 
al., 2017). In the kidney, ANP can reduce sodium reabsorption and increase urine 
production as well as inhibit the release of renin (Kurtz et al., 1986; Stevens et 
al., 1994; Wong et al., 2017). In the vasculature, ANP stimulates the production 
of nitric oxide (NO) which induces VSMC relaxation (Elesgaray et al., 2008). ANP 
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can also regulate the sympathetic nervous system, inducing vasodilation (Wong 
et al., 2017). 
1.9.3 The sympathetic nervous system 
Sympathetic neurons innervate the heart, blood vessels, kidneys and adrenal 
medulla, all of which contribute to BP regulation. The combination of vascular 
resistance and cardiac output affect BP, as does renal sodium excretion. These 
can all be regulated by the sympathetic nervous system (Guyenet, 2006). Some 
cases of hypertension are associated with elevated sympathetic nerve activity 
(Schlaich et al., 2003) and animal models have been used to demonstrate a role 
of sympathetic nerve activity in arterial pressure control. In the hypothalamus, 
the melanocortin receptor types 3 and 4 (MC3/4-R) are involved in BP 
regulation. Chronic MC3/4-R activation in rats increases arterial pressure whilst 
blockade of MC3/4-R lowers BP in spontaneously hypertensive rats (SHRs) (Da 
Silva et al., 2008; Kuo et al., 2003). In addition, both renal denervation and 
adrenergic blockade reduce arterial pressure in a hyperandrogenemic female rat 
model (Maranon et al., 2015). 
1.9.4 Perivascular adipose tissue 
Perivascular adipose tissue (PVAT) surrounds the outer adventitia layer of blood 
vessels and is comprised of adipocytes and immune cells. PVAT is a regulator of 
vascular function and BP by releasing paracrine factors that act on the blood 
vessel. These can be relaxing factors or contractile factors (Ramirez et al., 
2017). Relaxing factors include adiponectin, Ang-(1-7), hydrogen peroxide and 
hydrogen sulphide and can mediate the relaxation response through NO release, 
potassium channel modulation or cGMP generation (Deng et al., 2010; Gao et 
al., 2007; Lee et al., 2009; Ramirez et al., 2017; Schleifenbaum et al., 2010). 
Production of chemerin and superoxide by PVAT have been shown to induce a 
contractile response, along with certain cytokines such as TNF- (Gao et al., 
2006; Virdis et al., 2015; Watts et al., 2013). PVAT also expresses components of 
the RAS (Gálvez-Prieto et al., 2008). Inflammation of PVAT can result in 
dysregulation of vascular function and is associated with obesity, hypertension 
and atherosclerosis (Ramirez et al., 2017). 
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1.9.5 Vascular function and oxidative stress 
Vascular function involves the role of the endothelium in modulating vascular 
tone as well as the role of ECs in coagulation, angiogenesis and platelet 
adhesion. ECs release relaxing factors such as NO and prostaglandins and 
endothelial dysfunction occurs when endothelium-dependent relaxation is 
impaired (Frey et al., 2008; Godo and Shimokawa, 2017). This is associated with 
reduced NO bioavailability or reduced NO production by endothelial NO synthase 
(eNOS). Oxidative stress contributes to endothelial dysfunction as superoxide, 
derived from NADPH oxidase, reacts with NO to form peroxynitrite, reducing NO 
bioavailability (Frey et al., 2008; La Favor et al., 2016; Mordi et al., 2016). 
Endothelial dysfunction is associated with hypertension, atherosclerosis and 
obesity (Guzik et al., 2000; La Favor et al., 2016; Panza et al., 1994). 
1.9.6 Current treatments of hypertension 
There are five classes of antihypertensive agents. These are thiazide diuretics, 
beta-blockers, ACE inhibitors, Ang II receptor blockers (ARBs) and calcium 
channel blockers. Thiazide diuretics inhibit kidney sodium reabsorption through 
inhibition of the electroneutral sodium chloride cotransporter and have also 
been suggested to induce vasodilation. Adverse effects of thiazide diuretics 
include hyponatraemia, hypokalaemia and hypovolaemia (Blowey, 2016; 
Laurent, 2017). Beta-blockers target beta-adrenergic receptors and lower BP by 
reducing cardiac output and possibly reducing sympathetic activity. Some beta-
blockers are non-vasodilating, such as atenolol and metoprolol, whilst others like 
nebivolol can induce vasodilation. Beta-blockers can induce adverse effects such 
as hallucinations, insomnia and depression (Laurent, 2017). ACE inhibitors 
reduce the production of circulating and tissue Ang II, preventing the Ang II 
mediated mechanisms that increase BP. ACE inhibitors have also been shown to 
reduce arterial stiffness but have a few reported adverse effects, the main one 
being cough (Laurent, 2017; Law et al., 2003; Tropeano et al., 2006). ARBs 
antagonise the AT1 receptor, preventing the effects of Ang II. These drugs have 
similar efficacy to ACE inhibitors but do not produce adverse effects (Schmidt et 
al., 2004). Calcium channel blockers are vasodilatory drugs and classed as 
dihydropyridines (DHPs) and non-DHPs. DHPs block L-type calcium channels, 
inhibiting depolarisation of VSMCs and cardiomyocytes. Calcium channel blockers 
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can induce headaches, hypotension and pedal oedema (Eisenberg et al., 2004; 
Laurent, 2017). Often these treatments are combined and it has been shown 
that combining low dose drug treatments can increase efficacy and reduce 
adverse effects (Law et al., 2003). 
1.9.7 Models of hypertension 
Animal models of diseases enable the study of disease development as well as 
screening of therapeutics. Several models have been used to study hypertension. 
and these can be genetic models or based on endocrine or diet factors. The SHR 
is an inbred rat strain that has multiple genetic pathways contributing to the 
disease. Details of these genes are still to be elucidated, similar to human 
essential hypertension (Doris, 2017). SHRs develop hypertension at the age of 4-6 
weeks and this can be influenced by environmental factors. SHRs have been 
shown to develop renal inflammation and oxidative stress, suggesting they can 
be used to study end organ damage, as well as hypertension development 
(Dornas and Silva, 2011; Durante et al., 2010). Dahl salt-sensitive rats are 
another genetic model of hypertension that develop the disease with a high salt 
diet. These rats have reduced urinary sodium excretion and increased urinary 
potassium excretion (Jo et al., 2017). They are also prone to glomerulosclerosis, 
possibly due to podocyte injury (Nagase et al., 2006). The deoxycorticosterone 
acetate (DOCA)-salt rodent model of hypertension involves the administration of 
DOCA and a high salt diet and is sometimes combined with a uninephrectomy. 
DOCA increases sodium reabsorption in the kidney, leading to hypervolemia, 
whilst the high salt diet increases the onset of hypertension (Basting and 
Lazartigues, 2017). Nω-nitro-L-arginine methyl ester (L-NAME) is an eNOS 
inhibitor, administered to rodents to induce hypertension. This results in 
increased vasoconstriction and the development of glomerulosclerosis and 
cardiac hypertrophy (Dornas and Silva, 2011; Francois et al., 2008). 
Administration of Ang II is another rodent model of hypertension, resulting in 
increased BP, endothelial dysfunction and vascular oxidative stress (Mikolajczyk 
et al., 2016). Other hypertensive models include induction by environmental 
stress or neurogenic hypertension, such as denervation of sinoaortic 
baroreceptors (Dornas and Silva, 2011). 
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1.10 The immune system in hypertension 
There is a lot of evidence for a role of the immune system in hypertension and 
end organ damage. Leukocytes have been shown to infiltrate the kidneys and 
vasculature of hypertensive patients and animal models (Moore et al., 2015; 
Ozawa et al., 2006; Youn et al., 2013). Mice and rats lacking recombination 
activating gene 1 (Rag-1) have reduced T and B cell numbers and these have an 
attenuated hypertensive response to Ang II, DOCA or a high salt diet (Guzik et 
al., 2007; Mattson et al., 2013). Immunosuppressive treatments have been 
shown to reduce BP in animal models of hypertension. For example, 
mycophenolate mofetil (MMF) reduces BP, renal lymphocyte infiltration and 
renal oxidative stress in SHRs (Rodríguez-Iturbe et al., 2015). Immunosuppression 
with dexamethasone does not reduce BP but reduces renal macrophage and T 
cell infiltration (Muller et al., 2011). Targeting the immune system represents a 
possible strategy to treat hypertension. Patients with psoriasis or RA were 
treated with MMF and this was associated with reduced systolic and diastolic BP 
(Herrera et al., 2006). However, highly active antiretroviral therapy for HIV 
patients was associated with increased prevalence of hypertension (Seaberg et 
al., 2005). An improved understanding of the role of the immune system in 
hypertension is required to develop hypertensive treatments that target the 
immune system. 
1.10.1 Monocytes and macrophages 
Monocytes and macrophages have been reported to accumulate in the aorta, 
mesenteric arteries, PVAT, kidney and heart in various models of hypertension 
and are likely to contribute to end organ damage (Mikolajczyk et al., 2016; 
Moore et al., 2015; Ozawa et al., 2006; Thang et al., 2015; Wang et al., 2017). 
Depleting macrophages with clodronate liposomes in mice with DOCA-salt 
induced hypertension results in lower BP and reduced superoxide in mesenteric 
arteries compared to control DOCA-salt mice (Thang et al., 2015). A similar 
effect is seen in mice with Ang II induced hypertension and depletion of LysM+ 
monocytes. LysM+ monocyte depletion also attenuates endothelial dysfunction 
which is restored, along with an increase in BP, when mice are reconstituted 
with monocytes (Wenzel et al., 2011). Op/Op mice, which have reduced 
macrophage numbers, also respond to Ang II with a lower BP and reduced 
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endothelial dysfunction, superoxide and NADPH oxidase activation compared to 
WT mice. These mice also do not show accumulation of macrophages in the 
mesenteric arteries after Ang II treatment (De Ciuceis et al., 2005). Together 
these studies suggest that macrophages accumulate in the vasculature and 
modulate vascular function. This could be through NADPH oxidase activity and 
superoxide production. Macrophages from DOCA-salt treated mice express higher 
levels of the NADPH oxidase subunit p22phox than control normotensive mice 
(Thang et al., 2015). It has also been suggested that an increase in Ly6Chi 
monocytes in the aorta following Ang II treatment impairs eNOS function 
(Kossmann et al., 2014). Contrary to these studies, clodronate liposome 
depletion of macrophages in rats on a high salt diet increased BP compared to 
control rats (Machnik et al., 2009). This could be due to differences between 
salt and Ang II induced hypertension.  
Macrophages that accumulate in the heart are thought to regulate cardiac 
remodelling. Rats given a splenectomy prior to Ang II treatment had fewer 
macrophages in the heart than control rats and this was associated with reduced 
cardiac fibrosis. Rats that had undergone a splenectomy also responded to Ang II 
with an increase in BP, but this was not as high as the rats that did not have a 
splenectomy (Wang et al., 2017). As macrophages accumulate in the kidney in 
hypertension, it is possible they mediate kidney fibrosis and collagen deposition 
observed in hypertensive mice (Xiao et al., 2015). 
1.10.2 Dendritic Cells 
DCs have been implicated in hypertension as they activate T cells. The 
interaction of T cell CD28 and B7 ligands on DCs is required for activation. 
Blocking this interaction with CTLA4-Ig attenuates both Ang II and DOCA-salt 
induced hypertension (Vinh et al., 2010). This effect is also seen in B7-/- mice 
treated with Ang II whilst reconstituting B7-/- mice with WT bone marrow 
restores the response to Ang II (Vinh et al., 2010). Ang II increases the 
production of superoxide from DCs as well as the production of IL-6, IL-1β and 
IL-23 from splenic DCs (Kirabo et al., 2014). DCs accumulate isoketal protein 
adducts, a product of oxidative stress, in Ang II and DOCA-salt induced 
hypertension. It has been suggested that these DCs regulate hypertension, as 
treatment with the isoketal scavenger 2-HOBA prevents isoketal protein adduct 
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accumulation and reduces BP (Kirabo et al., 2014). DCs from hypertensive mice 
can support the proliferation and survival of T cells but DCs from normotensive 
mice do not. In addition, transfer of DCs from hypertensive, but not 
normotensive mice, to WT mice induces susceptibility to a low dose of Ang II 
that would not normally elicit a hypertensive response. This is not seen when 
the DCs are transferred to Rag-1-/- mice, suggesting that T cells are required for 
DC priming of hypertension (Kirabo et al., 2014). Expression of CD80 and CD86 by 
DCs increases with Ang II induced hypertension, showing activation of DCs. This 
is prevented, along with a blunted hypertensive response and reduced DC 
isoketal protein adduct accumulation, in mice subject to renal denervation (Xiao 
et al., 2015). Recently, a study has indicated that DCs could have a more 
essential role in hypertension as ablation of CD11c+ APCs, which includes DCs, 
prevents an increase in BP and cardiac hypertrophy following Ang II and salt 
treatment. Adoptive transfer of CD11c+ APCs to these mice restores the 
hypertensive response and it has been suggested that these effects are mediated 
through altered sodium excretion (Hevia et al., 2018). DCs have also been shown 
to increase in the PVAT of Ang II treated mice (Mikolajczyk et al., 2016). 
1.10.3 NK cells 
NK cells accumulate in the aorta and mesenteric arteries of hypertensive mice 
(Kossmann et al., 2013; Taherzadeh et al., 2010). Depletion of NK cells in Ang II 
treated mice can attenuate the Ang II induced vascular dysfunction (Kossmann et 
al., 2013). C57BL/6 mice are more susceptible to L-NAME induced hypertension 
than BALB/c mice and NK cells only accumulate in the arteries of C57BL/6 mice 
after L-NAME treatment, not BALB/c mice. This could be mediated by the NK 
gene complex as BALB/c mice expressing the C57BL/6 NK gene complex show a 
similar hypertensive response to L-NAME as C57BL/6 mice (Taherzadeh et al., 
2010). 
1.10.4 Neutrophils 
Depletion of neutrophils attenuates the increase in BP that occurs in the reduced 
utero-placental perfusion pressure and Sabra hypertension prone rat models of 
hypertension (Mazor et al., 2007; Regal et al., 2015). The number of neutrophils 
has also been shown to increase in the aortas of Ang II treated mice (Wenzel et 
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al., 2011). Neutrophils may contribute to hypertension through superoxide 
production. Neutrophils from pregnant women with hypertension produce more 
superoxide than neutrophils from healthy pregnant women (Tsukimori et al., 
2007). In addition, neutrophils from SHRs produce more superoxide than Wistar 
Kyoto rat (WKY) controls. However, this is not seen in the L-NAME or DOCA-salt 
models of hypertension (Ohmori et al., 2000). An elevated blood neutrophil to 
lymphocyte ratio correlates with risk of hypertension (Liu et al., 2015). 
1.10.5 T cells 
An increase in the number of circulating CD4+ and CD8+ T cells has been 
reported in hypertensive patients compared to normotensive controls and these 
T cells produce more IL-17A, IFNγ and TNF (Itani et al., 2016). T cells also 
accumulate in the kidneys and aortas of hypertensive mice (Guzik et al., 2007; 
Itani et al., 2016; Krebs et al., 2014). Rag-1-/- mice, which have a blunted 
hypertensive response to Ang II, undergo an increase in BP, vascular oxidative 
stress and endothelial dysfunction after the adoptive transfer of T cells. This 
suggests that T cells are required for Ang II induced hypertension (Guzik et al., 
2007). Further studies showed that adoptive transfer of CD8+ T cells, but not 
CD4+ T cells, to Rag-1-/- mice restores the blunted response to Ang II and that 
CD8-/- mice also have an attenuated response to Ang II (Trott et al., 2014). 
CD247-/- rats have a reduced number of T cells. When given a high salt diet, BP 
of CD247-/- rats is lower than CD247+/+ rats and they also have reduced renal 
damage (Rudemiller et al., 2014). 
Th17 cells may augment hypertension as circulating Th17 cells increase following 
Ang II treatment, along with kidney Th17 cell infiltration and production of IL-17 
by T cells. IL-17-/- mice also have lower BP and improved vascular function 
compared to WT mice when treated with Ang II. However, IL-17-/- mice have 
worse renal damage when hypertension is induced by DOCA and Ang II (Krebs et 
al., 2014; Madhur et al., 2010). Treg cells could be protective in hypertension. 
Adoptive transfer of Tregs to Ang II treated WT mice prevents an increase in 
systolic BP, endothelial dysfunction and aortic oxidative stress whilst adoptive 
transfer of Treg-deficient T cells to hypertensive Rag-1-/- mice exaggerates 
endothelial dysfunction and oxidative stress (Barhoumi et al., 2011; Mian et al., 
2015). 
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1.10.6 B cells 
Fewer studies have focused on the role of B cells in hypertension but some 
recent studies have started to reveal how B cells may contribute to the disease. 
Hypertensive patients and animal models have elevated circulating IgG 
antibodies (Chan et al., 2015, 2014) and when perfusion pressure in the kidney is 
increased, B cells have been shown to accumulate in the kidney (Evans et al., 
2017). Mice with depleted B cells, through B cell-activating factor receptor 
(BAFF-R) deficiency or treatment with anti-CD20 antibody, have an attenuated 
response to Ang II whilst adoptive transfer of B cells to BAFF-R-/- mice restores 
the response to Ang II. BAFF-R-/- mice also do not show an increase in serum IgG 
or aortic macrophage accumulation after Ang II treatment (Chan et al., 2015). 
Recently c-mybh/h mice, which have reduced circulating and kidney B cells, have 
been shown to have reduced baseline BP and a reduced response to DOCA-salt 
induced hypertension. This could possibly be due to increased sodium excretion 
(Dingwell et al., 2019). SLE is an autoimmune disease associated with an 
increase in the prevalence of hypertension. The proteasome inhibitor 
Bortezomib reduces bone marrow plasma cells and plasma IgG in mice with SLE 
as well as reducing mean arterial pressure and renal injury, suggesting IgG 
antibodies may be involved in hypertension in SLE (Taylor et al., 2018). Several 
targets of antibodies in hypertension have been suggested. These are AT1 
receptor, alpha1-adrenergic receptor and beta1-adrenergic receptor, L-type 
voltage gated calcium channels and HSP-70 (Chan et al., 2014). 
1.10.7 Immune cell summary 
Many different immune cells have been implicated in hypertension. Depletion of 
monocytes, macrophages, T cells or B cells have been shown to be protective in 
models of hypertension (Chan et al., 2015; Guzik et al., 2007; Thang et al., 
2015; Wenzel et al., 2011). DCs also contribute to the disease, possibly through 
activation of T cells, whilst it has been suggested that NK cells regulate vascular 
dysfunction and neutrophils contribute to oxidative stress in hypertension 
(Kirabo et al., 2014; Kossmann et al., 2013; Tsukimori et al., 2007). 
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1.10.8 Cytokines 
Various cytokines have been implicated in hypertension. T cells from Ang II 
treated mice have increased production of TNF- and IFN-γ whilst production of 
IL-2, IL-4 and IL-5 does not change after Ang II treatment (Guzik et al., 2007). 
Treatment of hypertensive patients with the AT1 receptor blocker Losartan 
reduces production of IFN-γ by peripheral blood lymphocytes (Weidanz et al., 
2005). In a mouse model of Ang II induced hypertension, TNF- deficiency 
attenuates the hypertensive response to Ang II as well as cardiac hypertrophy 
and renal injury. This is possibly due to increased eNOS expression and NO 
bioavailability in the kidneys of TNF--/- mice. By contrast, IFN-γ deficiency does 
not affect BP or renal injury in this model (Zhang et al., 2014). However, IFN-γ-/- 
mice are protected from Ang II induced vascular dysfunction (Kossmann et al., 
2013). Mice lacking the IFN-γ receptor respond to Ang II with an increase in BP 
similar to WT mice but have reduced cardiac hypertrophy and renal injury 
(Markó et al., 2012). Treatment of Ang II infused mice with anti-IFN-γ antibody 
does not affect the response to Ang II but treatment with Etanercept, a soluble 
TNF- receptor, reduces vascular superoxide production (Guzik et al., 2007). 
Ang II increases the production of IL-17 by circulating T cells and IL-17-/- mice 
have a lower BP than WT mice after 4 weeks of Ang II infusion. IL-17-/- mice are 
also protected from Ang II induced vascular dysfunction and superoxide 
generation as well as aortic T cell infiltration (Madhur et al., 2010). However IL-
17-/- mice show increased renal injury and impaired renal function compared to 
WT mice when treated with Ang II and DOCA. When this model is used for 14 
days, IL-17-/- mice also have a similar BP to WT mice (Krebs et al., 2014). This 
suggests that IL-17 has different roles in different tissues and this is affected by 
the model of hypertension used. IL-23 is important for expansion of Th17 cells. 
Mice deficient for IL-23p19 also show increased renal injury compared to WT 
mice after Ang II and DOCA treatment (Krebs et al., 2014). Anti-IL-23 receptor or 
anti-IL-17A antibodies have no effect on BP in Ang II treated mice (Markó et al., 
2012). 
The proinflammatory cytokine IL-6 may regulate BP in hypertension. Anti-IL-6 
antibody attenuates the BP elevation induced by high salt diet in Dahl salt 
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sensitive rats and IL-6-/- mice do not respond to Ang II with increased BP (Brands 
et al., 2010; Hashmat et al., 2016). 
Overall, deficiency of the cytokines TNF-, IFN-γ, IL-17 or IL-6 may protect from 
an elevation in BP, inflammation or vascular dysfunction and oxidative stress in 
hypertension (Brands et al., 2010; Kossmann et al., 2013; Madhur et al., 2010; 
Zhang et al., 2014). This demonstrates an important role for the immune system 
in the disease. However, the roles of these cytokines may vary between models 
and tissues. 
1.11 Chemokines and chemokine receptors in 
hypertension 
As important regulators of immune cells, it is likely that chemokines contribute 
to the pathogenesis of hypertension. Several chemokines and chemokine 
receptors have been reported to be upregulated in the vasculature and kidneys 
of hypertensive animal models and it has been suggested that this can regulate 
BP and end organ damage (Mikolajczyk et al., 2016; Moore et al., 2015; Xia et 
al., 2013). Most research has focused on CC or CXC chemokines and receptors 
whilst no studies on XC chemokines in the context of hypertension have been 
carried out to date. 
1.11.1 CC chemokines and receptors 
The role of CCR2 and its ligand CCL2 has been widely studied in hypertension. 
Circulating CCL2 is elevated in recently diagnosed, untreated, hypertensive 
patients (Antonelli et al., 2012; Madej et al., 2005) and CCR2 expression 
increases in the aorta of both Ang II treated mice and DOCA/salt treated mice 
(Chan et al., 2012; Moore et al., 2015). CCR2 expression by circulating 
monocytes is also increased in SHRs, Ang II treated mice and L-NAME treated rats 
(Ishibashi et al., 2004). CCR2 deficiency does not have an effect on BP in Ang II 
induced hypertension (Ishibashi et al., 2004) although treatment with a CCR2 
inhibitor can affect BP. Mice given the CCR2 antagonist INCB3344 after Ang II or 
DOCA-salt treatment showed a reduction in BP and aortic macrophage 
accumulation (Chan et al., 2012; Moore et al., 2015). However, the CCR2 
antagonist RS102895 did not affect the BP of rats treated with Ang II and a high 
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salt diet and resulted in a higher BP than controls in a mouse model of 
renovascular hypertension. RS102895 can however reduce renal fibrosis and 
macrophage accumulation in hypertension (Elmarakby et al., 2007; Kashyap et 
al., 2015). Despite having no effect on BP, CCR2 deficiency is protective against 
Ang II induced vascular remodelling (Ishibashi et al., 2004). In renovascular 
hypertension, CCL2 deficiency has no effect on BP but CCL2 deficiency does 
prevent an increase in BP in response to DOCA-salt. CCL2-/- mice may also be 
protected from renal injury and cardiac inflammation in hypertension (Kashyap 
et al., 2018; Shen et al., 2014). 
CCR5 and its ligands may have a role in hypertension. The CCR5Δ32 mutation has 
been associated with increased prevalence of hypertension but some studies 
have also suggested that CCR5Δ32 is not associated with the disease (Mettimano 
et al., 2006; Zhang et al., 2006). Renal, aortic and cardiac expression of CCR5 
can increase in hypertension as well as renal expression of CCL3 and CCL5 (Chan 
et al., 2012; Krebs et al., 2012). CCR5 deficiency has no effect on BP elevation, 
renal function, injury and inflammation or cardiac fibrosis in a DOCA and Ang II 
model of hypertension (Krebs et al., 2012). The role of CCL5 in hypertension may 
vary between tissues. CCL5 has been suggested to have a negative effect in the 
vasculature as CCL5-/- mice are protected from Ang II induced vascular 
dysfunction and superoxide production. Similar effects are seen when the CCL5 
inhibitor met-RANTES is given to Ang II treated mice (Mikolajczyk et al., 2016). 
In contrast, CCL5 may be protective in the kidney as CCL5-/- mice show worse 
renal injury and fibrosis compared to WT mice when treated with Ang II 
(Rudemiller et al., 2016). CCL5 deficiency does not affect BP in hypertension 
(Mikolajczyk et al., 2016; Rudemiller et al., 2016). VSMCs can express CCL5. 
VSMCs from SHRs have reduced CCL5 expression compared to WKY VSMCs and 
Ang II reduces the expression of CCL5 by SHR VSMCs (Yun et al., 2011). SHRs 
treated with CCL5 also show reduced BP (Kim et al., 2015). 
The percentage of T cells expressing CCR1, CCR3 and CCR5 in the PVAT increases 
in Ang II induced hypertension (Mikolajczyk et al., 2016). An increase of CCL7, 
CCL8 and CCL12 is also observed in the aortas of DOCA-salt treated mice (Chan 
et al., 2012). Studies of hypertension using CCR1-/- and CCR3-/- animals or CCR1 
and CCR3 inhibitors have not been carried out. 
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1.11.2 CXC chemokines and receptors 
Aortic and cardiac expression of CXCR2 increases in hypertensive models (Chan 
et al., 2012; Wang et al., 2016; Zhang et al., 2019). When treated with Ang II or 
DOCA-salt, CXCR2-/- mice have a blunted BP response compared to WT mice and 
are protected from vascular dysfunction and superoxide production. They are 
also protected from aortic wall thickening, fibrosis and macrophage and T cell 
infiltration. The same effect is seen when hypertensive mice are treated with 
the CXCR2 inhibitor SB265610. This protective effect is likely a result of 
disrupting CXCR2 signalling in myeloid cells (Wang et al., 2016). Reparixin, an 
inhibitor of CXCR2 activation, can reduce blood pressure and aortic wall 
thickness of SHRs. Reparixin can also increase the production of NO by VSMCs 
(Kim et al., 2011). Further, the CXCR2 inhibitor SB225002 reduces BP and 
attenuates cardiac remodelling, oxidative stress and inflammation in SHRs 
(Zhang et al., 2019). CXCL8 is a ligand for CXCR2 and expression of CXCL8 is 
higher in the aortas of SHRs than WKY controls. CXCL8 expression by VSMCs can 
be induced by Ang II (Kim et al., 2008). 
CXCR6 and its ligand CXCL16 may regulate hypertensive end organ damage. T 
cells and macrophages that accumulate in the kidneys of Ang II treated mice can 
express CXCR6. When treated with Ang II, CXCR6-GFP mice have a similar 
increase in BP to WT mice but are protected from kidney injury and fibrosis (Xia 
et al., 2014). CXCL16 expression is induced in the kidneys of Ang II and DOCA-
salt treated mice. CXCL16 deficiency does not protect from elevated BP in these 
models but does protect from renal injury, fibrosis and T cell and macrophage 
infiltration (Liang et al., 2016; Xia et al., 2013). 
The ligands for CXCR3, CXCL9, CXCL10 and CXCL11, have been reported to be 
elevated in the circulation of hypertensive patients (Antonelli et al., 2012; Youn 
et al., 2013). CXCR3-/- mice have a higher BP than WT mice at baseline and after 
a high salt diet (Hsu et al., 2009). CXCR7 has been implicated in endothelial 
progenitor cell mediated repair of the endothelium in hypertensive patients 
(Zhang et al., 2014). 
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1.11.3 CX3CL1 and CX3CR1 
Few studies have focused on CX3CL1 and CX3CR1 in hypertension but both have 
been shown to be upregulated in the kidneys during DOCA induced hypertension. 
BP increases in CX3CR1-/- mice when treated with DOCA to the same extent as 
WT mice but CX3CR1 deficiency attenuates renal fibrosis and macrophage 
infiltration (Shimizu et al., 2011). CX3CL1 expression has been reported to be 
higher in the mesenteric arteries of female SHRs than male SHRs, although it is 
unlikely that this affects BP (Sullivan et al., 2009). 
1.11.4 Chemokines and receptors summary 
Several chemokines and chemokine receptors have been implicated in 
hypertension. CCR2, CCR5 and CXCR2 expression is upregulated in the 
vasculature of hypertensive animal models whilst renal expression of CCR5 and 
CX3CR1 also increases in hypertension. Deficiency of these receptors and their 
ligands may protect against BP elevation, inflammation or end organ damage in 
hypertension but this could be model and tissue dependent (Krebs et al., 2012; 
Mikolajczyk et al., 2016; Moore et al., 2015; Shen et al., 2014; Shimizu et al., 
2011; Wang et al., 2016). 
1.12 Aims 
Chemokine receptors have a role in the pathogenesis of hypertension and 
consequent end organ damage but the exact role they play is unclear. Disrupting 
chemokine-chemokine receptor interactions may reduce BP and protect from 
end organ damage, as is seen in some animal studies (Mikolajczyk et al., 2016; 
Moore et al., 2015). The complexity of the chemokine system has limited our 
understanding of how these receptors contribute to the disease. As chemokine 
receptors have multiple ligands and share ligands with other receptors (Figure 
1-3), knocking out or blocking a receptor may not reveal the whole role of the 
receptor as it is compensated for by other receptors and chemokines. It is 
hypothesised that the iCCRs are important in regulating leukocyte migration in 
hypertension and that targeting these receptors will protect from elevated BP 
and end organ damage in the disease. The aim of this study was to investigate 
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this, increasing our understanding of how iCCRs contribute to hypertension and 
BP regulation. This was broken down into three aims. 
1. Characterisation of iCCR expression in Ang II induced hypertension. 
2. Investigation of how deficiency of all iCCRs affects Ang II induced 
hypertension. 
3. Investigation of how iCCR deficiency affects immune cells and molecules 
that are involved in BP regulation in the kidney. 
The results described here have added to our understanding of the role of iCCRs 
in hypertension. In doing this, potential chemokine receptors have been 
identified which can be targeted to reduce BP and hypertensive end organ 
damage. 
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2 Materials and methods 
2.1 Mice 
All genetically modified mice were bred at the biological services unit at the 
Beatson Institute for Cancer Research and then housed at the cardiovascular 
research unit or central research facility at the University of Glasgow. Mice were 
allowed to acclimatise for at least 7 days after arrival before carrying out any 
procedures. Once on procedure, mice were monitored for weight loss as a way 
to monitor their health. At the end of experiments, mice were euthanased by 
carbon dioxide asphyxiation or cervical dislocation. All experiments were 
approved and performed under the project licence of Professor Gerard Graham 
(70/8377) or Dr Delyth Graham (70/9021). 
2.1.1 C57BL/6 mice 
8-11 wk old male C57BL/6 WT mice were purchased from Charles River or bred 
in house. 
2.1.2 iCCR-reporter mice 
REP mice expressing fluorescent proteins under the control of iCCR gene 
promoters were generated on a C57BL/6 background by Dr Laura Medina-Ruiz. 
The reporter proteins used were Clover (CCR1), mRuby2 (CCR2), mTagBFP2 
(CCR3) and iRFP682 (CCR5). 
2.1.3 iCCR-KO mice 
The locus on mouse chromosome 9 containing the iCCR genes was deleted to 
produce iCCR deficient mice on a C57BL/6 background. These mice have no 
overt developmental abnormalities but have impaired inflammatory leukocyte 
recruitment (Dyer et al., 2019). WT littermates were used as controls. 
2.1.4 Individual receptor-KO mice 
CCR1 deficient, CCR2 deficient and CCR5 deficient mice were maintained on a 
C57BL/6 background and CCR3 deficient mice were maintained on a BALB/c 
background. The appropriate WT littermates were used as controls. 
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2.2 Ang II induced hypertension 
REP, WT and iCCR-KO mice were subjected to Ang II induced hypertension. 12-15 
wk old mice were given Ang II (Sigma-Aldrich) at a dose of 490 ng/min/kg in Ang 
II buffer (150 mM NaCl, 1 % acetic acid in distilled water) for 7 or 14 days via 
subcutaneous osmotic minipump (ALZET). Control mice underwent sham surgery. 
Mice were anaesthetised with 3-5 % isoflurane and oxygen at a flow rate of 2 
L/min. An area of skin on the back was shaved and wiped with povidone-iodine 
(Betadine). A small incision was made at the top of the back, below the neck, 
and forceps were used to make a pocket under the skin. The osmotic minipump 
was inserted into the pocket and the incision was closed with 2-3 sutures. Sham 
surgery involved creating the pocket but no minipump was implanted. All surgery 
was performed with aseptic technique and mice were given a subcutaneous 
injection of 100 µl of 1 mg/ml carprofen (Rimadyl) as analgesia before the 
incision was made. Before surgery, mice were housed with their littermates. 
After surgery, mice were housed individually to avoid fighting which could open 
the surgical wound. To demonstrate that the osmotic minipump had delivered 
the Ang II, BP of the mice was measured. 
2.3 Blood pressure measurements 
BP was measured non-invasively by tail cuff plethysmography or invasively using 
telemetry. 
2.3.1 Tail cuff measurements 
Systolic BP was measured with a BP 2000 Series II analysis system (Visitech 
Systems) at 37 C. 5 preliminary measurements were performed before recording 
10 measurements and the average of all valid measurements was taken. A 
measurement was excluded if the mouse was moving around during recording. If 
a mouse consistently moved during the measurements, the system was paused 
until the mouse was still again. Daily BP measurements were started 7 days 
before recording BP to train the mice for tail cuff BP measurements and 
measurements were taken at the same time each day. 
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2.3.2 Telemetry 
Telemetry probe implantation was carried out by Dr Ryszard Nosalski or Wendy 
Beattie. Mice were anaesthetised with 3-5 % isoflurane and oxygen at a flow rate 
of 2 L/min. An area of skin on the neck was shaved and wiped with povidone-
iodine (Betadine). Mice were given a subcutaneous injection of 100 µl of 1 
mg/ml carprofen (Rimadyl) before a small incision was made and the left 
common carotid artery was isolated. The artery was ligated and a catheter 
connected to a transducer was inserted into the artery, towards the aorta. 2 
sutures were used to hold the catheter in place. The transducer was positioned 
under the skin on the left flank of the mouse. Mice recovered for 1 wk before 
baseline BP was measured. After 7 days of baseline BP measurements, mice 
were treated with Ang II as in section 2.2 and BP continued to be measured for 
14 days. Telemetry measurements were taken every 10 minutes and the average 
for each day and night was calculated. 
2.4 Replacement, reduction and refinement (3Rs) 
When designing the in vivo experiments the 3Rs were taken into account. 
Replacing animal experiments was not possible as hypertension cannot be 
induced or measured using in vitro techniques. To reduce the number of mice 
used, the number of mice per group was decided based on previously published 
data (Mikolajczyk et al., 2016). Refinement, improving animal welfare, was 
considered and mice were given analgesia before surgery to minimise suffering. 
The Animal Research: Reporting in vivo experiments (ARRIVE) guidelines were 
also considered when designing experiments (Kilkenny et al., 2010). For 
example, mice were randomly assigned Ang II or sham treatments to remove 
subjective bias. This could not be done by blinding when analysing the results as 
it is obvious which mice had the osmotic minipump implant and which mice had 
the sham surgery. Further, the strain, sex and number of mice used for each 
experiment has been reported, along with details of the procedures used. 
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2.5 Lucigenin chemiluminescence assay 
2 mm segments of thoracic aorta were isolated from sham and Ang II treated 
mice and superoxide production was assessed using a lucigenin assay. Baseline 
luminescence of 5 µM lucigenin (Sigma-Aldrich) in Krebs-HEPES buffer (99 mM 
NaCl, 25 mM NaHCO3, 11.1 mM glucose, 20 mM HEPES, 4.7 mM KCl, 1.9 mM 
CaCl2, 1 mM KH2PO4, 1.2 mM MgSO4.7H2O; pH 7.35) was monitored at 37 ºC by a 
FB12 Luminometer (Titertek-Berthold) using FB12 Sirius software for 15 min. The 
aorta was added and luminescence was monitored for a further 15 min. The 
difference of average relative light units (RLU)/s before and after the addition 
of the aorta was calculated. The aorta was left to dry and weighed so that 
superoxide production could be expressed as RLU/s/mg of aorta. 
2.6 Myography 
Wire myography was carried out by Dr Dominik Skiba or Dr Ryszard Nosalski to 
determine endothelium-dependent and endothelium-independent relaxation of 
thoracic aorta and mesenteric artery segments from sham and Ang II treated 
mice. The PVAT was removed from the vessels before mounting them in 
myograph baths containing PSS and incubating for 30 min at 37 ºC. Vessels were 
pre-constricted with 3 x 10-8 M U46619 and cumulative concentration response 
curves were conducted by incrementally increasing the concentration of 
acetylcholine (ACh) or sodium nitroprusside (SNP). The concentration of ACh or 
SNP started at 1 x 10-10 M and gradually increased to 3 x 10-5 M. 
2.7 Flow cytometry 
2.7.1 Tissue processing 
Bone marrow, blood, thymus, spleen, kidney and PVAT were taken and 
processed using flow cytometry buffer (FB; 1 % FCS 2 mM EDTA in PBS) for flow 
cytometry with individual, optimised protocols. 
2.7.1.1 Bone marrow 
Legs were isolated and the fur and muscle were removed from the femur. The 
ends of the femur were cut off and bone marrow was isolated one of two ways. 
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1. A hole was pierced in the bottom of a 500 µl Eppendorf tube and this was 
placed in a 1.5 ml Eppendorf tube. The femur was put in the 500 µl tube, 
200 µl of PBS was added and this was centrifuged for 5 – 10 s. Cells 
pelleted in the 1.5 ml tube. 500 µl of ACK lysis buffer (Gibco) was added 
to the cells for 1 min before adding 500 µl of FB and centrifuging for 5 min 
at 400g and 4 C. Cells were resuspended in 0.3 – 0.5 ml of FB. 
2. The bone marrow was flushed out of the femur using a 5 ml syringe with a 
23 G needle with 5 ml of RPMI-1640 (Sigma-Aldrich)-10 % FCS. The cell 
suspension was then passed through a 70 µm cell strainer and centrifuged 
for 5 min at 400 g and 4 C. The supernatant was discarded and the cells 
were resuspended in 1 ml of ACK lysis buffer (Gibco) for 1 min. FB was 
added and the cells were centrifuged again for 5 min at 400 g and 4 C. 
The supernatant was discarded and cells were resuspended in 0.3 – 0.5 ml 
of FB. 
2.7.1.2 Blood 
Blood was collected via cardiac puncture or from the vena cava into 1 ml 
syringes containing 50 µl of 0.2 M EDTA. 10 ml of RBC lysis buffer (eBioscience) 
was added per 1 ml of blood and incubated for 5 min at room temperature (RT) 
on a shaker. Up to 10 ml of PBS was added and samples were centrifuged at 400 
g and 4 C for 5 min. The supernatant was discarded and cells were resuspended 
in 0.5 – 1 ml of FB or the lysis was repeated for 1 min if a lot of RBCs remained. 
2.7.1.3 Thymus 
The thymus was cut into small pieces in FB and passed through a 70 µm strainer 
into a 50 ml falcon tube. Up to 20 ml of FB was added and samples were 
centrifuged for 5 min at 400 g and 4 C. The supernatant was discarded and cells 
were resuspended in 0.5 ml of FB. 
2.7.1.4 Spleen 
Spleens were cut up into 3 pieces in FB and passed through a 70 µm strainer into 
a 50 ml falcon tube. Up to 20 ml of FB was added and samples were centrifuged 
for 5 min at 400 g and 4 C. The supernatant was discarded and cells were 
2 61 
 
resuspended in 5 ml of RBC lysis buffer (Biolegend) for 5 min at RT. Up to 20 ml 
of FB was added and samples were passed through another 70 µm strainer and 
centrifuged again for 5 min at 400 g and 4 C. The supernatant was discarded 
and cells were resuspended in 0.5 - 5 ml of FB. 
2.7.1.5 Kidney  
An enzyme mix of 73.4 mg Collagenase I (Sigma-Aldrich), 6.2 mg Collagenase XI 
(Sigma-Aldrich) and 5.3 mg Hyaluronidase (Sigma-Aldrich) in 20 ml of 20 mM 
Hepes-PBS containing calcium and magnesium was made on the day of use and 
kept on ice. Kidneys were cut into small pieces in a 12 well plate containing 1 ml 
of 20 mM Hepes-PBS containing calcium and magnesium and 1 ml of the enzyme 
mix was added. Final enzyme concentrations were 450 U/ml Collagenase I, 125 
U/ml Collagenase XI and 60 U/ml Hyaluronidase. Samples were incubated at 37 
C for 10 min, agitated with a pipette, and incubated for another 10 min at 37 
C. 500 µl of 10 % FCS-PBS was added to stop the enzyme reaction and samples 
were passed through a 70 µm strainer into a 50 ml falcon tube. Up to 20 ml of FB 
was added and samples were centrifuged for 5 min at 400 g and 4 C. The 
supernatant was discarded and cells were resuspended in 5 ml of RBC lysis buffer 
(Biolegend) for 5 min at RT. Up to 20 ml of FB was added and samples were 
passed through another 70 µm strainer and centrifuged again for 5 min at 400 g 
and 4 C. The supernatant was discarded and cells were resuspended in 0.3 - 5 
ml of FB. 
2.7.1.6 PVAT 
PVAT was isolated from the thoracic and abdominal aorta and was weighed. The 
PVAT was placed in 1 ml of 20 mM Hepes-PBS containing calcium and magnesium 
and cut into small pieces. 1 ml of the enzyme mix from section 2.7.1.5 was 
added. Samples were incubated at 37 C for 10 min, agitated with a pipette, and 
incubated for another 10 min at 37 C. 500 µl of 10 % FCS-PBS was added to stop 
the enzyme reaction and samples were passed through a 70 µm strainer into a 50 
ml falcon tube. Up to 20 ml of FB was added and samples were centrifuged for 5 
min at 400 g and 4 C. The supernatant was discarded and cells were 
resuspended in 0.3 - 0.5 ml of FB. 
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2.7.2 Cell staining 
Zombie violet fixable viability dye (Biolegend) was prepared by diluting 1/2000 
in PBS or fixable viability dye eFluor 506 (eBioscience) was prepared by diluting 
1/1000 in PBS. The appropriate antibody mix was prepared in FB with Fc block 
(Miltenyi Biotec), diluted 1/100. Antibodies used are detailed in Table 2-1. Cell 
suspensions, prepared as detailed above, were added to FACS tubes or a 96 well 
plate and washed in FB by centrifuging for 5 min at 400 g and 4 C. The 
supernatant was discarded and 100 µl of the appropriate viability dye was added 
to the cells and incubated at RT for 15 min. The cells were washed in FB, the 
supernatant was discarded and 100 µl of the antibody mix was added for 20 min 
at 4 C. Cells were washed again in FB and resuspended in 200 µl of FB. Samples 
were either analysed that day or fixed for 10 min in 1 % paraformaldehyde (PFA) 
at 4 C, washed in FB and stored at 4 C for analysis the next day. 
2.7.2.1 Chemokine binding assay 
AF647-CCL2 (Almac) was used to measure CCR2 expression by flow cytometry 
instead of using an antibody (Ford et al., 2014). Cell suspensions were prepared 
as described above and washed in 5 % BSA-RPMI by centrifuging for 5 min at 400 
g and 4 C. The supernatant was discarded and cells were resuspended in 100 µl 
of 25 nM AF647-CCL2 in 5 % BSA-RPMI for 60 min at 4 C. Cells were then washed 
again in 5 % BSA-RPMI and stained with the appropriate viability dye and 
antibodies, following the protocol above. 
2.7.2.2 Intracellular staining 
Intracellular staining was used to analyse MR expression. Cell suspensions were 
prepared and stained as detailed above and fixed in 4 % PFA for 10 min at 4 C. 
Cells were then washed, resuspended in Perm/Wash (BD Bioscience) for 15 min, 
and washed again. The anti-MR antibody (Novus Biologicals) was diluted 1/25 in 
Perm/Wash and 100 µl was added to the cells for 30 min at 4 C. Cells were 
washed again in Perm/Wash before adding 100 µl of anti-mouse IgG1-APC Cy7 
secondary antibody (Biolegend), diluted 1/100 in Perm/Wash, for 30 min at 4 C. 
Finally, cells were washed in Perm/Wash and resuspended in 200 µl of FB. 
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Antibody Clone Conjugate Company Catalogue 
number 
CCR3 J073E5 PE Cy7 Biolegend 144514 
CCR5 HM-CCR5(7A4) PE eBioscience 12-1951-82 
CD3 17A2 FITC Biolegend 100204 
CD3 17A2 APC Cy7 Biolegend 100222 
CD3e 145-2C11 PE Biolegend 100308 
CD4 GK1.5 APC-eF780 eBioscience 47-0041-82 
CD4 RM4.5 PE Cy7 eBioscience 25-0042-82 
CD8a 53-6.7 FITC Miltenyi Biotec 130-102-490 
CD8a 53-6.7 APC eF780 eBioscience 47-0081-82 
CD11b M1/70 AF700 Biolegend 101222 
CD11b M1/70 APC Cy7 Biolegend 101226 
CD11b M1/70 PE Cy7 Biolegend 101216 
CD11b M1/70 APC eBioscience 17-0112-82 
CD11c N418 PerCP Cy5.5  Biolegend 117328 
CD19 6D5 AF700 Biolegend 115528 
CD19 6D5 PerCP Cy5.5 Biolegend 115534 
CD44 IM7 PerCP Cy5.5 Biolegend 103032 
CD45 30-F11 BV510 Biolegend 103138 
CD45 30-F11 PerCP Cy5.5 Biolegend 103132 
F4/80 BM8 PE Cy7 eBioscience 25-4801-82 
F4/80 BM8 PE Biolegend 123110 
F4/80 BM8 BV605 Biolegend 123133 
Ly6C HK1.4 AF700 Biolegend 128024 
Ly6C HK1.4 APC Biolegend 128016 
MHC II M5/114.15.2 BV605 Biolegend 107639 
Table 2-1. Antibodies used for flow cytometry 
The target, clone, conjugated fluorophore, supplier and catalogue number of the antibodies used 
for flow cytometry. All antibodies were used at a dilution of 1/100. 
2.7.3 Flow cytometry analysis 
All data were acquired using a LSR II (BD bioscience) or Fortessa (BD bioscience) 
flow cytometer and data were analysed using Flowjo software. All samples were 
analysed with the same initial gating strategy (Figure 2-1). Cells were identified 
based on SSC-A and FSC-A. Single cells were then selected based on FSC-H and 
FSC-A and live cells were identified using the viability stain. 
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Figure 2-1. Initial gating strategy for flow cytometry analysis 
Cells were identified and from these, single cells were selected. Live cells were then gated from the 
single cells. 
2.7.4 Magnetic cell sorting 
Cell suspensions from mouse kidneys were isolated as described in section 
2.7.1.5. 107 cells were stained with an anti-F4/80-PE antibody (Biolegend), 
diluted 1/10 in FB, for 20 min at 4 C. Cells were washed and stained with anti-
PE Microbeads (Miltenyi Biotec) diluted 1/5 in FB, for 20 min at 4 C. Cells were 
washed again and resuspended in 500 µl of FB. 
F4/80+ cells were sorted using LS columns and a QuadroMACS separator (Miltenyi 
Biotec). The separator was attached to the magnetic multistand and the columns 
were placed in the separator. 1 ml of FB was run through the columns before 
adding the stained samples. 500 µl of FB was then run through the columns 3 
times and collected in Eppendorf tubes. This was the negative fraction. The 
columns were then removed from the magnet and 1 ml of FB was run through 
and collected in new Eppendorf tubes. This was the positive fraction. Samples of 
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pre-sorted cells, the negative fraction and the positive fraction were analysed 
using a MACSQuant (Miltenyi Biotec) flow cytometer to determine how well the 
sort worked. 
2.8 Histology 
2.8.1 Tissue processing 
Heart, kidney and thoracic aorta were taken from perfused mice and stored in 1 
% PFA overnight at 4 C. Tissues were then transferred to a solution of 30 % 
sucrose in distilled water and stored at 4 C overnight or until the tissue had 
sunk to the bottom of the solution. After this the tissues were frozen in O.C.T 
(TissueTek) on dry ice and stored at -80 C. 8-10 µm sections were cut with a 
cryostat and put onto SuperFrost slides (VWR). Sections were stored at -20 C 
until used for staining. 
2.8.2 Haematoxylin & Eosin (H&E) staining 
Frozen tissue sections were fixed in ice cold acetone for 5 min and allowed to air 
dry. Sections were hydrated by incubating them for 1 min in 100 % ethanol, 1 
min in 100 % ethanol again, 1 min in 70 % ethanol and washing in running water. 
Nuclei in the sections were stained with haematoxylin (Cell path) for 7 min 
before washing in running water. Sections were then dipped 12 times in 1 % acid 
alcohol, washed in running water and placed in Scotts tap water solution for 2 
min. Sections were washed again in running water and stained with eosin (Cell 
path) for 4 min. Sections were washed for a final time in running water for 2 min 
and dehydrated by incubating for 1 min in 70 % ethanol, 1 min in 100 % ethanol 
and 1 min in 100 % ethanol again. Sections were cleared in 3 changes of xylene 
for 1 min and mounted with DPX (Leica Biosystems). 
2.8.3 Picrosirius red staining 
Frozen tissue sections were fixed in ice cold acetone for 5 min and allowed to air 
dry. Sections were hydrated by incubating them for 1 min in 100 % ethanol, 1 
min in 100 % ethanol again, 1 min in 70 % ethanol and washing in running water. 
Sections were stained with 0.1 % picrosirius red solution (Direct Red 80 (Sigma 
Aldrich) in picric acid) for 60 min at RT and then washed in 2 changes of 
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acidified water (0.5 % acetic acid). Sections were dehydrated by incubating for 1 
min in 70 % ethanol, 1 min in 100 % ethanol and 1 min in 100 % ethanol again and 
then cleared in 3 changes of xylene for 1 min. DPX (Leica Biosystems) was used 
to mount the sections. 
2.8.4 Mounting sections from REP mice 
Frozen tissue sections were fixed in ice cold acetone for 5 min and allowed to air 
dry. Slides were mounted with ProLong gold antifade mountant with DAPI 
(Thermofisher) and sealed with clear nail polish.  
2.8.5 Microscopy 
H&E and picrosirius red stained sections were imaged using brightfield 
microscopy with an Axio Imager M2 microscope (Zeiss) and Zen software. Images 
were analysed with Fiji software. Fluorescent sections were imaged by 
fluorescent microscopy with an Axio Imager M2 microscope (Zeiss) or LSM 880 
confocal microscope (Zeiss) and Zen software. 
2.9 Molecular biology 
2.9.1 RNA extraction 
Tissues were harvested from euthanased mice and stored in RNAlater 
(Thermofisher) at 4 C for up to 7 days before RNA was extracted. Tissues were 
homogenised in Qiazol (Qiagen) using a TissueLyser LT (Qiagen) set at 50 
oscillations/s for up to 10 min. RNA was extracted with the miRNeasy kit 
(Qiagen), following the manufacturer’s protocol. The optional DNase digest was 
performed using the RNase-free DNase set (Qiagen). Once extracted, RNA was 
stored at -80 C. 
2.9.2 cDNA synthesis 
Concentration and quality of RNA was measured using a DeNovix DS-11+ 
spectrophotometer. 1 µg of RNA was used to make cDNA using the High Capacity 
RNA-to-cDNA kit (Applied Biosystems) following the manufacturer’s protocol and 
stored at –20 C. 
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2.9.3 Taqman qPCR 
Taqman probe/primer sets (Table 2-2) were used to determine relative mRNA 
expression in tissues. All reagents and samples were kept on ice while the plate 
was set up. A mastermix of RNase-free water (3 µl per sample), Taqman 
universal mastermix II, no UNG (Thermofisher; 5 µl per sample) and Taqman 
probe/primer (0.5 µl per sample) was made and 8.5 µl of mastermix was added 
to the appropriate wells of a 384 well plate. 1.5 µl of cDNA (prepared as in 
section 2.9.2) was added to the appropriate wells. The plate was sealed, 
centrifuged for 1 min at 300 g and 4 C and run on a Quant Studio 7 Flex qPCR 
machine (Applied Biosystems) with Quant Studio Real-Time PCR software. 
Samples were run in triplicate and target gene expression was calculated 
relative to Gapdh or Cox7a2l using the 2-ΔCT method (Livak and Schmittgen, 
2001). Gapdh was used as a housekeeping gene to compare gene expression 
within the same tissue and Cox72al was used to compare gene expression 
between different tissues (Barber et al., 2005; Li et al., 2017). No template 
controls and – reverse transcriptase controls were run to check for primer 
contamination and sample genomic contamination, respectively. 
Target 
gene 
Target name Catalogue number 
Ccr1 CCR1 Mm00438260_s1 
Ccr2 CCR2 Mm99999051_gH 
Ccr3 CCR3 Mm00515543_s1 
Ccr5 CCR5 Mm01963251_s1 
Cox7a2l Cytochrome c oxidase subunit 7a related protein Mm00784451_s1 
Gapdh GAPDH Mm99999915_g1 
Nr3c2 Mineralocorticoid receptor Mm01241596_m1 
Scnn1g Epithelial sodium channel (ENaC) Mm00441228_m1 
Sgk1 Serum/glucocorticoid-regulated kinase 1 (SGK1) Mm00441380_m1 
Slc9a3 Sodium-hydrogen exchanger 3 (NHE3) Mm01352473_m1 
Table 2-2. Taqman primer/probe sets used for qPCR 
Targets and catalogue numbers of primers used for qPCR. All used the dye FAM-MGB and were 
purchased from Thermofisher. 
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2.10 Plasma chemokine and cytokine detection 
2.10.1 Sample preparation 
Blood was collected from euthanased mice via cardiac puncture into tubes 
containing 50 µl of 0.2 M EDTA. Blood samples were centrifuged at 1000 g for 10 
min to isolate plasma which was collected and stored at -80 C.  
2.10.2 Luminex assay 
Plasma samples were diluted 1/2 and the concentration of chemokines and 
cytokines was measured using a mouse premixed multi-analyte kit (R&D 
Systems), following the manufacturers protocol. The samples were analysed 
using a Bio-Plex 200 system (Bio-Rad). 
2.11 Statistical analysis 
All statistical analyses were carried out with GraphPad Prism software. A t test, 
Mann Whitney test, Two-Way ANOVA with a post hoc Tukey test or Two-way 
ANOVA with repeated measures test was performed as appropriate. A p value of 
< 0.05 was determined as statistically significant. Data are presented as the 
mean ± standard deviation (SD) unless otherwise stated. 
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3 iCCR expression in Ang II induced hypertension 
3.1 Introduction 
There is a large amount of evidence for a role of the immune system in the 
pathogenesis of hypertension, particularly factors influencing end organ damage 
such as oxidative stress and vascular dysfunction (Herrera et al., 2006; Moore et 
al., 2015; Youn et al., 2013). Monocytes and macrophages accumulate in the 
kidneys and vasculature in hypertension and depleting macrophages in mice is 
protective against DOCA-salt induced hypertension (Moore et al., 2015; Ozawa et 
al., 2006; Thang et al., 2015). T cells also accumulate in the kidneys and 
vasculature and it has been suggested that T cells are required for Ang II induced 
hypertension in mice (Guzik et al., 2007; Itani et al., 2016; Krebs et al., 2014). 
Chemokines and their receptors are important in orchestrating leukocyte 
migration and inflammatory responses. Therefore, they are likely to regulate 
leukocytes in the context of hypertension and influence end organ damage. 
CCL5-/- mice are protected from Ang II induced vascular dysfunction and 
oxidative stress (Mikolajczyk et al., 2016) whilst CCL2-/- mice may be protected 
from hypertensive renal injury (Kashyap et al., 2018). CCR2 or CCR5 deficiency 
does not influence BP in hypertensive models but CCR2-/- mice are protected 
from Ang II induced vascular remodelling (Ishibashi et al., 2004; Krebs et al., 
2012). Inflammatory chemokine receptors influence hypertension and end organ 
damage but the exact role of these receptors is still unclear. 
iCCRs have been reported to be expressed by various leukocytes. For example, 
CCR1 is expressed by T cells and B cells (Armas-González et al., 2018; 
Mikolajczyk et al., 2016) whilst CCR2 is classically described as being expressed 
by monocytes and macrophages (Sierra-Filardi et al., 2014; Tacke et al., 2007). 
CCR3 is expressed by eosinophils and CCR5 has been reported to be expressed by 
T cells and NK cells (Fox et al., 2015; Lima et al., 2015). It is hypothesised that 
iCCRs regulate leukocyte migration in hypertension. Circulating monocytes have 
elevated CCR2 expression and T cells in the PVAT increase CCR1, CCR3 and CCR5 
expression in hypertension (Ishibashi et al., 2004; Mikolajczyk et al., 2016) but 
little else is known about which cell types in various tissues express these 
receptors in the disease. 
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The aim of this study was to characterise iCCR expression by different 
leukocytes in multiple tissues in mice with Ang II induced hypertension. WT or 
REP mice were subject to Ang II induced hypertension and iCCR expression was 
determined by flow cytometry, fluorescent microscopy and qPCR. Furthermore, 
plasma chemokine and cytokine levels were characterised. This revealed some 
differences in iCCR and chemokine expression between healthy and hypertensive 
states which may represent targets to treat elevated BP and end organ damage 
in hypertension. 
3.2 Response of REP mice to Ang II 
REP mice and WT littermate controls were treated with Ang II for 14 days and 
their response to Ang II was determined by measuring BP (Figure 3-1a) and 
assessing cardiac hypertrophy (Figure 3-1b). The ratio of heart weight to tibia 
length indicates how the weight of the heart changed over the experiment and 
therefore this was used to determine cardiac hypertrophy. The BP of both WT 
and REP mice increased in response to Ang II (WT sham 114 ± 1.2 vs WT Ang II 
172 ± 3.3 mmHg, p < 0.01, Two-Way ANOVA; REP sham 109 ± 1.8 vs REP Ang II 
159 ± 9.3 mmHg, p < 0.01, Two-Way ANOVA). Compared to Ang II treated WT 
mice, Ang II treated REP mice had a slightly lower BP (WT Ang II 172 ± 3.3 mmHg 
vs REP Ang II 159 ± 9.3 mmHg, p < 0.05, Two-Way ANOVA). The ratio of heart 
weight to tibia length increased in the WT mice treated with Ang II (WT sham 9.3 
± 0.8 vs WT Ang II 13.2 ± 1.3 mg/mm, p < 0.05, Two-Way ANOVA). This effect 
was not seen in the REP mice (REP sham 11.7 ± 2.5 vs REP Ang II 12.5 ± 0.2 
mg/mm, p = 0.88, Two-Way ANOVA). 
 
a b 
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Figure 3-1. Response of WT and REP mice to Ang II 
WT and REP mice were treated with Ang II for 14 days. BP (a) and the ratio of heart weight to tibia 
length (b), as a measure of cardiac hypertrophy, were assessed. * p < 0.05, ** p < 0.01, Two-Way 
ANOVA. Data are combined from two independent experiments. 
3.3 iCCR expression in REP mice following 7 days of Ang 
II induced hypertension 
To determine how iCCRs contribute to earlier stages of Ang II induced 
hypertension, REP mice were subject to 7 days of sham or Ang II treatment and 
iCCR expression by different subsets of leukocytes in the bone marrow, blood, 
spleen, kidney and PVAT was investigated using flow cytometry. The gating 
strategies used are detailed below. Fluorescent microscopy was used to 
determine CCR1, CCR2 and CCR5 expression in the kidneys, heart, aorta and 
PVAT. CCR3 was not looked at as mTagBFP2 fluoresces at the same wavelength 
as Dapi. 
3.3.1 Bone marrow 
B cells were identified as CD19+ cells from live, single CD45+ cells. CD11b+SSChi 
and CD11b+SSCint cells were also identified from the CD45+ cells (Figure 3-2). 
CD3 was used as a T cell marker but only a very small proportion of cells in the 
bone marrow were CD3+. These are likely to be T cell precursors (Klein et al., 
2003) so bone marrow CD3+ cells were not analysed. CCR1 was expressed by 
CD19+ B cells in the bone marrow of mice given sham or Ang II treatment for 7 
days. These cells also expressed low amounts of CCR2 (Figure 3-3a). 
CD11b+SSChi cells expressed high amounts of CCR3 (Figure 3-3b). CD11b+SSCint 
cells most highly expressed CCR2 whilst CCR1 and CCR3 could also be detected 
on these cells (Figure 3-3c). No differences were seen between sham and Ang II 
treated mice. 
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Figure 3-2. Gating strategy for the analysis of bone marrow cells from mice with Ang II 
induced hypertension 
CD45+ cells were gated from live, single cells. CD19+, CD11b+SSCint and CD11b+SSChi cells 
were gated from the CD45+ cells.  
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Figure 3-3. iCCR expression by leukocytes in the bone marrow of REP mice after 7 days of 
Ang II induced hypertension 
The expression of CCR1, CCR2, CCR3 and CCR5 by CD19+ cells (a), CD11b+SSChi cells (b) and 
CD11b+SSCint cells (c) in the bone marrow of REP mice after sham or Ang II treatment for 7 days. 
3.3.2 Blood 
Blood CD19+ B cells, CD3+ T cells and CD11b+ cells were gated from live CD45+ 
cells (Figure 3-4). CD11b+ cells were grouped into CD11b+SSChi, CD11b+SSCint 
and CD11b+SSClo populations. CD19+ B cells in the blood showed high CCR1 
expression after 7 days of sham or Ang II treatment (Figure 3-5a). A small 
proportion of CD3+ T cells expressed CCR2 and CCR5 was detected in only one 
sham sample (Figure 3-5b). Only CCR3 was expressed by CD11b+SSChi cells 
(Figure 3-5c) whilst a small proportion of CD11b+SSCint cells expressed CCR1, 
CCR2 or CCR3 (Figure 3-5d). CCR2 and CCR5 were expressed by CD11b+SSClo 
cells and some of these cells co-expressed these receptors (Figure 3-5e). No 
differences in iCCR expression by leukocytes in the blood were observed 
following 7 days of Ang II induced hypertension. 
a b 
c 
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Figure 3-4. Gating strategy for the analysis of blood cells from mice with Ang II induced 
hypertension 
CD45+ cells were gated from live, single cells. CD19+, CD3+, CD11b+SSClo, CD11b+SSCint and 
CD11b+SSChi cells were gated from the CD45+ cells.  
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Figure 3-5. iCCR expression by leukocytes in the blood of REP mice after 7 days of Ang II 
induced hypertension 
The expression of CCR1, CCR2, CCR3 and CCR5 by CD19+ cells (a), CD3+ cells (b), 
CD11b+SSChi cells (c), CD11b+SSCint cells (d) and CD11b+SSClo cells (e) in the blood of REP 
mice after sham or Ang II treatment for 7 days. 
3.3.3 Spleen 
In the spleen, live CD45+ cells were identified and from these, populations of 
CD19+ B cells, CD3+ T cells, F4/80+ macrophages and CD11b+ cells were 
determined (Figure 3-6). The CD11b+ cells were further gated into CD11b+SSChi, 
CD11b+SSCint and CD11b+SSClo cells. After 7 days of Ang II induced hypertension 
or sham treatment, CD19+ B cells expressed only CCR1 (Figure 3-7a) whilst CD3+ 
T cells showed low expression of CCR2 and CCR3 (Figure 3-7b). Both 
a b 
c d 
e 
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CD11b+SSChi and CD11b+SSCint cells expressed CCR3 and a small amount of 
CD11b+SSCint cells expressed CCR1 or CCR2 (Figure 3-7c, d). CCR2 and CCR5 
were expressed by CD11b+SSClo cells and these cells also showed co-expression 
of these receptors (Figure 3-7e, f). F4/80+ cells highly expressed CCR3 (Figure 
3-7g). There were no differences in iCCR expression between sham and Ang II 
treatments for any of the cell types analysed. 
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Figure 3-6. Gating strategy for the analysis of spleen cells from mice with Ang II induced 
hypertension 
CD45+ cells were gated from live, single cells. CD19+, CD3+, F4/80+ and CD11b+ cells were 
gated from the CD45+ population. The CD11b+ population was then gated into CD11b+SSClo, 
CD11b+SSCint and CD11b+SSChi cells.  
CD3 
C
D
1
9
 
CD11b 
F
4
/
8
0
 
FSC-A 
S
S
C
-A
 
CD45 
S
S
C
-A
 
3 79 
 
 
Figure 3-7. iCCR expression by leukocytes in the spleens of REP mice after 7 days of Ang II 
induced hypertension 
The expression of CCR1, CCR2, CCR3 and CCR5 by CD19+ cells (a), CD3+ cells (b), 
CD11b+SSChi cells (c), CD11b+SSCint cells (d), CD11b+SSClo cells (e) and F4/80+ cells (g) in 
the spleens of REP mice after sham or Ang II treatment for 7 days. A representative flow cytometry 
plot of CD11b+SSClo cell co-expression of CCR2 and CCR5 is shown (f). 
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3.3.4 Kidney 
Heterogeneous populations of F4/80+ cells and CD11b+ cells were identified 
which are likely to include macrophages, monocytes, DCs and neutrophils (Inoue 
et al., 2005; Misharin et al., 2013; Sahu et al., 2014). These cell types, along 
with CD19+ B cells and CD3+ T cells, were gated from live CD45+ cells (Figure 
3-8). Following 7 days of sham or Ang II treatment, CD19+ cells expressed CCR1 
and also showed low CCR5 expression (Figure 3-9a). CD3+ T cells expressed CCR2 
and CCR5. A small proportion of these CD3+ cells also expressed CCR1 (Figure 
3-9b). CD11b+ cells most highly expressed CCR2 and also expressed CCR5 (Figure 
3-9c). Co-expression of CCR2 and CCR5 by CD11b+ cells was observed (Figure 
3-10a) and revealed that all CCR5 expressing CD11b+ cells also expressed CCR2 
and that the majority of these cells only expressed CCR2. 
F4/80+ cells expressed CCR1, CCR2 and CCR5. Of these, CCR5 was the most 
highly expressed (Figure 3-9d). Co-expression of these receptors was also 
observed with the majority of these cells expressing both CCR1 and CCR5. About 
11 % of F4/80+ cells expressed none of the iCCRs and none expressed CCR1 
alone. Some expressed just CCR2 or just CCR5 and about 15 % were CCR2+CCR5+ 
(Figure 3-10b). No differences between sham and Ang II treated mice were 
observed. 
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Figure 3-8. Gating strategy for the analysis of kidney leukocytes from mice with Ang II 
induced hypertension 
CD45+ cells were gated from live, single cells. CD19+, CD3+, F4/80+ and CD11b+ cells were 
gated from the CD45+ cells. 
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Figure 3-9. iCCR expression by leukocytes in the kidneys of REP mice after 7 days of Ang II 
induced hypertension 
The expression of CCR1, CCR2, CCR3 and CCR5 by CD19+ cells (a), CD3+ cells (b), CD11b+ 
cells (c) and F4/80+ cells (d) in the kidneys of REP mice after sham or Ang II treatment for 7 days. 
a b 
c d 
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Figure 3-10. iCCR co-expression by kidney leukocytes from REP mice subject to 7 days of 
Ang II induced hypertension 
The co-expression of CCR1, CCR2 and CCR5 by CD11b+ cells (a) and F4/80+ cells (b) in the 
kidneys of REP mice after 7 days of Ang II or sham treatment. 
Only CCR5 could be seen after 7 days of treatment in the kidney when frozen 
tissue sections were imaged (Figure 3-11). These could be T cells or 
macrophages as CD3+, CD11b+ and F4/80+ cells were shown to express CCR5 
when determined by flow cytometry. There was also no apparent difference 
between sham and Ang II treatments. 
a 
b 
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Figure 3-11. Kidney iCCR expression in REP mice after 7 days of Ang II induced 
hypertension 
CCR1, CCR2, CCR5 and Dapi were detected in the kidneys of Rep mice by fluorescent 
microscopy. Representative images after 7 days of sham (a) or Ang II treatment (b) are shown. 
Scale bar = 50 µm. Yellow arrows point to some CCR5+ cells. 
3.3.5 Aorta and PVAT 
In the PVAT, CD19+ B cells, CD3+ T cells, CD11b+ cells, CD11b+F4/80+ cells and 
F4/80+ cells were gated from live, CD45+ cells (Figure 3-12). CD11b+, 
CD11b+F4/80+ and F4/80+ cells represent heterogeneous populations including 
macrophages and monocytes (Misharin et al., 2013; Xiong et al., 2018). 
Following 7 days of Ang II induced hypertension or sham treatment, PVAT CD19+ 
B cells expressed CCR1 and low amounts of CCR2 or CCR5 (Figure 3-13a). CD3+ 
cells expressed very low and variable amounts of all iCCRs (Figure 3-13b). 
Sham a 
CCR1 
  
CCR2 
  
CCR5 
  
DAPI 
  
CCR1 
  
CCR2 
  
CCR5 
  
DAPI 
  
b Ang II 
3 85 
 
CD11b+ cells most highly expressed CCR2 and also expressed CCR1 and CCR5 
(Figure 3-13c). When co-expression of these receptors was investigated, the 
majority of CD11b+ cells were found to not express any of the iCCRs and around 
20 % only expressed CCR2. A small proportion of CD11b+ cells were CCR2+CCR5+ 
or CCR1+CCR2+CCR5+ (Figure 3-14a). CD11b+F4/80+ cells also expressed these 
three receptors (Figure 3-13d). Most of these cells did not express any of the 
iCCRs whilst some were shown to be CCR2+, CCR5+, CCR1+CCR2+ or CCR1+CCR5+ 
(Figure 3-14b). F4/80+ cells expressed variable amounts of all the iCCRs (Figure 
3-13e). There were no differences in PVAT leukocyte iCCR expression between 
sham and Ang II treated mice. 
 
Figure 3-12. Gating strategy for the analysis of PVAT leukocytes from mice with Ang II 
induced hypertension 
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CD45+ cells were gated from live, single cells. CD19+, CD3+ and CD11b+ cells were gated from 
the CD45+ cells. 
 
Figure 3-13. iCCR expression by leukocytes in the PVAT of Rep mice after 7 days of Ang II 
induced hypertension 
The expression of, CCR1, CCR2, CCR3 and CCR5 by CD19+ cells (a), CD3+ cells (b), CD11b+ 
cells (c), CD11b+F4/80+ cells (d) and F4/80+ cells (e) in the PVAT of Rep mice after 7 days of 
sham or Ang II treatment. 
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Figure 3-14. iCCR co-expression by PVAT leukocytes from REP mice subject to 7 days of 
Ang II induced hypertension 
The co-expression of CCR1, CCR2 and CCR5 by CD11b+ cells (a) and CD11b+F4/80+ cells (b) in 
the PVAT of REP mice after 7 days of Ang II or sham treatment. 
Clear expression of CCR5 was observed in the adventitia and PVAT of aortas from 
sham and Ang II treated mice. These could be CD11b+ or F4/80+ cells. CCR1 was 
not expressed and very low amounts of CCR2 were observed in some samples 
(Figure 3-15). iCCRs were not detected in the medial or endothelial layer of the 
aorta and CCR5 expression did not appear to be effected by Ang II treatment. 
a 
b 
3 88 
 
 
Figure 3-15. Aortic iCCR expression in REP mice after 7 days of Ang II induced hypertension 
CCR1, CCR2, CCR5 and Dapi were detected in the aortas of Rep mice by fluorescent microscopy. 
Representative images after 7 days of sham (a) or Ang II treatment (b) are shown. Scale bar = 50 
µm. Yellow arrows point to some CCR5+ cells. 
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3.3.6 Heart 
Heart tissue was not analysed by flow cytometry as an effective cell isolation 
protocol had not been established but the tissue was analysed by microscopy. 
Low expression of CCR5 could be detected in the hearts after 7 days of sham or 
Ang II treatment, but it was not seen in all samples. CCR1 and CCR2 were not 
detected (Figure 3-16). CCR5 expression did not appear to be effected by Ang II 
induced hypertension. These CCR5+ cells could be macrophages or T cells as 
these cell types in other peripheral tissues, such as the kidney, expressed CCR5. 
 
Figure 3-16. Heart iCCR expression in REP mice after 7 days of Ang II induced hypertension 
CCR1, CCR2, CCR5 and Dapi were detected in the hearts of Rep mice by fluorescent microscopy. 
Representative images after 7 days of sham (a) or Ang II treatment (b) are shown. Scale bar = 50 
µm. Yellow arrows point to some CCR5+ cells. 
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3.4 iCCR expression in REP mice following 14 days of 
Ang II induced hypertension 
REP mice were subject to Ang II induced hypertension for 14 days and the 
expression of iCCRs by different subsets of leukocytes in the bone marrow, 
blood, spleen and kidneys was determined by flow cytometry. PVAT was not 
analysed as not all the lymph nodes in the PVAT were able to be removed during 
isolation. Gating strategies used were as detailed in section 3.3. CCR1, CCR2 and 
CCR5 expression in the kidneys, heart, aorta and PVAT was also investigated 
using fluorescent microscopy. 
3.4.1 Bone marrow 
After 14 days of Ang II induced hypertension about 15 – 20 % of CD19+ B cells 
expressed CCR1 (Figure 3-17a). This was slightly higher than the expression 
observed at the 7 day time point and CCR1 expression did not increase in the 
Ang II treated mice. CD11b+SSChi cells only expressed CCR3 (Figure 3-17b). 
CD11b+SSCint cells expressed CCR1 and CCR3, had the highest expression of 
CCR2 and did not express CCR5 (Figure 3-17c). These cell types showed a similar 
expression pattern to that seen after 7 days of sham or Ang II treatment and 
there were no differences in iCCR expression between sham and Ang II treated 
mice. 
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Figure 3-17. iCCR expression by leukocytes in the bone marrow of REP mice after 14 days 
of Ang II induced hypertension 
The expression of CCR1, CCR2, CCR3 and CCR5 by CD19+ cells (a), CD11b+SSChi cells (b) and 
CD11b+SSCint cells (c) in the bone marrow of REP mice after sham or Ang II treatment for 14 
days. Representative flow cytometry plots of CD19+ cell CCR1, CD11b+SSChi cell CCR3 and 
CD11b+SSCint cell CCR2 expression are shown. Data are combined from two independent 
experiments. 
3.4.2 Blood 
In sham and Ang II treated mice, blood CD19+ B cells expressed CCR1 whilst 
about 2 – 6 % of CD3+ T cells expressed CCR2 (Figure 3-18c, d). CD11b+SSChi 
cells expressed variable amounts of CCR3. This expression tended to be higher 
than that observed at the 7 day time point (Figure 3-18c). A small amount of 
CCR1, CCR2 and CCR3 could be detected on CD11b+SSCint cells (Figure 3-18d). 
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CD11b+SSClo cells were shown to express CCR2 and CCR5, with some cells co-
expressing both receptors (Figure 3-18e, f). Furthermore, about 40 % of 
CD11b+SSClo cells expressed CCR5 after 14 days of treatment but only about 20 
% were shown to be CCR5+ after 7 days. The expression of iCCRs by these cell 
subsets was not effected by Ang II treatment. 
 
Figure 3-18. iCCR expression by leukocytes in the blood of REP mice after 14 days of Ang II 
induced hypertension 
The expression of CCR1, CCR2, CCR3 and CCR5 by CD19+ cells (a), CD3+ cells (b) 
CD11b+SSChi cells (c), CD11b+SSCint cells (d) and CD11b+SSClo cells (e) in the blood of REP 
mice after sham or Ang II treatment for 14 days. A representative flow cytometry plot of 
CD11b+SSClo cell CCR2 and CCR5 co-expression is shown (f). Data are combined from two 
independent experiments. 
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3.4.3 Spleen 
After 14 days of Ang II induced hypertension, spleen leukocytes showed a similar 
iCCR expression pattern to that observed after 7 days. About 40 – 50 % of CD19+ 
B cells expressed CCR1, although this was slightly higher than the expression 
detected after 7 days (Figure 3-19a). A small proportion of T cells expressed 
CCR2, CCR3 or CCR5 (Figure 3-19b). CCR3 was expressed by CD11b+SSChi cells 
and CD11b+SSCint cells, which may also have expressed small amounts of CCR1, 
CCR2 and CCR5 (Figure 3-19c, d). CD11b+SSClo cells expressed CCR2 and CCR5. 
Co-expression of these receptors was observed and showed that most of the 
CCR5+ CD11b+SSClo cells also expressed CCR2 (Figure 3-19e, f). F4/80+ cells in 
the spleen most highly expressed CCR3 (Figure 3-19g, h). There were no 
differences in iCCR expression by any of these cell types between sham and Ang 
II treated mice. 
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Figure 3-19. iCCR expression by leukocytes in the spleens of REP mice after 14 days of Ang 
II induced hypertension 
The expression of CCR1, CCR2, CCR3 and CCR5 by CD19+ cells (a), CD3+ cells (b) 
CD11b+SSChi cells (c), CD11b+SSCint cells (d) CD11b+SSClo cells (e) and F4/80+ cells (g) in the 
spleen of REP mice after sham or Ang II treatment for 14 days. Representative flow cytometry plots 
of CD11b+SSClo cell CCR2 and CCR5 co-expression (f) and F4/80+ cell CCR3 expression (h) are 
shown. Data are combined from two independent experiments. 
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3.4.4 Kidney 
Up to 40 % of kidney CD19+ B cells expressed CCR1 after 14 days of both Ang II or 
sham treatment (Figure 3-20a). This is higher than the amount expressing CCR1 
after 7 days. CD3+ T cells expressed CCR2 and CCR5 (Figure 3-20b). CCR2 and 
CCR5 were also expressed by CD11b+ cells and F4/80+ cells whilst F4/80+ cells 
also expressed CCR1 (Figure 3-20c, d). Similar to the 7 day timepoint, most 
CD11b+ cells were CCR2+ or did not express any of the iCCRs and about 10 % 
were CCR2+CCR5+ (Figure 3-20e). Most F4/80+ cells expressed both CCR1 and 
CCR5 whilst 20 – 30 % only expressed CCR5 and about 20 % expressed both CCR2 
and CCR5 (Figure 3-20f). None of the cell types analysed showed a difference in 
iCCR expression between sham and Ang II treated mice. 
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Figure 3-20. iCCR expression by leukocytes in the kidneys of REP mice after 14 days of Ang 
II induced hypertension 
The expression of CCR1, CCR2, CCR3 and CCR5 by CD19+ cells (a), CD3+ cells (b) CD11b+ 
cells (c) and F4/80+ cells (d) and co-expression of CCR1, CCR2 and CCR5 by CD11b+ cells (e) 
and F4/80+ cells (f) in the kidneys of REP mice after sham or Ang II treatment for 14 days. Data 
are combined from two independent experiments. 
Both CCR5 and CCR2 could be seen in the kidney when frozen tissue sections 
were imaged after 14 days of sham or Ang II treatment. (Figure 3-21). These may 
represent CD3+ T cells, CD11b+ cells or F480+ cells. CCR5 appeared to be more 
highly expressed than CCR2 and there was no apparent difference between sham 
and Ang II treatments. 
 
Figure 3-21. Kidney iCCR expression in REP mice after 14 days of Ang II induced 
hypertension 
CCR1, CCR2, CCR5 and Dapi were detected in the kidneys of REP mice by fluorescent 
microscopy. Representative images after 14 days of sham (a) or Ang II treatment (b) are shown. 
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Scale bar = 50 µm. Red arrows point to some CCR2+ cells. Yellow arrows point to some CCR5+ 
cells. 
3.4.5 Aorta and PVAT 
After 14 days of Ang II induced hypertension, CCR2 and CCR5, but not CCR1, 
were detected in the aortic adventitia and PVAT of REP mice (Figure 3-22). 
These could be expressed by CD11b+ cells, which were shown to express CCR2 
and CCR5 at the 7 day time point. These iCCRs were not seen in the medial or 
endothelial layers of the aorta and no clear difference in iCCR expression 
between sham and Ang II treated mice was observed. 
 
Figure 3-22. Aortic iCCR expression in REP mice after 14 days of Ang II induced 
hypertension 
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CCR1, CCR2, CCR5 and Dapi were detected in the aortas of REP mice by fluorescent microscopy. 
Representative images after 14 days of sham (a) or Ang II treatment (b) are shown. Scale bar = 50 
µm. Red arrows point to some CCR2+ cells. Yellow arrows point to some CCR5+ cells. 
3.4.6 Heart 
In the hearts of sham and Ang II treated REP mice, CCR5 could clearly be 
detected. CCR2 was also observed in low amounts and CCR1 was not detected at 
all (Figure 3-23). This may indicate the presence of CD3+ cells, CD11b+ cells or 
F4/80+ cells in the heart. CCR2 and CCR5 expression did not appear to be 
affected by Ang II induced hypertension. 
 
Figure 3-23. Heart iCCR expression in REP mice after 14 days of Ang II induced 
hypertension 
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CCR1, CCR2, CCR5 and Dapi were detected in the hearts of REP mice by fluorescent microscopy. 
Representative images after 14 days of sham (a) or Ang II treatment (b) are shown. Scale bar = 50 
µm. Red arrows point to some CCR2+ cells. Yellow arrows point to some CCR5+ cells. 
3.5 Use of antibodies and chemokines to determine iCCR 
expression by flow cytometry 
To determine how flow cytometry with antibody staining compares to using REP 
mice, WT mice were subject to Ang II induced hypertension for 14 days and the 
expression of CCR2, CCR3 and CCR5 was investigated using flow cytometry. 
Antibodies for CCR3 and CCR5 and fluorescently labelled CCL2 to detect CCR2 
(Ford et al., 2014) were used. A specific antibody for CCR1 was unavailable. The 
bone marrow, blood, spleen, kidney and PVAT were analysed. The gating 
strategies used were as described in section 3.3. 
3.5.1 Bone marrow 
Following 14 days of Ang II or sham treatment, CCR2, CCR3 and CCR5 were not 
detected on CD19+ B cells in the bone marrow (Figure 3-24a). CD11b+SSChi cells 
expressed CCR3 (Figure 3-24b, d) and 10 – 15% of CD11b+SSCint cells expressed 
CCR2 (Figure 3-24c, e). Ang II treatment did not affect iCCR expression by these 
cell types. 
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Figure 3-24. iCCR expression by leukocytes in the bone marrow of WT mice after Ang II 
induced hypertension 
The expression of, CCR2 (using CCL2 conjugated to AF647), CCR3 and CCR5 by CD19+ cells 
(a), CD11b+SSChi cells (b) and CD11b+SSCint cells (c) in the bone marrow of WT mice after 14 
days of sham or Ang II treatment. Representative flow cytometry plots of CD11b+SSChi cell CCR3 
expression (d) and CD11b+SSClo cell CCR2 expression (e) are shown. Data are combined from 
three independent experiments. 
3.5.2 Blood 
Neither CCR2, CCR3 nor CCR5 were detected on CD19+ B cells in the blood of WT 
mice after sham or Ang II treatment and very little, if any, were observed on 
CD3+ T cells (Figure 3-25a, b). CD11b+SSChi cells highly expressed CCR3 (Figure 
3-25c, d). A small proportion of CD11b+SSCint cells expressed CCR2 (Figure 
3-25e) but CCR2 was most highly expressed by CD11b+SSClo cells. CCR2 
expression by these cells also increased in response to Ang II (Figure 3-25f; Sham 
CCL2 35.1 ± 5.0 vs Ang II CCL2 43.3 ± 8.4 % CD11b+SSClo cells, p < 0.05, t test). 
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Figure 3-25. iCCR expression by leukocytes in the blood of WT mice after Ang II induced 
hypertension 
The expression of, CCR2 (using CCL2 conjugated to AF647), CCR3 and CCR5 by CD19+ cells 
(a), CD3+ cells (b) CD11b+SSChi cells (c), CD11b+SSCint cells (e) and CD11b+SSClo cells (f) in 
the blood of WT mice after 14 days of sham or Ang II treatment. A representative flow cytometry 
plot of CD11b+SSChi cell CCR3 expression is shown (d). * p < 0.05, t test. Data are combined 
from two independent experiments. 
3.5.3 Spleen 
CCR2, CCR3 and CCR5 were not detected on spleen CD19+ B cells. Very low CCR2 
and CCR3 expression was shown by CD3+ T cells in both sham and Ang II treated 
mice (Figure 3-26a, b). CD11b+SSChi cells only expressed CCR3 and CD11b+SSCint 
cells expressed CCR2, CCR3 and CCR5 (Figure 3-26c, d). Only CCR2 was 
expressed by CD11b+SSClo cells and CCR3 was shown on F4/80+ cells (Figure 
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3-26e, f). There were no differences between the mice given sham or Ang II 
treatments.  
 
Figure 3-26. iCCR expression by leukocytes in the spleens of WT mice after Ang II induced 
hypertension 
The expression of, CCR2 (using CCL2 conjugated to AF647), CCR3 and CCR5 by CD19+ cells 
(a), CD3+ cells (b) CD11b+SSChi cells (c), CD11b+SSCint cells (d), CD11b+SSClo cells (e) and 
F4/80+ cells (f) in the spleens of WT mice after 14 days of sham or Ang II treatment. Data are 
combined from two independent experiments. 
3.5.4 Kidney 
CCR2 and CCR5 expression by leukocytes in the kidneys was determined but 
CCR3 could not be measured as the antibody showed nonspecific binding when 
used to stain kidney cells. CD19+ B cells in sham and Ang II treated mice did not 
express CCR2 but may have expressed CCR5 (Figure 3-27a). Some CD3+ T cells 
expressed low levels of CCR2 and variable levels of CCR5 (Figure 3-27b). Both 
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CCR2 and CCR5 expression were detected on CD11b+ cells (Figure 3-27c) and 
CCR5 expression was lower in Ang II treated mice (Sham CCR5 12.4 ± 2.5 vs Ang II 
CCR5 7.4 ± 2.4 % CD11b+ cells, p < 0.05, t test). F4/80+ cells showed high levels 
of CCR5 expression and some CCR2 expression but there were no differences 
between sham and Ang II treatment (Figure 3-27d). 
 
Figure 3-27. iCCR expression by leukocytes in the kidneys of WT mice after Ang II induced 
hypertension 
The expression of, CCR2 (using CCL2 conjugated to AF647) and CCR5 by CD19+ cells (a), CD3+ 
cells (b), CD11b+ cells (c) and F4/80+ cells (d) in the kidneys of WT mice after 14 days of sham or 
Ang II treatment. * p < 0.05, t test. Data are combined from three independent experiments, except 
CD11b+ cells. 
3.5.5 PVAT 
CD19+ B cells and CD3+ T cells did not express CCR2 or CCR3 but may have 
expressed a small amount of CCR5 (Figure 3-28a, b). CD11b+ cells expressed 
both CCR2 and CCR5 (Figure 3-28c) and CCR5 expression was higher in the Ang II 
treated mice (Sham CCR5 24.7 ± 7.9 vs Ang II CCR5 39.6 ± 5.2 % CD11b+ cells, p < 
0.05, Mann Whitney test). This was reflected in the representative flow 
cytometry plots that show more CCR5 staining of CD11b+ cells from Ang II 
treated mice (Figure 3-28e). There was also a higher number of CD11b+ cells in 
the mice treated with Ang II (Figure 3-28d; Sham 460 ± 200 vs Ang II 1560 ± 800 
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total cells/mg, p < 0.05, Mann Whitney test) The total number of cells was 
calculated per mg of tissue as the amount of PVAT isolated from each aorta was 
highly variable. F4/80+ cells were not detected in these samples. 
 
Figure 3-28. iCCR expression by leukocytes in the PVAT of WT mice after Ang II induced 
hypertension 
The expression of, CCR2 (using CCL2 conjugated to AF647), CCR3 and CCR5 by CD19+ cells 
(a), CD3+ cells (b) and CD11b+cells (c) and total CD11b+ cells (d) in the PVAT of WT mice after 
14 days of sham or Ang II treatment. Representative plots of CD11b+ cell CCR5 expression (e) are 
shown. * p < 0.05, Mann Whitney test. 
3.6 iCCR mRNA expression  
The expression of iCCRs in the kidneys, heart and aorta of WT mice subject to 14 
days of Ang II induced hypertension was next determined by qPCR. In the kidney, 
CCR1 and CCR3 mRNA was not detected whilst there was expression of CCR2 and 
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CCR5 in both sham and Ang II treated mice (Figure 3-29a). There was no 
difference in CCR2 and CCR5 expression between the two groups. CCR3 mRNA 
was not detected in the hearts of WT mice whilst variable amounts of CCR1, 
CCR2 and CCR5 were detected in both sham and Ang II treated mice (Figure 
3-29b). There was no difference in iCCR expression between the two groups. 
CCR3 was not detected in the aorta, including the PVAT, of sham and Ang II 
treated mice. Low levels of CCR1 were detected after Ang II treatment (Figure 
3-29c). Both CCR2 and CCR5 were detected and expression of these receptors 
increased with Ang II treatment (Sham CCR1 0.0005 ± 0.0001 vs Ang II CCR1 
0.001 ± 0.0005, p < 0.05, t test; Sham CCR2 0.002 ± 0.0008 vs Ang II CCR2 0.004 
± 0.003, p < 0.01, t test; Sham CCR5 0.002 ± 0.0006 vs Ang II CCR5 0.005 ± 0.003, 
p < 0.05, t test). 
 
Figure 3-29. Kidney, heart and aortic iCCR mRNA expression of WT sham and Ang II treated 
mice 
WT mice were treated with Ang II for 14 days and the expression of CCR1, CCR2, CCR3 and 
CCR5 in the kidneys (a), heart (b) and aorta (c) was determined by qPCR. * p < 0.05, ** p < 0.01, t 
test. Data are combined from two independent experiments. 
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3.7 Plasma chemokines and cytokines 
Identifying which chemokines are upregulated in hypertension indicates which 
receptors are important. Therefore, the concentration of chemokines and 
cytokines in the plasma of WT mice after 14 days of sham or Ang II treatment 
was measured and are detailed in Table 3-1. Of the CC chemokines measured, 
CCL3, CCL7, CCL8, CCL11, CCL12, CCL19, CCL21 and CCL22 could be detected 
whilst CCL2, CCL4 and CCL20 were not detected. CCL5 could be measured in 
some samples but not all and CCL21 was lower in the hypertensive mice 
compared to the control mice. CXCL12 and CXCL13 were measured in the plasma 
but CXCL10 was not detected. CXCL13 concentration was lower in the plasma of 
Ang II treated mice than the sham treated mice. Of the cytokines measured, IL-
1β, IL-10 and VEGF were detected but no differences between sham and Ang II 
treated mice were observed. TNF, IFNγ, IL-3, IL-6, IL-7, IL-17, IL-27 and GM-
CSF could not be detected in the plasma. 
Chemokine Sham Ang II 
CCL3 1.0 ± 0.2 0.8 ± 0.2 
CCL7 49.2 ± 28.6 27.3 ± 3.1 
CCL8 4910 ±1691 7923 ± 1978 
CCL11 969 ± 255 1086 ± 15.6 
CCL12 80.7 ± 10.4 84.1 ± 4.3 
CCL19 22.7 ± 19.2 12.5 ± 4.3 
CCL21 1490 ± 104 1107 ± 219 * 
CCL22 33.8 ± 16.0 38.2 ± 5.3 
CXCL12 736 ± 274 568 ± 81.7 
CXCL13 1049 ± 44.8 848 ± 131 * 
IL-1β 112 ± 6.7 110 ± 13.9 
IL-10 5.4 ± 2.4 4.5 ± 1.2 
VEGF 5.7 ± 1.3 4.5 ± 0.7 
Table 3-1. Plasma chemokine and cytokine concentration in Ang II induced hypertension 
WT mice were subject to 14 days of Ang II induced hypertension and the concentration of 
chemokines and cytokines (pg/ml) in the plasma was measured by a Luminex assay. * p < 0.05, 
Mann Whitney test. 
3.8 Discussion 
Leukocyte iCCR expression in sham and Ang II treated mice has been investigated 
using flow cytometry, fluorescent microscopy and qPCR. The data here show 
that expression of some iCCRs can be affected by Ang II and this depends on the 
tissue. 
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3.8.1 Using antibodies and fluorescent reporter mice for flow 
cytometry 
Flow cytometry is a well-established technique used to identify leukocyte 
populations. However, using antibodies can lead to inaccurate results if the 
antibody binds to nonspecific, off-target proteins or does not effectively bind 
the target. The data here show various discrepancies in iCCR expression as 
determined using antibodies and using the REP mice (Table 3-2). For example, 
using fluorescently labelled CCL2, up to 40 % of kidney CD11b+ cells were found 
to express CCR2 whereas at least 60 % of kidney CD11b+ cells in the REP mice 
expressed CCR2. This was also seen for CD11b+SSClo cells in the spleen with up 
to 30 % of cells expressing CCR2 when detected with CCL2 compared to up to 80 
% of cells expressing CCR2 in the spleens of REP mice. In the blood of REP mice, 
some CD11b+SSClo cells expressed CCR5 whereas the CCR5 antibody did not 
detect any CCR5 expression by these cells. However, this antibody did detect 
CCR5 on F4/80+ cells in the kidney at similar levels to that observed in the REP 
mice. The CCR3 antibody produced similar results to the REP mice when spleen, 
blood and bone marrow leukocytes were analysed but this antibody showed a lot 
of nonspecific staining when used to analyse kidney leukocytes. This suggests 
that how an antibody binds to its target depends on the tissue. This could be a 
result of the cell isolation protocol. 
The REP mice did not respond to Ang II in the exact same way as WT mice. BP 
increased in the REP mice after Ang II treatment but was not as high as the WT 
mice. This is probably due to the variability of measurements taken using the 
tail cuff method and it is likely that if measured by telemetry, REP and WT mice 
would not have a difference in BP. Also, cardiac hypertrophy was shown in the 
Ang II treated WT mice but not the REP mice. This was probably due to 
variability of the sham treated REP mice. Carrying out a power calculation would 
have informed on the appropriate number of REP mice to use to show the effect 
of Ang II on cardiac hypertrophy and this should be considered for future 
experiments. Fluorescent protein expression by the REP mice reflects iCCR 
expression whilst antibodies are less accurate and less reliable than fluorescent 
reporter proteins. Therefore, the rest of this discussion will focus on data 
obtained from the REP mice. However differences in response to Ang II between 
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the WT and REP mice needs to be considered when interpreting the data from 
the REP mice. 
Tissue Cell type  iCCRs detected by 
antibodies 
iCCRs detected with REP 
mice 
Bone 
marrow 
   
 B cells None CCR1 CCR2 CCR5 
 CD11b+SSChi CCR3 CCR3 
 CD11b+SSCint CCR2 CCR3 CCR1 CCR2 CCR3 
Blood    
 B cells None CCR1 
 T cells CCR2 CCR3 CCR5 CCR2 CCR5 
 CD11b+SSChi  CCR3 CCR3 
 CD11b+SSCint CCR2 CCR3 CCR1 CCR2 CCR3 
 CD11b+SSClo  CCR2 CCR2 CCR5 
Spleen    
 B cells None CCR1 CCR5 
 T cells CCR2 CCR3 CCR2 CCR3 CCR5 
 CD11b+SSChi  CCR3 CCR3 
 CD11b+SSCint CCR2 CCR3 CCR1 CCR2 CCR3 CCR5 
 CD11b+SSClo CCR2 CCR2 CCR5 
 F4/80+ CCR3 CCR3 
Kidney    
 B cells None CCR1 CCR5 
 T cells CCR2 CCR5 CCR2 CCR5 
 CD11b+  CCR2 CCR5 CCR2 CCR5 
 F4/80+ CCR2 CCR5 CCR1 CCR2 CCR5 
PVAT    
 B cells CCR5 CCR1 CCR2 CCR5 
 T cells CCR5 CCR1 CCR2 CCR3 CCR5 
 CD11b+  CCR2 CCR5 CCR1 CCR2 CCR5 
Table 3-2. Antibody and reporter iCCR detection on leukocytes 
iCCR expression by leukocytes in the bone marrow, blood, spleen, kidney and PVAT was detected 
by flow cytometry using antibodies and fluorescent chemokines or REP mice. An antibody for 
CCR1 was not used as a specific CCR1 antibody was unavailable.  
3.8.2 Leukocyte iCCR expression 
B cells were shown to consistently express CCR1 in all tissues looked at here, 
although expression was variable between tissues. The highest expression of 
CCR1 by B cells was in the spleen and blood whilst the lowest was in the bone 
marrow. It is possible that CCR1 expression is upregulated once B cells have 
egressed from the bone marrow, and is involved in migration of B cells to, and 
localisation within, tissues. In some tissues, low levels of CCR2 or CCR5 were 
also detected. Few studies on B cell iCCR expression have been reported but 
expression of CCR1 and CCR2 by human peripheral blood B cells and CCR1, CCR2 
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and CCR5 by human tonsil B cells has been demonstrated by PCR or flow 
cytometry (Corcione et al., 2002; Kholodnyuk et al., 2017). 
T cells in the kidney, spleen and blood express low levels of CCR2 and CCR5. 
Only up to 10 % of T cells express these receptors and expression varied between 
tissues. Most studies investigating iCCR expression by T cells have been carried 
out using human peripheral blood T cells. The data shown here are consistent 
with reports of CCR2 expression by 5 – 10 % of human T cells (Moon et al., 2011). 
However, CCR5 expression has been reported to be higher in these cells (Fukada 
et al., 2002; Szczepańska et al., 2015). Few studies on splenic T cell iCCR 
expression in mice have been reported. Kidney T cells have been shown to 
express CCR1 in a mouse model of renal injury, determined by RT-PCR (Anders et 
al., 2004). Different subsets of T cells were not analysed in this study but it is 
likely that Tc, Th1, Th2, Th17 and Treg cells have different iCCR expression 
patterns. For example, human Tregs have been shown to express CCR3 and CCR5 
(Ahern et al., 2009). T cell subset iCCR expression in hypertension could be 
further investigated.  
F4/80+ cells are a heterogenous population consisting of macrophages, 
eosinophils and some DC subsets (Misharin et al., 2013; Sheng et al., 2017). This 
study has shown that kidney F4/80+ cells express CCR1, CCR2 and CCR5 which 
has also recently been shown in a mouse model of renal injury (Kaneko et al., 
2018). CCR2 was shown to be most highly expressed by F4/80+ cells in the renal 
injury model, whereas the data here suggest that CCR5 is expressed the most. 
This difference is possibly a result of using antibodies instead of reporter 
proteins or the effect of renal injury. In addition, mean fluorescence intensity 
(MFI) was used instead of expression as a percentage of cells so the actual 
proportion of F4/80+ cells expressing these receptors is not indicated. F4/80+ 
cells in the kidney and CD11b+F4/80+ cells in PVAT co-express CCR1, CCR2 and 
CCR5. This suggests that in peripheral tissues, as macrophages differentiate from 
CCR2+ monocytes, they upregulate CCR1 and CCR5. In the kidney 40 – 50 % of 
F4/80+ cells are CCR1+CCR5+. CCR1 and CCR5 may be important for localisation 
and activation within peripheral tissues whilst CCR2 is more important for 
recruitment to the tissue. However, 20 % of kidney F4/80+ cells are CCR2+CCR5+ 
so CCR2 may also be involved in localisation within tissues. It is unclear if iCCR 
3 110 
 
combinatorial expression is a result of redundancy or if each receptor has a 
unique function. It is also possible that iCCR combinatorial expression marks 
different macrophage lineages and functions. In the spleen, F4/80+ cells express 
high levels of CCR3. These cells are likely to be red pulp macrophages, cells that 
phagocytose red blood cells (Franken et al., 2015; Kurotaki et al., 2015). 
CD11b+SSChi cells are likely to be eosinophils (Geslewitz et al., 2018; Suzukawa 
et al., 2008). These cells have consistently been shown here to express only 
CCR3 in the spleen, blood and bone marrow. Expression of CCR3 by eosinophils 
has been widely reported (Kong et al., 2016; Phillips et al., 2003; Ueki et al., 
2013). In certain contexts, CCR3 expression by eosinophils can be altered. For 
example retinoic acid and IL-5 induce increased CCR3 expression (Stirling et al., 
2001; Ueki et al., 2013). However, Ang II induced hypertension had no effect on 
eosinophil CCR3 expression which therefore is unlikely to be involved in the 
pathogenesis of the disease. Few studies have associated eosinophils with 
hypertension but eosinophils have been shown to mediate the anti-contractile 
properties of PVAT (Withers et al., 2017) so CCR3 and eosinophils may be 
important in basal BP regulation. 
CD11b+SSCint cells in the spleen and blood represent a heterogeneous 
population of cells. Neutrophils are likely to form a high proportion of this 
population and monocytes, NK cells and DCs may also be included (Lakschevitz 
et al., 2016; Rose et al., 2012). Variable and low expression of CCR1 and CCR2 
by CD11b+SSCint cells is shown in this study, likely due to the heterogeneity of 
cell types in the population. In the spleen, these cells also expressed CCR3 which 
may be due to eosinophils being included in the population. Similar to the data 
here, mouse blood neutrophils have been shown to express low levels of CCR1 
and CCR2 (Mercer et al., 2014). CCR1 and CCR2 expression is higher in lung 
neutrophils than blood neutrophils so expression of these receptors may be 
upregulated when neutrophils infiltrate tissues (Mercer et al., 2014). 
CD11b+SSClo cells in the spleen and blood constitute a population of monocytes. 
NK cells and DCs may also be included (Lakschevitz et al., 2016; Rose et al., 
2012). These cells have high CCR2 expression and some CCR5 expression. Both of 
these receptors have been shown to be expressed by mouse blood monocytes 
(Tacke et al., 2007). Some of these cells also co-express the two iCCRs with the 
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majority of CCR5+ CD11b+SSClo cells also expressing CCR2. Whether CCR5 has a 
unique function on these cells or acts redundantly with CCR2 is unclear. It has 
been suggested that Ly6Clo monocytes use CCR5 to migrate to plaques in a 
model of atherosclerosis (Tacke et al., 2007). It is possible that these cells use 
CCR5 to migrate in a tissue specific manner. Monocytes were not separated into 
Ly6Chi and Ly6Clo populations in this study which should be carried out to 
further characterise monocyte iCCR expression as this could highlight differences 
of CCR2 and CCR5 expression between monocyte subsets. Similar to CD11b+SSClo 
cells, the CD11b+ cells identified in the kidneys and PVAT in this study also 
showed CCR2 and CCR5 expression. These cells were either CCR2+, CCR2+CCR5+ 
or did not express any of the iCCRs. These may represent different cell types 
that are CD11b+ and could be further identified with more specific cell markers. 
3.8.3 Altered iCCR and chemokine expression in Ang II induced 
hypertension 
RNA was extracted from combined aorta and PVAT tissue and CCR2 and CCR5 
mRNA expression significantly increased following 14 days of Ang II treatment. 
This has previously been observed in DOCA-salt induced hypertension (Chan et 
al., 2012). An increase in CCR2+ and CCR5+ leukocytes in the aorta and PVAT 
may influence the mRNA expression of these receptors detected in the whole 
tissue. In this study, Ang II did not affect PVAT leukocyte infiltration but 
previously PVAT infiltration by T cells, including CCR5+ T cells, and macrophages 
has been reported in hypertensive mice (Guzik et al., 2007; Mikolajczyk et al., 
2016). CCR5 has been implicated in monocyte migration to atherosclerotic 
plaques and monocyte CCR5 expression increased in a mouse model of 
atherosclerosis (Tacke et al., 2007). CCR5+ monocytes may accumulate in the 
aorta in hypertension and could be involved in the increased risk of 
atherosclerosis observed in the disease. It is also possible that EC and VSMC 
CCR2 and CCR5 expression is upregulated after Ang II treatment, although this 
was not seen in microscopy images. 
After 7 and 14  days of Ang II induced hypertension, no differences in iCCR 
expression by the leukocytes analysed in the kidney were observed. CCR2 and 
CCR5 mRNA expression in the whole kidney also did not change in response to 
Ang II treatment. Contrasting to this, the DOCA-Ang II model increased CCR5 
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mRNA expression in the renal cortex (Krebs et al., 2012), possibly an effect only 
seen in longer hypertension models.  
Microscopy images showed CCR5 and low CCR2 expression in the heart and 
kidney as well as clear CCR2 and CCR5 expression in the PVAT. There were no 
obvious differences between sham and Ang II treated mice. Any differences in 
iCCR expression in these tissues could be subtle and vary between cell types so 
are unlikely to be revealed in 2D microscopy images. In addition, the kidney and 
heart are highly autofluorescent and it is possible some positive cells will not be 
seen. 
Human circulating monocytes have been shown to have increased CCR5 
expression in hypertensive patients compared to normotensive controls as well 
as expression of CCR1 (Syrbe et al., 2007). This was not seen here but that may 
be a result of species differences. Human monocyte CCR2 expression has been 
shown to not differ between hypertensive and normotensive individuals (Syrbe et 
al., 2007) which is similar to the results in this study. 
In the spleen, iCCR expression by all leukocytes analysed in this study was not 
affected by Ang II. The spleen is a secondary lymphoid organ that facilitates the 
interaction of APCs and lymphocytes. The spleen regulates the immune response 
so could be altered in hypertension. It has been suggested that infiltrating T 
cells in the kidney and aorta originate from the spleen and splenectomised mice 
are protected from Ang II induced BP elevation (Carnevale et al., 2014). 
Leukocyte iCCR expression may not be affected by Ang II in the spleen, but iCCR 
expression could change once leukocytes have migrated, or are migrating, to 
target organs such as the aorta. 
The iCCR ligands CCL2, CCL3 and CCL5 have been shown to be elevated in the 
plasma of hypertensive patients (Parissis et al., 2002). CCL2 was not detected 
with the Luminex assay used in this study and CCL5 was only detected in half of 
the samples analysed. The concentration of these chemokines should be verified 
using an ELISA. Only very low levels of CCL3 were detected and Ang II had no 
effect on CCL3 concentration. This contrasts to observations in hypertensive 
patients and may be a result of species differences. The concentration of CCL21 
in the plasma was lower in the Ang II treated mice compared to the control 
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mice. CCL21 is a homeostatic chemokine involved in the homing of T cells and 
DCs to secondary lymphoid organs (Förster et al., 2008) and has not previously 
been implicated in hypertension. Through reducing CCL21 production, it is 
possible that T cell and DC migration is redirected from lymphoid organs to 
peripheral tissues. CCL21 binds to CCR7, not any of the iCCRs, so it is unlikely 
that altered CCL21 expression relates to iCCR expression in Ang II induced 
hypertension. The iCCR ligands CCL7, CCL8 and CCL11 were detected in the 
plasma but Ang II had no effect on their concentration. CXCL13 was lower in the 
hypertensive mice. CXCL13 binds to CXCR5 and few studies have focused on 
these in hypertension. However, a CXCL13 gene polymorphism has been 
associated with hypertension (Timasheva et al., 2018). 
3.9 Conclusion 
In this chapter, iCCR expression by leukocytes in the kidney, PVAT, spleen, blood 
and bone marrow in Ang II induced hypertension has been characterised. 
Antibodies and mice expressing iCCR reporter proteins were used for flow 
cytometry and it was determined that REP mice were better for analysis of iCCR 
expression. No changes in iCCR expression in response to Ang II were identified 
for the cell types analysed but CCR2 and CCR5 mRNA expression was shown to be 
elevated in the aortas and PVAT of Ang II treated mice. 
Altered vasculature iCCR expression could be involved in the pathogenesis of 
hypertension. Further studies could use the Ang II model of hypertension with 
CCR5-/- mice as CCR5 mRNA expression in the vasculature was increased in 
response to Ang II. The longer DOCA-Ang II model of hypertension has been used 
to study CCR5-/- mice (Krebs et al., 2012) but there are no reports of CCR5-/- 
mice with 14 days of Ang II induced hypertension. As well as this, iCCR 
expression at more time points could be looked at, such as after 3 and 28 days of 
Ang II induced hypertension. This would reveal the temporal changes of iCCR 
expression that occur during the disease. 
Overall, this chapter highlights potential involvement of aortic CCR2 and CCR5 in 
hypertension but further understanding is required in order to identify how these 
could be therapeutically targeted to treat hypertension and end organ damage.
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The effect of iCCR deficiency in Ang II induced 
hypertension
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4 The effect of iCCR deficiency in Ang II induced 
hypertension 
4.1 Introduction 
Due to the complexity of the chemokine system, identifying the exact role of 
chemokine receptors in various contexts has been a challenge. This has resulted 
in the development of only three successful drugs that target chemokine 
receptors. These are the CCR5 antagonist Maraviroc, the CXCR4 antagonist 
Plerixafor and the monoclonal antibody to CCR4 Mogamulizumab (Dorr et al., 
2005; Duvic et al., 2015; Teusink et al., 2016). When studying iCCRs, it has so far 
only been practical to generate mice deficient for a single iCCR as the genes for 
each receptor are in close genomic proximity and it is not practical to generate 
compound receptor deficient mice by interbreeding. The full role, combinatorial 
or individual, of the iCCRs may not be revealed when using single receptor 
deficient mice as there could be compensation from the other receptors. To 
overcome this, mice deficient for the whole genomic cluster containing the iCCR 
genes (iCCR-KO) have been generated (Dyer et al., 2019). 
Some of the iCCRs and their ligands have been implicated in the pathogenesis of 
hypertension. For example, the expression of CCR2 and CCR5 in the aorta and 
the expression of CCR5 in the kidney have been shown to be elevated in 
hypertensive animal models (Chan et al., 2012; Krebs et al., 2012; Moore et al., 
2015). As well as this, hypertensive patients have elevated circulating CCL2 
(Antonelli et al., 2012; Madej et al., 2005). The previous chapter revealed that 
after 14 days of Ang II induced hypertension, aortic CCR2 and CCR5 expression 
increases. A deficiency of CCR2 or CCR5 has not been shown to effect BP in 
hypertension. However, CCR2-/- mice are protected against Ang II induced 
vascular remodelling (Ishibashi et al., 2004; Krebs et al., 2012). The effect of 
CCR1 or CCR3 deficiency in hypertension has not been studied. 
As only single iCCR deficient mice have been used to study hypertension, the 
exact role of each iCCR in the disease is not fully understood. Therefore, the 
aim of the experiments described in this chapter was to investigate the effect of 
deficiency in all iCCRs in Ang II induced hypertension. iCCR-KO mice were 
subject to 14 days of Ang II infusion. BP, vascular function and oxidative stress 
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were assessed, along with plasma chemokine concentration, inflammation of the 
kidneys, spleen and PVAT and Ang II induced hypertrophy. This has shown how 
lack of all four iCCRs affects the pathogenesis of hypertension, increasing our 
understanding of iCCRs in the disease. 
4.2 Blood pressure 
WT and iCCR-KO mice were subject to Ang II induced hypertension and BP was 
measured for 14 days by the tail cuff method (Figure 4-1) or by telemetry 
(Figure 4-2). In both WT and iCCR-KO mice, upon Ang II infusion, systolic BP 
started to increase 1 day after treatment and increased by about 40 mmHg by 
day 14 (Figure 4-2a). Diastolic BP increased by about 30 mmHg (Figure 4-2b). 
There was no difference in BP between the WT and iCCR-KO mice. When BP was 
measured in sham treated mice by the tail cuff method, the WT mice had a 
higher BP than the iCCR-KO mice at days 12 – 14. There was no difference in 
baseline BP before Ang II infusion, measured by both the tail cuff method and 
telemetry. 
 
Figure 4-1. The effect of iCCR deficiency on BP measured by the tail cuff method 
WT and iCCR-KO mice were subject to Ang II induced hypertension or sham treatment for 14 days 
and systolic BP was measured by the tail cuff method. WT sham n = 8; WT Ang II n = 8; iCCR-KO 
sham n = 10; iCCR-KO Ang II n = 11. Data are combined from two independent experiments. * p < 
0.05, ** p < 0.01, Two-Way ANOVA with repeated measures. 
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Figure 4-2. The effect of iCCR deficiency on BP measured by telemetry 
Telemetry probes were implanted into WT and iCCR-KO mice and BP was measured. After 
recovery the mice were given Ang II for 14 days and systolic (a) and diastolic (b) BP was 
measured. WT n = 7; iCCR-KO n = 7. Data are combined from two independent experiments.  
4.3 Vascular function and oxidative stress 
ACh induces blood vessel relaxation through eNOS activation in ECs and the 
subsequent production of NO. NO then induces VSMC relaxation (Gewaltig and 
Kojda, 2002). Vascular function of the aorta and mesenteric arteries, resistance 
vessels that contribute to systemic BP, from sham or Ang II treated WT and iCCR-
KO mice was determined by measuring the relaxation response of the vessels to 
ACh. This measured endothelium-dependent relaxation. Endothelium-
independent relaxation was also determined by measuring the relaxation 
response to the NO donor SNP (Patik et al., 2016). The relaxation response to 
ACh was impaired in both WT and iCCR-KO aortas following Ang II infusion 
a 
b 
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compared to sham aortas. However, the iCCR-KO aortas showed a slight 
protection from this impairment compared to WT aortas. There was also a 
difference in the relaxation response between sham treated WT and iCCR-KO 
aortas. There was no difference in relaxation response to SNP between the WT 
and iCCR-KO aortas (Figure 4-3a). The mesenteric arteries from Ang II treated 
iCCR-KO mice showed improved relaxation to ACh compared to the mesenteric 
arteries from WT Ang II treated mice but no differences in the response to SNP 
(Figure 4-3b). 
Oxidative stress in the aortas of sham and Ang II treated WT and iCCR-KO mice 
was assessed by measuring superoxide levels. Superoxide reacts with NO to form 
peroxynitrite, reducing NO bioavailability (Mordi et al., 2016). Increased vascular 
superoxide has been associated with impaired vascular function (Guzik et al., 
2007). There were no differences in aortic superoxide between the WT and iCCR-
KO mice. Upon Ang II infusion, superoxide levels were more variable than after 
sham treatment and tended to be higher but this was not significant (Figure 
4-3c). 
Overall, the aorta and mesenteric arteries of iCCR-KO mice are slightly 
protected from Ang II induced vascular dysfunction compared to WT mice but 
iCCR deficiency or Ang II treatment did not affect aortic superoxide levels. 
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Figure 4-3. The effect of iCCR deficiency on vascular function and oxidative stress in Ang II 
induced hypertension 
WT and iCCR-KO mice were subject to Ang II induced hypertension and vascular function was 
determined by measuring the relaxation response of the aorta (a) and mesenteric arteries (b) to 
increasing concentrations of ACh or SNP. Oxidative stress was measured by detecting superoxide 
in the aorta (c). Aorta vascular function: WT sham n = 3; WT Ang II n = 7; iCCR-KO sham n = 7; 
iCCR-KO Ang II n = 9. Data are combined from two independent experiments. Error bars = SEM. 
Mesentery vascular function WT Ang II n = 5; iCCR-KO Ang II n = 5. # p < 0.05 WT sham vs iCCR-
KO sham; * p < 0.05 WT Ang II vs iCCR-KO Ang II; $ p < 0.05 iCCR-KO sham vs iCCR-KO Ang II, 
Two-Way ANOVA with repeated measures. 
4.4 Plasma chemokines 
Chemokine expression may increase in Ang II induced hypertension to enhance 
migration of leukocytes to tissues that regulate BP such as the kidneys and 
vasculature. Any changes to chemokine expression could indicate which 
chemokine receptors are important. Therefore, the concentration of CC 
chemokines was determined in the plasma of WT and iCCR-KO mice following 14 
b 
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days of Ang II or sham treatment and are described in Table 4-1. Plasma CCL3 
and CCL7 levels were significantly higher in the iCCR-KO mice compared to WT 
mice. This was observed for both sham and Ang II treated mice. In the iCCR-KO 
mice, Ang II treatment induced an increase in plasma CCL3 concentration. CCL5, 
CCL8, CCL11, CCL12, CCL19, CCL21 and CCL22 were detected in the plasma but 
neither iCCR deficiency nor Ang II treatment had an effect on plasma 
concentration. CCL2 and CCL4 were not detected. CCL20 was detected in some, 
but not all samples. 
Chemokine WT Sham WT Ang II iCCR-KO Sham iCCR-KO Ang II 
CCL3 1.4 ± 0.3 1.4 ± 0.1 98.7 ± 37 ** 191 ± 81.6 ##; † 
CCL5 171 ± 21.4 121 ± 48.7 315 ± 103 283 ± 116 
CCL7 57.9 ±21.7 59.9 ± 49.5 748 ± 431 ** 509 ± 263 ## 
CCL8 7881 ± 1734 6335 ± 1313 8051 ± 3089 5245 ± 1290 
CCL11 1328 ± 681 994 ± 715 1902 ± 786 1546 ± 851 
CCL12 334 ± 126 254 ± 288 776 ± 483 620 ± 399 
CCL19 29.2 ± 1.9 26.4 ± 8.2 31.0 ± 9.2 30.3 ± 7.0 
CCL21 5520 ± 101 5330 ± 440 5543 ± 153 4274 ± 1852 
CCL22 182 ± 84.7 116 ± 91.3 155 ± 62.2 122 ± 74.5 
Table 4-1. Plasma chemokine concentration in Sham and Ang II treated WT and iCCR-KO 
mice 
The concentration (pg/ml) of CC chemokines in the plasma of WT and iCCR-KO mice following 14 
days of sham or Ang II treatment was measured using a Luminex assay. ** p < 0.01 vs WT sham; 
## p < 0.01 vs WT Ang II; † p < 0.05 vs iCCR-KO Sham, Two-Way ANOVA. 
4.5 Inflammation 
The accumulation of leukocytes in the kidneys and vasculature has been 
implicated in hypertension (Guzik et al., 2007; Mikolajczyk et al., 2016; Ozawa 
et al., 2006). Therefore, the infiltration of CD19+ B cells, CD3+ T cells, CD4+ and 
CD8+ T cells and CD11b+F4/80+ cells was investigated in the kidneys and PVAT of 
WT and iCCR-KO mice following 14 days of sham or Ang II treatment. These cell 
types were also analysed in the spleen as this could indicate whether these cells 
migrate from, or accumulate, in the spleen in hypertension. In addition, CD11b+ 
monocyte and CD11c+MHC II+ DC populations were investigated in the bone 
marrow and blood of Ang II treated WT and iCCR-KO mice as these cells have 
been implicated in hypertension (Vinh et al., 2010; Wenzel et al., 2011). This 
also indicates how these cells migrate from the bone marrow to the blood and 
then to tissues. This analysis revealed some differences between WT and iCCR-
KO mice. The gating strategy for kidney, PVAT and spleen analysis is detailed 
below (Figure 4-4). 
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Figure 4-4. Gating strategy for the analysis of kidney, PVAT and spleen leukocytes from WT 
and iCCR-KO mice with Ang II induced hypertension 
CD45+ cells were gated from live, single cells. CD19+ and CD3+ cells were gated from the CD45+ 
population then CD8+ and CD4+ cells were gated from the CD3+ population. F4/80+ cells were 
gated from CD11b+ cells. 
4.5.1 Bone marrow 
The effect of iCCR-deficiency on bone marrow CD11b+ monocyte and DC 
populations in Ang II induced hypertension was investigated. CD11b+Ly6C- cells, 
which could be neutrophils, CD11b+Ly6C+ patrolling monocytes and 
CD11b+Ly6C++ inflammatory monocytes (Evrard et al., 2018; Kratofil et al., 
2017) were gated from CD11b+ cells, as were CD11c+MHC II+ DCs (Figure 4-5). 
Sham treated mice were not used as these experiments were carried out using 
the Ang II treated mice subject to telemetry BP measurements. iCCR-KO mice 
had more CD11b+Ly6C- cells (Ang II WT 1.2 ± 0.1 vs Ang II iCCR-KO 1.7 ± 0.1 % 
CD45+ cells, p < 0.01, Mann Whitney test) and more CD11b+Ly6C++ cells (Ang II 
WT 6.8 ± 0.5 vs Ang II iCCR-KO 8.4 ± 0.9 % CD45+ cells, p < 0.05, Mann Whitney 
test) in the bone marrow than WT mice (Figure 4-6). There was also an increase 
in CD11b+CD11c+MHC II+ cells in the bone marrow of iCCR-KO mice (Ang II WT 
0.3 ± 0.1 vs Ang II iCCR-KO 1.0 ± 0.2 % CD45+ cells, p < 0.01, Mann Whitney test). 
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These differences are demonstrated by representative flow cytometry plots 
(Figure 4-6d, f). 
 
Figure 4-5. Gating strategy for the analysis of bone marrow leukocytes in 14 day Ang II 
treated WT and iCCR-KO mice 
CD45+ cells were gated from live, single cells. CD11b+ cells were gated on CD45+ cells and gated 
into Ly6C-, Ly6C+, Ly6C++ and CD11c+MHC II+ cells. 
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Figure 4-6. The effect of iCCR deficiency on bone marrow leukocytes in Ang II induced 
hypertension 
WT and iCCR-KO mice were treated with Ang II for 14 days and the number of CD11b+Ly6C- cells 
(a), CD11b+Ly6C+ cells (b), CD11b+Ly6C++ cells (c) and CD11b+CD11c+MHC II+ cells in the 
bone marrow was determined. Representative flow cytometry plots of CD11b+Ly6C+ (d) and 
CD11c+MHC II+ (f) populations are shown. * p < 0.05; ** p < 0.01, Mann Whitney test.  
4.5.2 Blood 
The effect of iCCR-deficiency on blood B cell and T cell populations in Ang II 
induced hypertension was investigated, along with the CD11b+ monocyte and DC 
populations described above. CD19+ B cells and CD3+ T cells were gated from 
CD45+ cells. Expression of CD44, a marker of activated and memory T cells 
(Baaten et al., 2010; Maeshima et al., 2011), was also determined (Figure 4-7). 
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As with the bone marrow analysis, sham treated mice were not used for these 
experiments. 
 
Figure 4-7. Gating strategy for the analysis of leukocytes in the blood of WT and iCCR-KO 
Ang II treated mice 
CD45+ cells were gated from live, single cells. CD19+ and CD3+ cells were gated from the CD45+ 
population. The CD3+ cells were gated into CD44-, CD44+ and CD44++ populations. CD11b+ cells 
were gated from CD45+ cells and further gated into Ly6C-, Ly6C+, Ly6C++ and CD11c+MHC II+ 
cells. 
Similar to the bone marrow, iCCR-KO mice had more CD11b+Ly6C- cells in the 
blood than WT mice (Ang II WT 7.1 ± 0.4 vs Ang II iCCR-KO 9.6 ± 1.3 % CD45+ 
cells, p < 0.01, Mann Whitney test). However, there were fewer CD11b+Ly6C++ 
cells in the blood of WT mice (Ang II WT 5.9 ± 0.9 vs Ang II iCCR-KO 1.5 ± 0.6 % 
CD45+ cells, p < 0.01, Mann Whitney test) which contrasts to the bone marrow 
(Figure 4-8). The blood of iCCR-KO mice also had fewer CD11b+CD11c+MHC II+ 
cells than the blood of WT mice (Ang II WT 0.5 ± 0.1 vs Ang II iCCR-KO 0.3 ± 0.1 
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% CD45+ cells, p < 0.05, Mann Whitney test), contradicting the observations for 
the bone marrow. These reductions are reflected in the representative flow 
cytometry plots (Figure 4-8d, f). 
 
Figure 4-8. The effect of iCCR deficiency on blood leukocytes in Ang II induced 
hypertension 
WT and iCCR-KO mice were treated with Ang II for 14 days and the number of CD11b+Ly6C- cells 
(a), CD11b+Ly6C+ cells (b), CD11b+Ly6C++ cells (c) and CD11b+CD11c+MHC II+ cells in the 
blood was determined. Representative flow cytometry plots of CD11b+Ly6C+ (d) and CD11c+MHC 
II+ (f) populations are shown. * p < 0.05; ** p < 0.01, Mann. Whitney test. 
Blood B cells were reduced in Ang II treated iCCR-KO mice (Ang II WT 43.5 ± 8.5 
vs Ang II iCCR-KO 32.4 ± 1.5 % CD45+ cells, p < 0.05, Mann Whitney test) whilst 
blood T cells were increased (Ang II WT 14.2 ± 1.4 vs Ang II iCCR-KO 18.7 ± 1.4 % 
CD45+ cells, p < 0.01, Mann Whitney test) compared to Ang II treated WT mice 
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(Figure 4-9a, b). CD44 expression by T cells was also assessed (Figure 4-9c). 
There were more CD44- T cells (Ang II WT 4.0 ± 0.4 vs Ang II iCCR-KO 5.8 ± 0.4 % 
CD45+ cells, p < 0.01, Mann Whitney test) and CD44+ T cells (Ang II WT 5.0 ± 0.7 
vs Ang II iCCR-KO 7.1 ± 0.5 % CD45+ cells, p < 0.01, Mann Whitney test) in the 
blood of iCCR-KO mice than WT mice. CD44++ T cells did not differ between WT 
and iCCR-KO mice. These differences are demonstrated in representative flow 
cytometry plots (Figure 4-9d). 
 
Figure 4-9. In Ang II induced hypertension, iCCR deficiency reduces the proportion of B 
cells in the blood whilst increasing the proportion of CD44- and CD44+ T cells 
WT and iCCR-KO mice were treated with Ang II for 14 days. The proportion of circulating CD19+ 
cells was lower in the iCCR-KO mice (a) whilst the proportion of CD3+ cells was higher (b). 
CD3+CD44- and CD3+CD44+ cells were increased in iCCR-KO mice but CD3+CD44++ cells were 
not affected by iCCR deficiency (c). Representative flow cytometry plots of CD19+, CD3+, 
CD3+CD44-, CD3+CD44+ and CD3+CD44++ populations are shown (d). * p < 0.05, ** p < 0.01, 
Mann Whitney test. 
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4.5.3 Spleen 
The spleens of iCCR-KO mice had fewer CD45+ cells as a proportion of live cells 
than WT mice after both sham and Ang II treatment (Figure 4-10a; Sham WT 92.8 
± 1.3 vs Sham iCCR-KO 84.2 ± 1.4 % live+ cells, p < 0.05, Two-Way ANOVA; Ang II 
WT 92.0 ± 2.0 vs Ang II iCCR-KO 80.3 ± 6.8 % live+ cells, p < 0.01, Two-Way 
ANOVA). This difference was not obvious from representative flow cytometry 
plots and was not reflected in the total number of CD45+ cells (Figure 4-10b, d). 
CD45+ cell infiltration was not affected by Ang II treatment. Ang II infusion also 
did not affect the infiltration of CD11b+F4/80+ cells, B cells and T cells in both 
WT and iCCR-KO mice (Figure 4-10, Figure 4-11) but iCCR deficiency did alter the 
infiltration of T cells in the spleen (Figure 4-11b, c). After Ang II treatment, the 
total number of T cells in the spleen was lower in the iCCR-KO mice (Ang II WT 
1.5 x 107 ± 2.8 x 106 vs Ang II iCCR-KO 1.0 x 107 ± 2.4 x 106 total cells, p < 0.05, 
Two-Way ANOVA). There were also fewer CD8+ T cells in the Ang II treated iCCR-
KO mice (Ang II WT 12.5 ± 2.4 vs Ang II iCCR-KO 8.5 ± 1.7 % CD45+ cells, p < 
0.05, Two-Way ANOVA). These differences were not seen in sham treated mice. 
Overall, iCCR deficiency reduced the proportion of CD45+ cells in the spleen. In 
the context of Ang II induced hypertension, iCCR deficiency reduced the total 
number of splenic T cells and the proportion of infiltrating CD8+ T cells. 
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Figure 4-10. iCCR deficiency and leukocytes in the spleen in Ang II induced hypertension 
The accumulation of CD45+ cells (a), total CD45+ cells (b) and CD11b+F4/80+ cells (c) in the 
spleens of WT and iCCR-KO mice given Ang II or sham treatment for 14 days was determined. 
Representative flow cytometry plots of CD45+ cells are shown (d). * p < 0.05, ** p < 0.01, Two-Way 
ANOVA. 
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Figure 4-11. The effect of iCCR deficiency on T and B cells in the spleen in Ang II induced 
hypertension 
The proportion of CD3+ cells (a), total CD3+ cells (b), CD8+ cells (c), CD4+ cells (d) CD4-CD8- 
cells (e) and CD19+ cells (f) was measured in the spleens of WT and iCCR-KO mice subject to 14 
days of Ang II induced hypertension. * p < 0.05, Two-Way ANOVA. 
4.5.4 Kidney 
Infiltration of CD45+ leukocytes, B cells and CD11b+ F4/80+ cells in the kidneys 
was not affected by Ang II treatment or iCCR deficiency (Figure 4-12). Overall T 
cell infiltration was also not effected by Ang II treatment or iCCR deficiency but 
there was a higher infiltration of double negative CD4-CD8- T cells in the kidneys 
of Ang II treated iCCR-KO mice compared to Ang II treated WT mice (Ang II WT 
1.7 ± 0.5 vs Ang II iCCR-KO 2.6 ± 0.5 % CD45+ cells, p < 0.01, Two-Way ANOVA). 
There were no differences in CD8+ and CD4+ T cells between all groups (Figure 
4-13). 
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Figure 4-12. iCCR deficiency and kidney infiltration of leukocytes in Ang II induced 
hypertension 
The infiltration of CD45+ cells (a), CD19+ cells (b) and CD11b+F4/80+ cells (c) was determined in 
the kidneys of WT and iCCR-KO mice following Ang II induced hypertension for 14 days. 
 
Figure 4-13. iCCR deficiency and kidney T cell infiltration in Ang II induced hypertension 
The infiltration of CD3+ cells (a), CD8+ cells (b), CD4+ cells (c) and CD4-CD8- cells (d) in the 
kidneys of WT and iCCR-KO mice after 14 days of sham or Ang II treatment was determined. ** p 
< 0.01, Two-Way ANOVA. 
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4.5.5 PVAT 
Infiltration of leukocytes in the PVAT was measured as a proportion of cells and 
total number of cells per mg of tissue. There were no differences for any cell 
types analysed, including B cells, T cell subsets and CD11b+F4/80+ cells, 
between sham and Ang II treated WT and iCCR-KO mice (Figure 4-14, Figure 
4-15). 
 
Figure 4-14. iCCR deficiency and PVAT infiltration of leukocytes in Ang II induced 
hypertension 
The infiltration as a proportion and total number of CD45+ cells (a), CD19+ cells (b) and 
CD11b+F4/80+ cells (c) was determined in the PVAT of WT and iCCR-KO mice following Ang II 
induced hypertension for 14 days. 
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Figure 4-15. iCCR deficiency and PVAT T cell infiltration in Ang II induced hypertension 
The infiltration as a proportion and total number of CD3+ cells (a), CD8+ cells (b), CD4+ cells (c) 
and CD4-CD8- cells (d) in the PVAT of WT and iCCR-KO mice after 14 days of sham or Ang II 
treatment. 
4.6 Cardiac and vascular remodelling 
Hypertension induces the development of cardiac hypertrophy and interstitial 
fibrosis which can lead to heart failure (Suthahar et al., 2017). Further, Ang II 
can induce phenotypic switching of VSMCs from a contractile phenotype to a 
proliferative phenotype which leads to hypertrophy and inflammation 
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(Montezano et al., 2014). The effect of iCCR-deficiency on the aortic and cardiac 
hypertrophic effects of Ang II was investigated in WT and iCCR-KO mice after 14 
days of Ang II induced hypertension. 
4.6.1 Aortic hypertrophy 
After 14 days of sham or Ang II treatment, the thickness of the aortic medial 
layer was measured for the aortas of WT and iCCR-KO mice to assess aortic 
hypertrophy. No differences were observed between the groups, although there 
appeared to be a trend for increased aortic hypertrophy in the Ang II treated 
mice (Figure 4-16). 
 
WT Sham WT Ang II 
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Figure 4-16. The effect of iCCR deficiency on aortic hypertrophy in Ang II induced 
hypertension 
WT and iCCR-KO mice were subject to Ang II induced hypertension and aortic hypertrophy was 
assessed by measuring the width of the aortic medial layer (a) Representative H&E stained images 
are shown (b). Scale bar = 50 µm. 
4.6.2 Cardiac hypertrophy and fibrosis 
As a risk factor for heart failure, cardiac remodelling in hypertension should be 
treated. This was assessed in sham and Ang II treated WT and iCCR-KO mice by 
measuring the heart weight and looking at collagen deposition with a picrosirius 
red stain. When normalised to body weight, the heart weight increased in Ang II 
treated mice (Sham WT 5.7 ± 0.3 vs Ang II WT 7.2 ± 0.5 mg/g, p < 0.01, Two-Way 
ANOVA; Sham iCCR-KO 5.9 ± 0.8 vs Ang II iCCR-KO 7.3 ± 0.5 mg/g, p < 0.01, Two-
Way ANOVA) and there were no differences between WT and iCCR-KO mice 
(Figure 4-17a). When normalised to tibia length, there was only an increase in 
heart weight in the iCCR-KO mice following Ang II treatment (Sham iCCR-KO 8.1 
± 1.6 vs Ang II iCCR-KO 10.4 ± 1.0 mg/mm, p < 0.05, Two-Way ANOVA) although 
there was a trend for Ang II to increase heart weight in WT mice (Figure 4-17b). 
Collagen deposition in the heart did not differ between the groups (Figure 4-17c, 
d). 
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Figure 4-17. The effect of iCCR-deficiency on cardiac remodelling in Ang II induced 
hypertension 
WT and iCCR-KO mice were subject to Ang II induced hypertension and cardiac hypertrophy was 
assessed by measuring the ratio of heart weight to body weight (a) and tibia length (b) and 
collagen deposition by picrosirius staining (c). Representative images are shown (d). Red staining 
indicates collagen. Scale bar = 100 µm. * p < 0.05, ** p < 0.01, Two-Way ANOVA. 
4.7 Discussion 
iCCR-KO mice were subject to 14 days of Ang II induced hypertension and 
hypertensive phenotypes were assessed. These included BP, vascular function 
and oxidative stress as well as inflammation and cardiac hypertrophy. This has 
revealed how iCCR deficiency affects hypertension, increasing our understanding 
of how iCCRs contribute to the disease. 
4.7.1 iCCRs and BP, vascular function and oxidative stress 
The BP of both WT and iCCR-KO mice increased in response to Ang II and there 
was no difference between the Ang II treated WT and iCCR-KO mice. Previously 
b a 
WT Sham WT Ang II 
iCCR-KO Sham iCCR-KO Ang II 
c 
d 
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it has been shown that CCR2 or CCR5 deficiency also does not affect BP in 
hypertension (Ishibashi et al., 2004; Krebs et al., 2012). This would suggest that 
the iCCRs are not involved in elevating BP in hypertension. However, treatment 
of mice subject to Ang II or DOCA-salt induced hypertension with the CCR2 
antagonist INCB3344 reduces BP (Chan et al., 2012; Moore et al., 2015). This 
could suggest that CCR2, and possibly other iCCRs, contribute to BP regulation in 
hypertension but other mechanisms that compensate for this are established 
when the mice are deficient for the receptors from birth. This could be 
investigated using a combination of iCCR antagonists. 
IL-17-/- mice subjected to Ang II induced hypertension undergo an initial 
elevation in BP that is similar to WT mice at the 14 day time point but then falls 
to a level lower than that of WT mice by 21 and 28 days of Ang II treatment 
(Madhur et al., 2010). 14 days of Ang II induced hypertension may not be long 
enough to see the effect of iCCR deficiency on BP and this model could be run 
for longer. Further, depletion of macrophages, T cells and B cells have all been 
associated with reduced BP in hypertensive animal models (Chan et al., 2015; 
Rudemiller et al., 2014; Thang et al., 2015). Factors other than iCCRs may have 
influenced leukocyte migration, enabling them to still regulate Ang II induced BP 
elevation in iCCR-KO mice. 
The BP of sham treated WT mice was higher than the sham treated iCCR-KO 
mice at days 12 – 14 of tail cuff BP measurements. At this time point, the mice 
were 14 – 15 weeks old. No differences in baseline BP were seen between WT 
and iCCR-KO mice when measured by telemetry, when the mice were 11 – 12 
weeks old. This difference in BP may be related to age and only occurs once the 
mice are around 14 weeks old. Measuring the BP of aged mice using the more 
reliable telemetry method would reveal if iCCR deficiency can protect from an 
increase in BP associated with aging (Parati et al., 2015). 
Aortic vascular function was impaired in Ang II treated mice compared to sham 
treated mice, as has been shown before (Guzik et al., 2007). The iCCR-KO mice 
showed some protection from this impairment, although variability between 
mice meant that there was not a large protection. CCL5-/- mice have been shown 
to be protected from Ang II induced aortic dysfunction (Mikolajczyk et al., 
2016). As CCL5 binds to CCR1 and CCR5, leukocytes may be recruited to the 
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aorta via these receptors and contribute to vascular dysfunction. Recruitment of 
NK cells to the aorta has been associated with Ang II induced vascular 
dysfunction (Kossmann et al., 2013) and mice with depleted monocytes are also 
protected from Ang II induced aortic dysfunction (Wenzel et al., 2011). 
Leukocytes have a role in vascular dysfunction and it is likely that iCCR 
deficiency is protective from Ang II induced vascular dysfunction through altered 
leukocyte recruitment. The infiltration of leukocytes in the PVAT was 
determined in this study but further analysis of the whole aorta is required. 
iCCR-KO mesenteric arteries showed improved relaxation to ACh after Ang II 
treatment compared to Ang II treated WT vessels. Sham treated mice were not 
used so the extent of the effect of the Ang II was not determined, although 
impaired relaxation to ACh of hypertensive mesenteric arteries compared to 
controls has been shown (Ye et al., 2019). The improved relaxation seen in iCCR-
KO mice may be due to altered leukocyte recruitment. NK cells accumulate in 
mesenteric arteries from L-NAME treated mice (Taherzadeh et al., 2010) but 
further characterisation of mesenteric artery leukocyte infiltration in 
hypertension is required. The response of both vessel types to SNP was not 
effected by iCCR deficiency, showing that iCCRs may mediate endothelium-
dependent, but not -independent, relaxation. 
Multiple studies have associated increased vascular superoxide with impaired 
vascular function and mice which are protected from Ang II induced vascular 
dysfunction, such as Op/Op, Rag-1-/- and CCL5-/- mice, are also protected from 
Ang II induced vascular superoxide elevation (De Ciuceis et al., 2005; Guzik et 
al., 2007; Mikolajczyk et al., 2016). No differences in aortic superoxide were 
shown between sham and Ang II treated WT and iCCR-KO mice. There was a 
trend for the Ang II treated mice to have increased aortic superoxide but the 
data were variable and therefore, not significant. A way to verify superoxide 
levels would be to determine the expression and activity of NADPH oxidases. As 
there was no difference in aortic superoxide between the WT and iCCR-KO mice, 
it is likely that superoxide level is not mediating the protection from Ang II 
induced vascular dysfunction in the iCCR-KO mice. NO release by mesenteric 
arteries has been shown to be reduced in the vessels of hypertensive rats 
compared to control rats (Stankevicius et al., 2002). It is possible that vessels 
4 138 
 
from hypertensive iCCR-KO mice release more NO than vessels from hypertensive 
WT mice and this should be further investigated. 
4.7.2 iCCRs and plasma chemokines 
iCCR-KO mice have a higher concentration of CCL3 and CCL7 in the plasma than 
WT mice and there was a trend to have increased CCL5. This was seen in both 
sham and Ang II treated mice. CCL3 binds to CCR1 and CCR5 whilst CCL7 binds to 
CCR1, CCR2, CCR3 and CCR5. Previously, iCCR-KO mice have been shown to have 
elevated plasma levels of CCL5, CCL7 and CCL11 (Dyer et al., 2019). This 
increase suggests that these chemokines have a homeostatic role and that the 
iCCRs scavenge these chemokines.  
CCL3 concentration was higher in the plasma of Ang II treated iCCR-KO mice 
compared to sham treated iCCR-KO mice. This effect was not seen in the WT 
mice. Expression of the iCCRs may have been enough to scavenge any CCL3 that 
had been produced in response to Ang II and therefore no overall increase was 
observed. It is also possible that in WT mice, leukocytes migrate towards CCL3 
and provide a feedback mechanism which switches off Ang II induced CCL3 
expression. CCL3 mRNA expression has been shown to be elevated in the kidneys 
of hypertensive mice and to be higher in hypertensive CCR5-/- mice than 
hypertensive WT mice (Krebs et al., 2012). This suggests that CCR5 is involved in 
leukocyte migration towards CCL3 in the kidney. A limitation of looking at 
plasma chemokine concentration is that it is not possible to identify where the 
chemokines originated. 
There is evidence of elevated CCL2 and CCL5 plasma concentration in 
hypertensive patients (Parissis et al., 2002). CCL2 was not detected by the 
Luminex assay used in this study and CCL5 concentration was not affected by 
Ang II. These differences could be due to differences between mice and humans. 
Data from the previous chapter showed that plasma CCL21 concentration slightly 
decreased in Ang II induced hypertension. This is not shown in this chapter and 
the data here show that some chemokine concentrations differ to those 
previously shown. This could be due to sample collection occurring at different 
times. 
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4.7.3 iCCRs and inflammation in hypertension 
Ang II did not induce an increase in any of the leukocytes analysed in the kidneys 
of WT or iCCR-KO mice, in contrast to previous studies (Evans et al., 2017; Itani 
et al., 2016; Ozawa et al., 2006). This could be due to different cell isolation 
protocols or gating strategies and could be further investigated by IHC. CCR2 
blockade with RS102895 reduces renal macrophage infiltration in hypertensive 
mice (Elmarakby et al., 2007; Kashyap et al., 2015) whilst CCR5 deficiency has 
no effect on T cell and macrophage infiltration in DOCA + Ang II induced 
hypertension (Krebs et al., 2012). This suggests that macrophages require CCR2, 
but not CCR5, to migrate to the kidney. However, as Ang II did not increase 
leukocyte infiltration in this study, the role of iCCRs could not be identified. 
iCCR deficiency resulted in an increase of kidney CD4-CD8- T cells in the 
hypertensive mice which was not seen in the sham treated mice. This could be 
due to iCCR induced changes in T cell subsets, which may only occur in 
hypertension. CD4-CD8- T cells have been shown to reside in the kidney and 
these cells are reduced in renal ischaemia reperfusion injury (Ascon et al., 
2008). 
T cells, macrophages and DCs have been shown to infiltrate the PVAT in Ang II 
induced hypertension and the expression of CCR1, CCR3 and CCR5 by T cells 
increases in the PVAT (Guzik et al., 2007; Mikolajczyk et al., 2016). In this study, 
Ang II was not shown to have this effect meaning that identifying how iCCR 
deficiency influences PVAT leukocyte infiltration was challenging. CCL5-/- and IL-
17-/- mice are both protected from Ang II induced PVAT leukocyte infiltration 
(Madhur et al., 2010; Mikolajczyk et al., 2016). It is hypothesised that CCL5 
recruits T cells to the PVAT via iCCRs. which then produce cytokines that 
mediate oxidative stress and endothelial dysfunction. If this is the case, Ang II 
treated iCCR-KO mice would have fewer infiltrating T cells, and possibly other 
leukocytes, which was not observed. 
As inflammation develops in hypertension, it is likely that changes are seen in 
lymphoid organs. In the spleen, Ang II had no effect on the number of the 
leukocyte types analysed here. CD69 expression, a marker of activation, has 
been shown to increase by splenic T cells following Ang II treatment (Caillon et 
al., 2017). Activation of T cells was not investigated here but it is possible iCCR 
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deficiency could influence T cell activation. The monocyte population in the 
spleen may be reduced in rats after Ang II treatment and it has been suggested 
that this is due to migration from the spleen to the heart (N. P. Wang et al., 
2017). Only splenic macrophages were analysed in this study and these were not 
affected by Ang II in WT and iCCR-KO mice. Additional markers such as Ly6C 
would be required to further analyse splenic monocytes. 
iCCR deficiency altered certain splenic populations. The proportion of total 
leukocytes was reduced in the spleens of iCCR-KO mice compared to WT mice, 
suggesting that a small number of leukocytes require iCCRs to migrate to, or be 
retained in, the spleen. Hypertensive iCCR-KO mice also have a reduced total 
number of T cells compared to hypertensive WT mice, although this was not 
seen in the sham treated mice. Splenic CD8+, but not CD4+, T cells were 
reduced in the hypertensive iCCR-KO mice. In a model of viral infection, CD8+ T 
cells have been shown to increase in the spleen and this is associated with CCR2 
and CCR5 expression (Nansen et al., 2000). It is possible that CD8+ T cells 
require these iCCRs to migrate to the spleen when challenged by a virus and, 
possibly, Ang II.  
iCCR-KO mice had fewer Ly6C+ monocytes in the blood and more in the bone 
marrow, suggesting that iCCR deficiency prevents monocyte egress from the 
bone marrow to the blood. This has been previously shown in resting iCCR-KO 
mice and it is likely that this is dependent on CCR2 (Dyer et al., 2019). The same 
effect is seen for CD11b+ DCs but it is unknown which of the iCCRs these DCs 
require to migrate from the bone marrow. It is unclear if these differences are 
affected by Ang II and this should be repeated with sham and Ang II treated 
mice. Reconstituting WKY rats with the bone marrow from SHRs results in an 
increase in BP (Santisteban et al., 2015), suggesting that leukocytes in the bone 
marrow are important in hypertension. Further studies identifying leukocyte 
changes in the blood and bone marrow in hypertension and how these are 
regulated by iCCRs should be carried out. 
B and T cells were also analysed in the blood of Ang II treated WT and iCCR-KO 
mice. The proportion of B cells decreased while T cells increased in iCCR-KO 
mice. Further analysis of T cell activation revealed that there were more CD44- 
and CD44+ T cells in the iCCR-KO mice but no difference in the CD44++ T cells. 
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The increase in CD44+ T cells in the iCCR-KO mice may reflect a more 
proliferative state. However, there are also more CD44- T cells so this may just 
reflect an overall increase in T cells. Ang II has been shown to increase the 
number of circulating CD4+ T cells expressing CD44 (Guzik et al., 2007). This 
should be verified by repeating the experiment with sham treated mice. A 
population of CD4+CD44hiCD62Llo T cells can produce ACh and have been 
suggested to deliver ACh to ECs, mediating vascular relaxation (Olofsson et al., 
2016). It would be interesting to see if this population of T cells is affected by 
iCCR deficiency as this could contribute to BP regulation. 
4.7.4 iCCRs and cardiac and vascular remodelling 
Vascular hypertrophy has been demonstrated in several hypertensive animal 
models and hypertensive patients (Al-gburi et al., 2017; Guzik et al., 2007; 
Schiffrin et al., 2000). Aortic hypertrophy in sham and Ang II treated WT and 
iCCR-KO mice was assessed by measuring the medial thickness of the aortas. Ang 
II did not induce an increase in aortic medial thickness in both WT and iCCR-KO 
mice. As there was no increase in medial thickness, it is hard to determine if 
iCCR deficiency has any effect on vascular hypertrophy. However, there was a 
trend for aortic medial thickness to increase in the Ang II treated iCCR-KO mice 
compared to sham treated iCCR-KO mice, suggesting that iCCR deficiency does 
not influence Ang II induced vascular hypertrophy. This contrasts to CCR2-/- mice 
which are protected from Ang II induced aortic hypertrophy (Ishibashi et al., 
2004). However, the protection in CCR2-/- mice was seen after 28 days of Ang II 
treatment. It is possible that it takes more than 14 days for this effect to be 
seen and aortic hypertrophy should be determined in the iCCR-KO mice after a 
longer model of Ang II induced hypertension.  
Cardiac hypertrophy, as determined by measuring the ratio of heart weight to 
body weight, increased in both WT and iCCR-KO mice after Ang II treatment. 
This is also seen in hypertensive CCR5-/- and CCL2-/- mice (Krebs et al., 2012; 
Shen et al., 2014), suggesting that iCCRs do not affect cardiac hypertrophy in 
hypertension. Cardiac fibrosis was determined by measuring the deposition of 
collagen in the heart and there were no differences in collagen between any of 
the groups. However, it was expected that Ang II treatment would result in an 
increase in cardiac collagen as this has been shown previously (Wei et al., 2017). 
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A longer model may have been required to observe this. CCL2-/- mice are 
protected from hypertension induced collagen deposition in the heart (Shen et 
al., 2014), suggesting that CCR2 may be involved in fibrosis. If this is the case, it 
is likely iCCR-KO mice would be protected from Ang II induced cardiac fibrosis. 
Macrophages accumulate in the hearts and aortas of hypertensive mice and this 
is associated with remodelling (Falkenham et al., 2015; Ishibashi et al., 2004; 
Moore et al., 2015). Following monocyte depletion, fewer monocytes infiltrate 
the hearts of mice after Ang II treatment and there is reduced cardiac fibrosis 
(Falkenham et al., 2015). iCCR-KO mice have been shown to have reduced 
circulating monocytes and impaired recruitment of monocytes to sites of 
inflammation, similar to CCR2-/- mice (Dyer et al., 2019). It is hypothesised that 
there will be fewer macrophages recruited to the heart and aortas of Ang II 
treated iCCR-KO mice compared to WT mice and that this will result in reduced 
fibrosis but this has yet to be investigated. 
4.8 Conclusion 
The effect of iCCR deficiency in Ang II induced hypertension has been 
investigated (Table 4-2). The BP of iCCR-KO mice increased to the same extent 
as WT mice but the iCCR-KO mice were protected from vascular dysfunction. 
Vascular oxidative stress was the same in WT and iCCR-KO mice and iCCR 
deficiency did not affect Ang II induced inflammation in the PVAT or kidneys. 
However, the effect of Ang II on inflammation and oxidative stress in WT mice 
seen here was not as expected, or as has been demonstrated before, so the role 
of iCCR deficiency in Ang II induced inflammation may not be fully revealed by 
these experiments. iCCR-KO mice also showed cardiac hypertrophy similar to WT 
mice. 
Overall, this study has revealed that iCCRs are involved in vascular dysfunction 
in Ang II induced hypertension. Leukocyte infiltration into the aorta and 
mesenteric arteries should be investigated to see how leukocytes may mediate 
vascular function. Although iCCRs do not appear to regulate BP, through 
protecting vascular function the risk of atherosclerosis is reduced. Therefore, 
iCCRs represent potential targets to improve end organ damage in hypertension. 
Further studies are required to identify any individual or combinatorial roles of 
the iCCRs in Ang II induced hypertension. 
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Hypertension 
phenotype 
WT iCCR-KO Further experiments 
needed 
BP Increased Increased -- 
Vascular function Impaired Protected Mesenteric sham vessels 
Aortic oxidative 
stress 
No increase 
detected 
No increase 
detected 
Measure NADPH oxidase 
activity 
Plasma CCL3 No increase Increased -- 
Kidney inflammation No increase 
detected 
No increase 
detected 
Repeat/IHC 
PVAT inflammation No increase 
detected 
No increase 
detected 
Repeat/IHC 
Aortic hypertrophy No increase 
detected 
No increase 
detected 
Longer model 
Cardiac hypertrophy Increased Increased -- 
Cardiac fibrosis No increase No increase Longer model 
Table 4-2. The effect of iCCR deficiency in Ang II induced hypertension 
WT and iCCR-KO mice were subject to 14 days of Ang II induced hypertension. BP, vascular 
function, aortic oxidative stress, inflammation and hypertrophy were assessed and the effect of 
iCCR deficiency was determined. 
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Chapter 5 
The effect of iCCR deficiency on kidney immune 
cells and regulators of blood pressure
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5 The effect of iCCR deficiency on kidney immune 
cells and regulators of blood pressure 
5.1 Introduction 
The kidney is an important organ for the maintenance of BP through the 
regulation of salt excretion and fluid homeostasis. This involves reabsorption of 
sodium in the nephrons of the kidney and the retention of water (Soundararajan 
et al., 2010). Increased sodium reabsorption can result in hypertension, as is 
seen in certain diseases such as Liddle disease or Gordon’s syndrome (Sabbadin 
and Armanini, 2016). Work in the previous chapter demonstrated that iCCR-KO 
mice could have slightly reduced baseline BP compared to WT mice, potentially 
in older mice. This could be due to altered kidney function. Therefore, the 
effect of iCCR deficiency on the kidney was investigated. iCCR-KO mice have 
been shown to have reduced macrophage and monocyte numbers in the spleen, 
skin and lung (Dyer et al., 2019) so the presence of these cells and other 
leukocytes in the kidney was determined along with the expression of genes 
involved in sodium reabsorption and BP regulation. Mice deficient in individual 
iCCRs were also used to determine if any differences could be a result of lacking 
one iCCR or multiple iCCRs. In addition, the structure of the kidneys in WT and 
iCCR-KO mice was investigated. This increases understanding of how iCCRs could 
affect BP regulation. 
5.2 Kidney leukocyte infiltration 
The infiltration of CD45+ cells, CD11b+F4/80+ cells, CD11b+F4/80+Ly6C- cells 
and CD11b+F4/80+Ly6C+ cells in the kidneys of iCCR-KO and individual iCCR 
deficient mice was investigated by flow cytometry, using the gating strategy 
below (Figure 5-1). Cells that were CD11b+ and F4/80+ were gated from CD45+ 
cells and these were divided based on Ly6C expression. Kidney T cells and B cells 
were characterised in iCCR-KO mice following the gating strategy in the previous 
chapter (Figure 4-4). 
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Figure 5-1. Gating strategy for the analysis of macrophages and monocytes in the kidneys 
of resting WT, iCCR-KO, CCR1-KO, CCR2-KO, CCR3-KO and CCR5-KO mice 
CD45+ cells were gated from live, single cells. CD11b+ cells were gated from the CD45+ 
population and from these a population of F4/80+ cells were identified. The CD11b+F4/80+ cells 
were gated into CD11b+F4/80+Ly6C- and CD11b+F4/80+Ly6C+ populations. 
5.2.1 Macrophages and monocytes in iCCR-KO mice 
The accumulation of CD45+ cells (Figure 5-2a) in the kidneys of iCCR-KO mice did 
not differ from the WT mice but there was a reduction in CD11b+F4/80+ cells 
(Figure 5-2b; WT 5.5 ± 1.0 vs iCCR-KO 3.4 ± 0.6 % CD45+ cells, p < 0.01, Mann 
Whitney test). This was shown to be explained by a reduction in 
CD11b+F4/80+Ly6C+ cells (WT 1.9 ± 0.3 vs iCCR-KO 0.6 ± 0.1 % CD45+ cells, p < 
0.01, Mann Whitney test) but not CD11b+F4/80+Ly6C- cells (Figure 5-2c, d). 
Representative flow cytometry plots demonstrate the reduction of 
CD11b+F4/80+ cells in the iCCR-KO mice (Figure 5-2e). 
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Figure 5-2. Infiltration of macrophages and monocytes in the kidneys of resting iCCR-KO 
mice 
The infiltration of CD45+ cells (a), CD11b+F4/80+ cells (b), CD11b+F4/80+Ly6C- cells (c) and 
CD11b+F4/80+Ly6C+ cells (d) in the kidneys of resting iCCR-KO mice was determined by flow 
cytometry. Representative flow cytometry plots of CD11b+F4/80+, CD11b+F4/80Ly6C- and 
CD11b+F4/80+Ly6C+ populations are shown (e). ** p < 0.01, Mann Whitney test. 
5.2.2 Macrophages and monocytes in CCR1-KO, CCR2-KO, CCR3-
KO and CCR5-KO mice 
To determine if the reduction in CD11b+F4/80+Ly6C+ cells in the iCCR-KO mice 
was a result of a deficiency of a single iCCR or multiple iCCRs, the infiltration of 
CD11b+F4/80+ cells, CD11b+F4/80+Ly6C- cells and CD11b+F4/80+Ly6C+ cells in 
the kidneys of individual iCCR deficient mice was investigated. CD45+ cells 
represented up to 5 % of total cells and CD11b+F4/80+ cells accounted for up to 
10 % of CD45+ cells in the CCR1-KO, CCR2-KO, CCR3-KO mice and their WT 
controls (Figure 5-3, Figure 5-4, Figure 5-5). Analysis of the CCR5-KO mice and 
WT controls showed that up to about 45 % of kidney CD45+ cells were 
CD11b+F4/80+ (Figure 5-6). CCR1, CCR3 or CCR5 deficiency had no effect on 
these cell types in the kidney but CCR2 deficiency resulted in a reduction of 
CD11b+F4/80+ cells, CD11b+F4/80+Ly6C- cells and CD11b+F4/80+Ly6C+ cells 
(CD11b+F4/80+: WT 6.4 ± 1.4 vs CCR2-KO 2.8 ± 0.5 % CD45+ cells, p < 0.01, Mann 
Whitney test; CD11b+F4/80+Ly6C-: WT 4.1 ± 0.8 vs CCR2-KO 2.2 ± 0.4 % CD45+ 
cells, p < 0.01, Mann Whitney test; CD11b+F4/80+Ly6C+: WT 1.7 ± 0.5 vs CCR2-
KO 0.4 ± 0.2 % CD45+ cells, p < 0.01, Mann Whitney test). This reduction is 
demonstrated by representative flow cytometry plots (Figure 5-4). 
5 149 
 
 
Figure 5-3. Infiltration of macrophages and monocytes in the kidneys of resting CCR1-KO 
mice 
The infiltration of CD45+ cells (a), CD11b+F4/80+ cells (b), CD11b+F4/80+Ly6C- cells (c) and 
CD11b+F4/80+Ly6C+ cells (d) in the kidneys of resting CCR1-KO mice was determined by flow 
cytometry. 
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Figure 5-4. Infiltration of macrophages and monocytes in the kidneys of resting CCR2-KO 
mice 
The infiltration of CD45+ cells (a), CD11b+F4/80+ cells (b), CD11b+F4/80+Ly6C- cells (c) and 
CD11b+F4/80+Ly6C+ cells (d) in the kidneys of resting CCR2-KO mice was determined by flow 
cytometry. Representative flow cytometry plots of CD11b+F4/80+, CD11b+F4/80Ly6C- and 
CD11b+F4/80+Ly6C+ populations are shown (e). ** p < 0.01, Mann Whitney test. 
 
Figure 5-5. Infiltration of macrophages and monocytes in the kidneys of resting CCR3-KO 
mice 
The infiltration of CD45+ cells (a), CD11b+F4/80+ cells (b), CD11b+F4/80+Ly6C- cells (c) and 
CD11b+F4/80+Ly6C+ cells (d) in the kidneys of resting CCR3-KO mice was determined by flow 
cytometry. 
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Figure 5-6. Infiltration of macrophages and monocytes in the kidneys of resting CCR5-KO 
mice 
The infiltration of CD45+ cells (a), CD11b+F4/80+ cells (b), CD11b+F4/80+Ly6C- cells (c) and 
CD11b+F4/80+Ly6C+ cells (d) in the kidneys of resting CCR5-KO mice was determined by flow 
cytometry. 
5.2.3 iCCR expression by macrophages and monocytes 
REP mice were used to identify which iCCRs macrophages and monocytes express 
to aid the understanding of which iCCRs may be used for migration to and within 
the kidney (Figure 5-7). Neither CD11b+F4/80+Ly6C- cells nor 
CD11b+F4/80+Ly6C+ cells expressed CCR3 but they did express CCR1, CCR2 and 
CCR5. CD11b+F4/80+Ly6C- cells most highly expressed CCR5 whilst CCR2 was 
most highly expressed by CD11b+F4/80+Ly6C+ cells. Co-expression of CCR1, 
CCR2 and CCR5 by CD11b+F4/80+Ly6C- cells was also assessed but there were 
too few CD11b+F4/80+Ly6C+ cells to analyse iCCR co-expression. About 30 % of 
CD11b+F4/80+Ly6C- cells were CCR1+CCR5+ and 20 % were CCR5+ but none 
expressed just CCR1. About 5 % of these cells expressed just CCR2 and up to 15 % 
a b 
c d 
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expressed both CCR2 and CCR5. Further, about 30 % of these cells did not 
express any of the iCCRs (Figure 5-7c). 
 
Figure 5-7. Macrophage and monocyte iCCR expression 
The expression of CCR1, CCR2, CCR3 and CCR5 by CD11b+F4/80+Ly6C- cells (a) and 
CD11b+F4/80+Ly6C+ cells (b) was measured using REP mice. Co-expression of CCR1, CCR2 
and CCR5 by CD11b+F4/80Ly6C- cells was determined (c). 
5.2.4 T cells and B cells in iCCR-KO mice 
Infiltrating CD19+ B cells and overall CD3+ T cells were not affected by iCCR 
deficiency (Figure 5-8a, e). T cells were further analysed as CD4+, CD8+ and 
CD4-CD8- and these were also not affected by the lack of iCCRs (Figure 5-8b, c, 
d). 
a b 
c 
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Figure 5-8. Infiltrating T cells and B cells in the kidneys or resting iCCR-KO mice 
The infiltration of CD3+ cells (a), CD3+CD4+ cells (b), CD3+CD8+ cells (c), CD3+CD4-CD8- cells 
(d) and CD19 + cells (e) in the kidneys of resting iCCR-KO mice was determined by flow cytometry. 
5.3 Kidney blood pressure regulators 
As iCCR deficiency may reduce baseline BP, iCCR deficiency may affect 
regulators of sodium reabsorption, and therefore BP, in the kidney. The 
a b 
c d 
e 
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expression of the genes for MR, serum/glucocorticoid-regulated kinase 1 (SGK1), 
ENaC and sodium/hydrogen exchanger 3 (NHE3) were assessed by qPCR. MR is a 
nuclear receptor transcription factor that binds to aldosterone and regulates 
transcription of genes involved in sodium reabsorption. One of these genes is 
SGK1. SGK1 regulates activation of ENaC, a channel that facilitates sodium 
reabsorption (Shibata and Fujita, 2011). NHE3 also regulates sodium 
reabsorption and is important in BP maintenance (Fenton et al., 2017). 
5.3.1 iCCR-KO mice 
The mRNA expression of MR was reduced in the iCCR-KO mice (Figure 5-9a; WT 
100 ± 41 vs iCCR-KO 30 ± 14 % WT mRNA expression, p < 0.01, Mann Whitney 
test). SGK1, ENaC and NHE3 expression were not altered in the iCCR-KO mice 
compared to WT mice (Figure 5-9b, c, d). 
 
Figure 5-9. iCCR-KO kidney MR, SGK1, ENaC and NHE3 expression 
a b 
c d 
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The expression of MR (a), SGK1 (b), ENaC (c) and NHE3 (d) in the kidneys of resting WT and 
iCCR-KO mice was determined by qPCR. ** p < 0.01, Mann Whitney test. 
5.3.2 CCR1-KO, CCR2-KO, CCR3-KO and CCR5-KO mice 
To evaluate whether the reduction in MR mRNA expression in the iCCR-KO mice 
was a result of an individual iCCR deficiency or is specific to iCCR-KO mice, the 
expression of MR, SGK1, ENaC and NHE3 was determined in each of the 
individual iCCR deficient mice. Analysis of CCR1-KO mice showed the same MR, 
SGK1 and NHE3 expression as the WT mice but ENaC expression was lower in the 
CCR1-KO mice (Figure 5-10c; WT 100 ± 7 vs CCR1-KO 81 ± 10 % WT mRNA 
expression, p < 0.05, Mann Whitney test). CCR2 or CCR3 deficiency had no effect 
on the expression of MR, SGK1, ENaC and NHE3 (Figure 5-11, Figure 5-12). The 
expression of MR, ENaC and NHE3 in the kidneys of CCR5-KO mice was not 
different from the WT mice but SGK1 expression was higher in the CCR5-KO mice 
(Figure 5-13b; WT 100 ± 13 vs CCR5-KO 139 ± 28 % WT mRNA expression, p < 
0.05, Mann Whitney test). 
 
a b 
d c 
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Figure 5-10. CCR1-KO kidney MR, SGK1, ENaC and NHE3 expression 
The expression of MR (a), SGK1 (b), ENaC (c) and NHE3 (d) in the kidneys of resting WT and 
CCR1-KO mice was determined by qPCR. * p < 0.05, Mann Whitney test. 
 
Figure 5-11. CCR2-KO kidney MR, SGK1, ENaC and NHE3 expression 
The expression of MR (a), SGK1 (b), ENaC (c) and NHE3 (d) in the kidneys of resting WT and 
CCR2-KO mice was determined by qPCR. 
a b 
c d 
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Figure 5-12. CCR3-KO kidney MR, SGK1, ENaC and NHE3 expression 
The expression of MR (a), SGK1 (b), ENaC (c) and NHE3 (d) in the kidneys of resting WT and 
CCR3-KO mice was determined by qPCR. 
a b 
c 
d 
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Figure 5-13. CCR5-KO kidney MR, SGK1, ENaC and NHE3 expression 
The expression of MR (a), SGK1 (b), ENaC (c) and NHE3 (d) in the kidneys of resting WT and 
CCR5-KO mice was determined by qPCR. * p < 0.05, Mann Whitney test. 
5.4 Immune cell MR expression 
Macrophages and monocytes have been shown to express MR (Lim et al., 2007; 
Rickard et al., 2009). It is possible that the reduction of MR expression in the 
kidneys of iCCR-KO mice is a reflection of the reduction of CD11b+F4/80+Ly6C+ 
cells. Therefore, MR expression by immune cells, including macrophages, in WT 
and iCCR-KO mice was investigated. 
5.4.1 Macrophage sort 
F4/80+ cells were isolated from the kidneys of WT and iCCR-KO mice using 
magnetic columns and the MR expression by these cells was determined. 
Representative flow cytometry plots of the negative fraction, positive fraction 
and cells before the sort are shown (Figure 5-14). F4/80+ cells represented a 
a b 
c d 
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very small fraction of the total cells in the kidney. These cells were depleted in 
the negative fraction but only slightly enriched in the positive fraction. The 
majority of the positive fraction consisted of F4/80- cells and therefore isolating 
F4/80+ cells was unsuccessful and MR expression was not tested. 
 
Figure 5-14. Magnetic sort of kidney F4/80+ cells 
F4/80+ cells were sorted from kidney cells using magnetic columns. Representative flow cytometry 
plots of the cells before the sort (pre-sort) and the negative and positive fractions are shown. 
5.4.2 Flow cytometry 
The expression of MR by leukocytes in the kidneys of WT and iCCR-KO mice was 
next investigated using flow cytometry. Overall, about 4 % of kidney cells were 
shown to express MR in both WT and iCCR-KO mice. Representative flow 
cytometry plots of total kidney cells stained with the MR antibody and FMO 
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control are shown with a heatmap of CD45 expression. This suggests that the 
majority of MR+ cells are CD45+ (Figure 5-15a). 60 % of CD3+ T cells and up to 95 
% of CD19+ B cells were shown to be MR+ and the majority of CD11b+F4/80+ 
cells were MR+ (Figure 5-15b, c, d). Slightly more CD11b+F4/80+ cells expressed 
MR in the iCCR-KO mice compared to WT mice (WT 93 ± 4 vs iCCR-KO 98 ± 1 % 
CD11b+F4/80+ cells, p < 0.05, Mann Whitney test). Representative flow 
cytometry plots of FMO controls and MR stained samples illustrate high MR 
staining by CD3+, CD19+ and CD11b+F4/80+ cells. 
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Figure 5-15. The expression MR in the kidneys of WT and iCCR-KO mice 
Overall MR expression (a) and MR expression by CD3+ cells (b), CD19+ cells (c) and 
CD11b+F4/80+ cells (d) in the kidneys of WT and iCCR-KO mice was determined by flow 
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cytometry. Representative flow cytometry plots of MR staining by these cell types and an FMO 
control are shown. CD45 expression is presented as a heat map in a. * p < 0.05, Mann Whitney 
test. 
5.4.3 Lymphoid MR expression 
The high expression of MR by kidney leukocytes demonstrated by flow cytometry 
was unexpected and it is likely that the antibody is showing non-specific binding 
to these cells. To clarify this, MR expression in the spleen, thymus and kidney 
was determined by flow cytometry and qPCR. The spleen and thymus consist 
mostly of leukocytes whereas only up to 5 % of kidney cells are leukocytes. 
Therefore these experiments indicate whether leukocytes express MR or if the 
antibody binds non-specifically to them. Flow cytometry showed that the spleen 
had the highest MR expression, with about 4 x 106 MR+ cells. The thymus had 1.5 
x 106 MR+ cells. This was much higher than the 8 x 104 MR+ cells in the kidney 
(Figure 5-16a). In contrast to this, qPCR revealed that MR expression was about 
10-fold higher in the kidney compared to the spleen and thymus (Figure 5-16b). 
Very low levels of MR mRNA, if any, were detected in the spleen and thymus 
with ct values over 30. 
 
Figure 5-16. Spleen, thymus and kidney MR expression 
The total expression of MR in the spleen, thymus and kidneys of WT mice was determined by flow 
cytometry (a) and qPCR (b). 
5.5 iCCR-KO Kidney structure 
Macrophages have been shown to be involved in development. They regulate 
angiogenesis, lymphangiogenesis and development of various organs such as the 
mammary glands (Fantin et al., 2010; Lee et al., 2014; Wilson et al., 2017). 
a b 
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Chemokines and their receptors are also involved as ACKR2 has been shown to 
regulate branching morphogenesis in the mammary gland and both ACKR2 and 
CCR2 regulate lymphangiogenesis (Lee et al., 2014; Wilson et al., 2017). 
Therefore, the effect of iCCR deficiency on kidney structure was investigated as 
this may be effected by altered kidney monocyte and macrophage populations. 
There appeared to be no differences in the structure of the WT and iCCR-KO 
kidneys, demonstrated by representative images (Figure 5-17a). The number of 
glomeruli were counted to indicate nephron formation and this did not differ 
between WT and iCCR-KO kidneys (Figure 5-17b). 
 
Figure 5-17. The effect of iCCR deficiency on kidney structure 
The structure of kidneys from WT and iCCR-KO mice was assessed by H&E staining (a) and the 
average number of glomeruli per field of view (FOV) was measured (b). Arrows point to glomeruli. 
Scale bar = 100 µm. 
WT iCCR-KO 
WT iCCR-KO 
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5.6 Discussion 
The effect of total iCCR and individual iCCR deficiency on kidney leukocytes, BP 
regulators and kidney structure was investigated. This has revealed how iCCRs 
contribute to macrophage and monocyte infiltration in the kidney and showed 
that MR expression is influenced by iCCRs or iCCR expressing cells. 
5.6.1 Kidney monocytes and macrophages 
Ly6C expression was used to identify monocyte and macrophage populations. 
CD11b+F4/80+Ly6C+ cells represent inflammatory monocytes whilst 
CD11b+F4/80+Ly6C- cells represent macrophages (Clements et al., 2016; Lin et 
al., 2009). iCCR deficiency resulted in fewer CD11b+F4/80+Ly6C+ cells in the 
kidney but CD11b+F4/80+Ly6C- cells were unaffected. CCR1, CCR3 and CCR5 
deficiency had no effect on these populations whilst CCR2-KO mice had fewer 
CD11b+F4/80+Ly6C+ and CD11b+F4/80+Ly6C- cells. This suggests that only CCR2 
is required for the migration of these cells to the kidney. The reason 
CD11b+F4/80+Ly6C- cells were reduced in CCR2-KO mice but not iCCR-KO mice is 
unclear but this has also been demonstrated in the lung (Dyer et al., 2019). It 
has been suggested that Ly6Chi monocytes differentiate into macrophages and 
that these macrophages have a role in renal fibrosis (Lin et al., 2009). Whether 
monocyte derived macrophages and tissue resident macrophages have a role in 
resting kidney function has not been investigated. Cardiac macrophages have 
been shown to have a role in cardiac conduction (Hulsmans et al., 2017) so it is 
possible that kidney macrophages have functions in the kidney outside their 
immune and inflammatory roles. Depletion of monocytes and macrophages or 
CCR2 deficiency do not affect baseline BP (Huang et al., 2018; Ishibashi et al., 
2004) which would suggest that the observed changes in kidney monocytes and 
macrophages in iCCR-KO mice are not responsible for any changes in BP 
compared to WT mice. 
The majority of CD11b+F4/80+Ly6C- cells in the kidney express both CCR1 and 
CCR5 whilst CD11b+F4/80+Ly6C+ cells most highly express CCR2. This could 
suggest that as CD11b+F4/80+Ly6C+ cells differentiate, they downregulate CCR2 
expression and upregulate CCR1 and CCR5 expression. This has been 
demonstrated by human monocytes in vitro (Kaufmann et al., 2001). The role of 
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CCR1 and CCR5 on kidney macrophages is unclear but these may regulate 
migration within the kidney or macrophage function. CCR5 may regulate 
macrophage polarisation as it has been suggested that CCR5 deficiency increases 
alternative activation of macrophages (Dehmel et al., 2010). CCR1 deficient 
peritoneal macrophages show increased phagocytosis and cytotoxicity, 
suggesting that CCR1 can regulate macrophage innate immune responses (Ness 
et al., 2004). At rest, CCR2 appears to regulate kidney monocyte and 
macrophage recruitment but other iCCRs may be involved in disease states. For 
example, CCR1 may regulate macrophage infiltration in renal ischaemia-
reperfusion injury (Furuichi et al., 2008). 
CD11b+F4/80+Ly6C- cells can be CCR2+, CCR5+, CCR1+CCR5+ or CCR2+CCR5+ 
and these may represent distinct subpopulations. None of these cells were just 
CCR1+ which could suggest a redundant role for CCR1. Some of these cells did 
not express any of the iCCRs and these may depend on other chemokine 
receptors for migration such as CX3CR1 (Geissmann et al., 2003). A population of 
CD11b+F4/80-Ly6C+ monocytes could reside in the kidney and these cells in 
iCCR-KO and individual iCCR deficient mice could be further explored, along 
with their iCCR expression. 
5.6.2 MR, SGK1, ENaC and NHE3 
It is unlikely that the reduction of CD11b+F4/80+Ly6C+ cells in the kidneys of 
iCCR-KO mice directly affects BP. Therefore, other regulators of BP in the kidney 
were investigated. These were MR, SGK1, ENaC and NHE3. NHE3 expression was 
not effected by individual or total iCCR deficiency. MR is a transcription factor 
that regulates SGK1 expression (Shibata and Fujita, 2011). MR expression was 
reduced in iCCR-KO mice but SGK1 expression was not effected by iCCR 
deficiency, suggesting that there was enough MR protein or that other 
transcription factors were able to regulate SGK1 expression. SGK1 expression 
was increased in CCR5-KO mice. How CCR5 effects SGK1 expression has not been 
investigated but T cell SGK1 has been shown to be important in hypertension 
(Norlander et al., 2017). It is possible that CCR5 regulates T cell SGK1 expression 
or that CCR5+ cells regulate the expression of SGK1 by other cells types such as 
epithelial cells. The increase of SGK1 expression in CCR5-KO mice would also be 
expected in the iCCR-KO mice and it is unclear why this was not observed. SGK1 
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inhibits ENaC degradation, leading to increased levels of ENaC and increased 
activity (Debonneville et al., 2001). ENaC expression was reduced in CCR1-KO 
mice. The effect of CCR1 deficiency on BP has not been looked at but it is 
possible that a reduction in ENaC would result in lower BP. ENaC is also 
expressed by epithelial cells in the lung, colon and bladder and expression may 
also be reduced in these tissues in CCR1-KO mice. ENaC expression was not 
reduced in the iCCR-KO mice, which would have been expected. 
MR mRNA expression was reduced in the iCCR-KO mice and this effect was not 
seen in any of the individual iCCR deficient mice, suggesting that this is a result 
of loss of multiple iCCRs. Because MR can be expressed by monocytes and 
macrophages (Lim et al., 2007; Rickard et al., 2009), it is possible that the 
reduction in expression reflected the reduction in CD11b+F4/80+Ly6C+ cells. 
However, this may not be the case as a reduction in MR expression in CCR2-KO 
mice would also be expected. Nonetheless, the expression of MR by monocytes, 
macrophages and other leukocytes in WT and iCCR-KO mice was investigated. 
The data here show that B cells, T cells and macrophages express MR. There is 
some evidence for MR expression by T cells and macrophages. Mice with MR 
deficient T cells have reduced BP at baseline and after Ang II treatment and 
deletion of MR in macrophages protects against DOCA-salt induced hypertension 
(Rickard et al., 2009; Sun et al., 2017). Macrophages in iCCR-KO mice were 
shown to express slightly more MR than WT mice, although this difference is 
small and unlikely to be biologically relevant. 
The antibody based data here suggest that only 4 % of kidney cells express MR 
and that the majority of these are CD45+ which is surprising as MR is expressed 
by epithelial cells in the distal convoluted tubules of the kidney (Funder, 2005; 
Hirasawa et al., 1997). It is therefore likely that the antibody used did not work 
effectively and could bind to leukocytes non-specifically. To check this, MR 
expression was measured in the spleen, thymus and kidney by flow cytometry 
and qPCR. The flow cytometry data suggested that the spleen had the most MR+ 
cells, followed by the thymus, and the kidney had 50-fold fewer MR+ cells than 
the spleen. qPCR revealed that MR expression was highest in the kidney whilst 
MR was almost undetectable in the spleen and thymus with ct values higher than 
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30. This suggests that the MR antibody used for flow cytometry was binding non-
specifically to immune cells and that the data obtained using it is unreliable. 
Although the expression of MR by leukocytes shown here is unreliable, it is still 
possible that MR expression by these cells is affected by iCCR deficiency. It is 
also possible that iCCR expressing leukocytes can regulate MR expression, 
potentially through cytokine production. The MR gene may be transcribed at the 
same rate in WT and iCCR-KO mice, but the mRNA could be degraded faster in 
the iCCR-KO mice. This could be regulated by MicroRNAs such as miR-124 and 
miR-135a, which have been shown to regulate MR expression. However this is 
likely through regulation of translation, not mRNA stability (Sõber et al., 2010). 
The study here was limited by the fact that only mRNA expression was measured 
and not protein expression. However, an antibody that could be used to measure 
MR expression by IHC or western blotting was not available. 
Another explanation for reduced MR expression is if the iCCR-KO kidneys have a 
different structure to WT kidneys such as fewer nephrons and epithelial cells. 
This could be influenced by macrophages and may also affect BP. ACKR2 
deficient mice show increased macrophage recruitment to developing mammary 
glands which is associated with an increase in ductal epithelial network density 
(Wilson et al., 2017). Macrophages have been shown to accumulate near renal 
tubules in the developing kidney and CSF-1 treated kidney explant cultures 
develop an increased number of nephrons (Rae et al., 2007). The data here 
indicate that the structure of the WT and iCCR-KO kidneys does not differ which 
suggests that kidney development is not affected by iCCR deficiency or reduced 
macrophage populations. However, this could be verified by studying kidney 
development and macrophage populations in embryonic iCCR-KO mice. 
The vasculature is also important in regulating BP and how iCCR deficiency 
affects leukocytes and BP regulation by the vasculature should be investigated. 
MR has been shown to be expressed by endothelial cells and VSMCs and this is 
important in regulating BP (Galmiche et al., 2014; Nguyen et al., 2010). It is 
possible that iCCR-KO mice have reduced MR expression in the vasculature as 
well as the kidney. Older iCCR-KO mice tended to have a lower BP than WT mice 
so how iCCRs contribute to BP regulation in older mice and in age related 
hypertension would be interesting. 
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5.7 Conclusion 
This study shows that the kidneys of iCCR-KO mice have fewer 
CD11b+F4/80+Ly6C+ cells than WT mice and that this is likely due to lack of 
CCR2. iCCR-KO mice also have reduced MR expression in the kidneys which may 
influence BP and this is specific to the iCCR-KO mice. The reason for MR 
expression downregulation is still unclear. As CCR2-KO mice do not show a 
reduction in kidney MR expression, the reduction of CD11b+F4/80+Ly6C+ cells is 
unlikely to be involved with the reduced MR expression. Kidney MR protein 
expression needs to be verified, along with which cells are expressing MR and 
whether reduced MR expression is responsible for any differences in BP.  
Overall, this study reveals some ways that iCCR deficiency influences the 
kidneys. Further work on whether this influences BP needs to be done, along 
with studies focusing on the vasculature, but this could start to identify ways 
that iCCRs can be targeted to regulate BP.
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6 Discussion 
6.1 General discussion 
The immune system is an important factor in the pathogenesis of hypertension, 
with the depletion of T cells, B cells, monocytes and macrophages having been 
shown to be protective in various hypertensive models (Chan et al., 2015; Guzik 
et al., 2007; Thang et al., 2015; Wenzel et al., 2011). Further, inflammation of 
the vasculature and kidneys develops in hypertension and this is associated with 
end organ damage (Moore et al., 2015; Ozawa et al., 2006). 
As regulators of leukocyte migration and inflammation, chemokines and their 
receptors have been implicated in hypertension. Of the iCCRs, CCR2 has been 
most widely studied. CCR2-/- mice are protected from Ang II induced vascular 
remodelling, but not elevated BP, whilst the CCR2 antagonist INCB3344 reduces 
BP in Ang II induced hypertension (Ishibashi et al., 2004; Moore et al., 2015). The 
deficiency of CCR5 has not been shown to influence BP or kidney function and 
inflammation in hypertension but CCR5 expression does increase in hypertensive 
kidneys and aortas (Chan et al., 2012; Krebs et al., 2012). CCR1 and CCR3 have 
not previously been studied in hypertension. 
Studying the role of chemokine receptors in hypertension, and other contexts, 
has been challenging due to the complexity of the chemokine system. To 
overcome this, iCCR-KO mice have been developed (Dyer et al., 2019) as well as 
REP mice which can be used to detect individual and combinatorial iCCR 
expression. In the experiments described here, these mice were used to 
investigate the role of iCCRs in hypertension. Firstly, through characterising 
leukocyte iCCR expression in Ang II induced hypertension and secondly, through 
investigating how iCCR deficiency affects Ang II induced hypertension. Finally, 
how iCCR deficiency may affect the regulation of BP by the kidney was 
investigated. 
For the characterisation of leukocyte iCCR expression, B cells, T cells, 
monocytes and macrophages were analysed in the bone marrow, blood, spleen, 
kidney and PVAT by flow cytometry, using REP mice. This was carried out after 7 
or 14 days of Ang II induced hypertension and there were no changes in iCCR 
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expression by the cell types analysed at either of the time points. However, iCCR 
expression in the kidney, heart and aorta (including PVAT) was also analysed by 
qPCR after 14 days of Ang II induced hypertension and this revealed an increase 
in aortic CCR2 and CCR5 expression in the Ang II treated mice. This suggests that 
CCR2 and CCR5 are important in regulating vascular inflammation in 
hypertension. Leukocytes expressing CCR2 and CCR5 may be involved in the 
vascular dysfunction that occurs in hypertension as iCCR-KO mice subject to Ang 
II induced hypertension had improved aortic and mesenteric artery function 
compared to Ang II treated WT mice. A similar effect is seen in CCL5-/- mice 
(Mikolajczyk et al., 2016). CCL5, and possibly other ligands for CCR5 or ligands 
for CCR2, could be important for the recruitment of leukocytes that impair 
vascular function. Vascular oxidative stress is associated with vascular 
dysfunction in hypertension (Guzik et al., 2007) but iCCR deficiency had no 
effect on aortic superoxide so it is possible that other factors were mediating 
the protection from vascular dysfunction. 
Inflammation of the kidneys and vasculature is widely reported in hypertension 
(Mikolajczyk et al., 2016; Moore et al., 2015; Ozawa et al., 2006). However, the 
results here do not show Ang II to increase inflammation of the kidneys or PVAT. 
This may be due to different protocols for cell isolation or different flow 
cytometry gating strategies. It was hypothesised that there would be fewer 
inflammatory monocytes and macrophages in the kidneys and PVAT of Ang II 
treated iCCR-KO mice but any effect of iCCR deficiency on kidney and PVAT 
inflammation was difficult to identify when the overall effect of Ang II was not 
observed. 
The BP of Ang II treated iCCR-KO mice increased to the same extent as WT mice. 
This, along with studies of CCR2 and CCR5 deficient mice (Ishibashi et al., 2004; 
Krebs et al., 2012), suggests that iCCRs do not influence blood pressure in 
hypertension. As a deficiency in T cells, B cells or macrophages has been 
reported to prevent a BP increase in hypertension, it is likely that other 
chemokine receptors are involved in the migration of these cells to where they 
regulate BP. 
A difference in BP was observed between the WT and iCCR-KO sham treated 
mice after 12 - 14 days of BP measurements, suggesting that iCCR deficiency 
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results in reduced BP, an effect that might only be seen in older mice. To 
understand this observation, factors that regulate BP were investigated in WT 
and iCCR-KO mice. As a regulator of salt retention and fluid homeostasis, the 
experiments described here focused on the kidney. The iCCR-KO mice were 
shown to have fewer CD11b+F4/80+Ly6C+ cells in the kidney. Analysis of 
individual receptor KO mice suggested that CCR2 is the iCCR responsible for this 
phenotype. The iCCR-KO mice also had reduced kidney MR expression and this 
was not seen in any of the individual receptor KO mice. The reduction in 
inflammatory monocytes in the kidneys of iCCR-KO mice is unlikely to be 
associated with MR expression as CCR2-KO mice also had fewer monocytes in the 
kidney but MR expression was similar to that of WT mice. 
6.2 Future work 
CCR2 and CCR5 were identified as upregulated in the aortas of Ang II treated WT 
mice. In addition, mice deficient for the iCCRs were shown to have improved 
vascular function in Ang II induced hypertension compared to WT mice. It is 
hypothesised that CCR2 and CCR5 regulate vascular dysfunction in hypertension 
and this needs to be further investigated. The cells expressing these receptors in 
the aorta should be identified, as CCR2+ and CCR5+ leukocytes may not be 
recruited to the aorta in iCCR-KO mice and this could be protective against Ang 
II induced vascular dysfunction. Additionally, vascular function in CCR2-/- and 
CCR5-/- mice following Ang II induced hypertension should be determined as this 
may identify whether just one of these receptors is responsible for the effects 
seen in the iCCR-KO mice or whether both receptors are involved. This could 
also be carried out using CCR2 and CCR5 inhibitors. Whether these inhibitors can 
be protective in hypertension that has already been established would also be 
interesting to investigate and more clinically relevant. Although CCR1 and CCR3 
were not upregulated in the hypertensive aortas, how CCR1-/- and CCR3-/- mice 
respond to Ang II would still be interesting to determine as this has not 
previously been done. 
Reversible iCCR-KO mice are currently being generated. These mice are 
conditionally null for the iCCRs but expression of individual receptors can be 
switched on, in multiple combinations. CCR1-CCR2+CCR3-CCR5-, CCR1-CCR2-
CCR3-CCR5+ and CCR1-CCR2+CCR3-CCR5+ mice could be subjected to Ang II 
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induced hypertension and vascular function assessed. This would show if mice 
that only express CCR2, CCR5 or CCR2 and CCR5 experience vascular dysfunction 
similar to WT mice, indicating how important these receptors are in regulating 
vascular dysfunction in hypertension. 
It would also be interesting to see if iCCR-KO mice are protected from cardiac 
and vascular remodelling after 28 days of Ang II treatment as this was not 
observed after 14 days. Remodelling can be regulated by monocytes and 
macrophages (Falkenham et al., 2015; Moore et al., 2015). It is hypothesised 
that fewer monocytes would be recruited to the hearts and aortas of iCCR-KO 
mice and this would result in reduced pathogenic remodelling. CCR2 deficiency 
has already been shown to be protective against Ang II induced vascular 
remodelling (Ishibashi et al., 2004). WT and iCCR-KO mice could be treated with 
Ang II for 28 days and the infiltration of monocytes and macrophages in the aorta 
and heart could be determined, along with fibrosis markers such as collagen and 
matrix metalloproteinases (Giannandrea and Parks, 2014). 
The effect of iCCR deficiency on MR expression was unexpected. How the lack of 
iCCRs affects other tissues and how they function would be interesting to 
investigate. For understanding BP regulation, characterising how iCCR deficiency 
affects the vasculature needs to be carried out. This would involve determining 
the infiltration of monocytes and macrophages in the vasculature. Assessing 
vascular function in resting WT and iCCR-KO mice would also be interesting as a 
slight difference between sham treated WT and iCCR-KO mice was identified. 
The effect of PVAT on vascular function in these mice should also be 
investigated by carrying out wire myography with and without PVAT as the 
experiments described here only focused on vessels after the removal of the 
PVAT. 
6.3 Final conclusion 
Overall, the work described here has increased understanding of how iCCRs 
influence hypertension and BP regulation. Characterising iCCR expression in Ang 
II induced hypertension has shown that Ang II has few effects on iCCR expression. 
However, aortic CCR2 and CCR5 mRNA expression increased in response to Ang 
II. iCCR deficiency was shown to be protective against Ang II induced vascular 
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dysfunction, but had no effect on BP. iCCR deficiency was also shown to reduce 
the infiltration of monocytes in the kidney and reduce kidney MR expression. 
Further experiments are required to understand if this influences BP. 
These experiments have identified iCCRs as possible targets to improve vascular 
function in hypertension which could reduce the risk of complications of 
hypertension such as atherosclerosis, MI and stroke. 
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